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Chapter I.  Introduction 
 
1.1 Epidemiology of brain tumors 
 
According to the Central Brain Registry Of The United States (CBTRUS) statistical report (February 2012) 
the incidence rate of all primary non malignant and malignant brain and central nervous system tumors is 
19.89 cases per 100.000 (11.58 for non-malignant tumors and 7.31 for malignant tumors). Malignant brain 
tumors account for only 1% to 2% of all adult cancers. As a comparison, in 2012, the incidence of women 
breast cancer was 121.2 (per 100.000). Tumors of neuroepithelial tissue are the most frequent malignant 
brain tumors with an incidence rate of 6.16. The most common tumor of neuroepithelial tissue is the 
glioblastoma (GBM) with an incidence of 3.2. Other histologies e.g. astrocytoma, oligodendroglioma or 
mixed oligoastrocytoma have an incidence rate lower than 0.5.
 1,2 
The incidence of brain tumors increases 
with age, with an incidence rate is 8.59 for young patients (age 20-34) and 55.8 for elderly patients (age 65-
74). Age distributions also differ by histology and grade. Glioblastoma peaks in incidence at age 65-74 and 
oligodendroglioma and low grade astrocytoma at age 35-44. Causes of brain tumors are still largely 
unknown. Various categories of risk factors are investigated in epidemiologic studies: geographic and 
ethnic, environmental (irradiation, pollution), lifestyle (food, alcohol, smoking bits, use of cell phone), 
medical treatments and conditions (allergies, infections), familial or hereditary. To date, inherited genetic 
syndromes, therapeutic ionizing irradiation are the only generally accepted risk factors of glioma genesis.
4,5
 
In the last decade, advances in microarray and sequencing technologies allowed the realization of large gene 
expression and genome wide association studies (GWAS). Recently, two GWAS provided more insight into 
the genetic variants that influence an individual susceptibility to develop gliomas.
 6,7,8
  In addition to 
germline genetic risk factors, recent studies showed that acquired somatic genetic changes were associated 
with treatment response, disease progression and overall survival.
9,10
   
 
1.2 Classification of brain tumors 
 
The international classification of human tumours published by the World Health Organization (WHO) was 
initiated through a resolution of the WHO Executive Board in 1956 and the World Health Assembly in 
1957. The primary goal was to define internationally recognized histopathological and clinical criteria for 
typing and grading human brain tumors. An ancillary objective was to promote the conduct of 
epidemiological studies and clinical trials beyond the local institution or national bounderies. The first 
edition of the WHO “Blue Book” was published in 1979 and included a list of histological types. 11 In the 
second edition (1993), advances brought by the use of immunohistochemistry were integrated.
 12
 Anaplastic 
oligoastrocytoma was recognized as a new entity. The third edition (2000) incorporated the results of 
epidemiological and clinical studies including prognostic and predictive factors, imaging and genetic 
profiles.
 13
 In the fourth edition (2007), new entities and variants were integrated.
 14 
Anaplastic 
oligoastrocytoma with necrosis was associated with worse prognosis and was reclassified as “glioblastoma 
with oligodendroglioma component”. New studies showed that most of these tumors had a similar prognosis 
and genetic profiles compared to standard glioblastoma.
15
 Finally, genetic alterations were considered to 
define new tumor subsets, such as 1p/19q codeletion in oligodendrogliomas although these molecular 
characteristics are still not integrated in the classification system.
 16 
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1.3 Inter-observer disagreement in the diagnosis of brain tumors 
 
Despite this huge international effort to harmonize the classification of brain tumours, their diagnosis and 
grading remain controversial and subject to large inter-observer disagreement. Diagnosis of gliomas is 
usually performed by local neuro-pathologists in academic or community hospitals. In clinical trials, 
diagnosis made by local pathologist can be reviewed by one or a panel of central neuro-pathologists. With 
new and advanced technologies, this review can be more easily performed by virtual microscopy (VM). 
With VM, histological images can be shared via internet over large distances without physical transfer of the 
original glass slides.
17
 Central pathology review in clinical trials is realized either before or after patient 
entry into the trial. In the former case, the eligility of a patient to be enrolled a trial can be affected (e.g. if 
diagnosis is not confirmed by one of two central reviewers), in the latter case, patients is enrolled based on 
the local diagnosis. In both cases, patient management and/or prognosis can significantly change. Patients 
with low grade tumor but diagnosed and treated as high grade tumor are overtreated. Conversely, improperly 
diagnosed high grade tumors can be undertreated. Recent studies showed that disagreement on the diagnosis 
at central review was higher when the first diagnosis was obtained in community hospitals. Especially in 
community hospitals without a trained neuropathologist.
18
 In a cohort of patients diagnosed with 
oligodendrogliomas, disagreement was less frequent among neuropathologists than between surgical 
pathologists. A reason might be the particularity of some pathological features for neuropathology (e.g. 
microvascular changes) requiring specific training.  It was found that only a limited number of features was 
reproducible and were found to have significant correlation with survival in multivariate Cox models. 
19 
In 
another study, inter-observer disagreement was higher for astrocytomas with anaplastic foci (AAF) 
compared to Glioblastomas (GBM).  Patients with AAF reclassified into GBM had GBM-like survival while 
GBM reclassified as AAF had intermediate survival between confirmed AAF and GBM.
20
 Some inter-
observer variability might be explained by sampling error or poor quality of slides. More critical is the 
subjectivity and ambiguity of some definitions in the WHO classifications. 
21
  
 
1.4 Role of prognosis in clinical research   
 
Diagnosis, prognosis and therapy of a disease are key in medical practice. Diagnosis is about “examining” 
disease at a fixed time point with the intent of grouping patients into homogenous disease entities while 
prognosis is about “predicting” individual disease status or patient outcome and is dynamic over time by 
nature. Both diagnosis and prognosis are closely related. In neuro-oncology, tumor grade is still widely used 
to differentiate between groups of disease and prognosis but also to guide treatment decision. Knowledge of 
both disease diagnosis and patient prognosis should help clinicians to decide the best therapeutic decision 
for their patient, including giving no anti-tumor treatment. Although it is questionable whether collect data is 
rational if their use is not relevant for treatment decision, but on the other hand, gather relevant prognostic 
information may lead to a better understanding of the disease. Prognostic information is only a decision aid 
and in general will not tell who to treat or not or especially if patients with a worse prognosis will benefit 
similar to a therapy compared to good prognosis patients. This information will only matter if the prognosis 
is too poor to justify further treatments. Only properly designed, controlled and if possible, randomized trials 
can provide answer about patient prognosis and its interaction with treatment. The ultimate objective of a 
treatment decision will be to significantly improve patient prognosis.
22
    
 
1.5 Prognostic factors 
  
In oncology, although molecular factors are receiving more and more importance, disease diagnosis is still 
fundamentally guided by tumor site and histology. Additionally, “prognostic factors” are identified to 
account for some of the heterogeneity associated with the expected course and outcome of the disease.
 
 
Prognostic factors are useful in patient counseling and for therapeutic decision e.g. to avoid exposing 
patients with good prognosis to aggressive treatment and vice versa, treating patients that are unlikely to 
benefit.  In clinical research, they can be used to decide the inclusion of patients in clinical trials. When used 
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as stratification factors, they make the randomization process more efficient by ensuring a better balance of 
major prognostic variables between treatment groups.
 
With the advancement of science, new molecular 
prognostic factors are expected to provide a better understanding of disease biology and to direct further 
research.  
 
1.6 Prognostic factors in brain tumors 
 
Histological grade and type, extent of surgery, age and performance status are the most consistently 
described prognostic factors in primary brain tumor patients. In addition, several pathological features with 
prognostic value have been reported (e.g. in diffuse low grade astrocytomas, the presence of gemistocytes is 
related to more rapid malignant transformation).
 23
 The fraction of Ki-67 positive tumor cells is a 
proliferation marker which correlates with higher grade gliomas and poorer survival.
 24 
Over the past few 
years, several molecular characteristics have been identified that complement pathological diagnosis and 
provide a better understanding of disease biology. Among them, the loss of heterozygosity (LOH) on 
chromosome 1p and 19q is a genetic alteration reported with positive prognostic effect in patients with 
oligodendroglioma.
25
 Many reports have confirmed the value of 1p/19q LOH as a predictor of response to 
chemotherapy.
26 
A large EORTC study showed that GBM patients with MGMT promoter gene methylation 
had a superior clinical outcome when they were treated by chemo-irradiation with temozolomide (TMZ) 
compared to patients with unmethylated MGMT genes or those treated with radiotherapy alone 
independently of their MGMT methylation status.
27,28
 Fewer reports evaluated the prognostic and/or 
predictive value of MGMT methylation in other grades and types. Results are controversial and still need 
confirmation in prospective clinical trials. 
29,30
 Epidermal Growth Factor Receptor (EGFR) amplification 
distribution is different between grades and types and might also help better distinguishing between 
pathological entities when inter-observer variability is high e.g. to differentiate oligoastrocytomas (AOA) 
from GBM. Recent updates on prognostic and predictive value of molecular markers in neuro-oncology 
were presented in van den Bent et al (2007).
31
   
 
1.7 Development of statistical prognostic models 
 
Many sources of uncertainty prevent the precise prediction of the outcome of individual patient. At best, is it 
possible to quantify the chance for a patient to reach or not a certain outcome (e.g. being free of disease 
progression at a certain time point) based on statistical prognostic models developed on data from groups of 
patients with the same disease or similar characteristics. The development of a statistical prognostic model is 
a complex multistep process and finally, it is not sure that such model will provide accurate individual 
predictions. The most obvious cause of failure is the absence of unknown important predictors in the model 
but other critical reasons of inaccuracy are the violations of the assumptions underlying the statistical model 
and in small datasets, the risk of overfitting i.e. of describing random fluctuations rather than true 
relationships with the outcome. In the current work, the guidelines developed by F. Harrell et al. (1996) 
were applied.
32
 The sections below explain and describe the statistical techniques used in this thesis to 
analyse survival data. 
 
1.7.1 Cox regression model  
 
Regression modeling is commonly used to establish the relationship between an outcome variable and 
candidate prognostic factors. The term "regression" was created by Francis Galton in the nineteenth century 
to describe the phenomenon that the heights of descendants of tall ancestors tend to regress down towards a 
normal average, a phenomenon also known as regression toward the mean.
 33 
The selection of a regression 
model depends on the measurement scale of the outcome variable (i.e. binary, categorical, continuous, time 
to event,…). Survival models relate the time that passes before some event occurs (e.g. death) to one or 
more factors that may be associated with that quantity. If the event can’t be observed during the study period 
or if the patient is lost to follow-up, survival times are declared right-censored. The Cox regression model is 
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a popular model used in survival modeling. It relates possibly influential prognostic factors to survival times 
through the hazard function defined as the individual rate of failure measured over an infinitely short period 
of time.
34
  In addition, the impact of these factors on important clinical measurements (such as median 
survival) can be described. In the Cox model, the hazard for individual i is expressed as the product of two 
functions: 
 
) x + · · · +  x +  xexp(  (t)h = (t)h ikki22i110i   
 
h0(t) is the baseline hazard function that describes the risk at time t for individuals with all factors equal to 0 
(exp(0)=1) which serves as a reference, and exp{βxi} is the relative risk, a proportionate increase or 
reduction in risk, associated with a set of individual factors xi. It insures that the hazard function remains 
positive. In Cox model, the ratio of two individual hazards is proportional and independent of time. The Cox 
model is therefore often referred to as the proportional hazards (PH) model.  
 
1.7.2 Checking Cox model assumptions 
 
Cox regression model relies on a set of statistical assumptions. Violation of these assumptions can severely 
invalidate study results. In Cox model, it is assumed that censoring is non-informative. To satisfy this 
assumption, the design of the underlying study must ensure that the mechanisms giving rise to censoring of 
individual subjects are not related to the probability of an event occurring i.e.  the duration of follow-up does 
not depend on patient outcome. Other assumptions are the linearity and additivity which are implicit in the 
linear predictor “βxi” and finally PH assumption. If this last assumption is severely violated, the Cox model 
is incorrect and a more sophisticated analysis is required to estimate the factor effects.  
The assumption of non-informative censoring can generally be assumed in data collected from randomized 
control cancer trial where disease is assessed according to pre-specified schedules and/or most patients are 
followed until death. Other assumptions are evaluated by graphical methods and/or statistical testing. The 
simplest way to assess proportional hazards assumption is to examine classical Kaplan Meier curves split by 
the categories of the factor, For instance, for PH assumption to hold, low grade glioma patients enrolled in 
EORTC 22844 or 22845 trials with mental disturbance caused by their disease with twice the risk of dying 
one year after enrollment in the trial compared to patients without the mental disturbance, should also have 
twice the risk of death at any other time (Figure I.1).  
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Figure I.1: PFS split by mental disturbance status. 
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The PH property can be more effectively assessed by examining the log cumulative hazard plot over the log 
survival time (log(-log)). As can be seen below, under the proportional hazards model, the transformation 
will result in a straight line.  
 
exp(bx) (t)S=S(t) 0  
))((-log(S exp(bx)-log(S(t))=H(t) 0 t  
))(log(-log(Sbx(t)))log(-log(S 0 t  
 
In case of the two mental disturbance statuses, two (almost) straight and parallel lines indicate that PH 
assumptions are valid and the factor can enter a Cox model (Figure I.2).   
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Figure I.2: Log-minus-log SDF vs log survival time plot split by mental disturbance status. 
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Residuals are quantities which can be used to check model assumptions. In linear or other regression 
models, residuals are defined as the difference between observed and values predicted by the model. As 
there is no obvious analog for PH model, different alternative methods have been developed.
35,36
 Schoenfeld 
proposed the first set of residuals for PH models.
 37 
Schoenfeld residuals are computed for each patient and 
for each factor based on the individual contributions to the derivative of the log partial likelihood function. 
The Schoenfeld residual is the value of a factor k for an individual i (xik ) who actually died at time ti minus 
the weighted average of the factor expected value for all individual at risk at time ti. Weights are defined by 
each individual’s likelihood of dying at ti  
 




)(
1
residual Schoenfeld
itRj
i
jkjik pxx  
 
By definition, Schoenfeld residuals are not defined for censored individuals. Gramsch and Therneau 
proposed to increase the diagnostic power of Schoenfeld residuals by scaling them with an estimator of the 
variance of the residuals. 
38 
Since the Schoenfeld residuals are, in principle, independent of time, a plot that 
shows a non-random pattern against time (a trend) is evidence of PH assumption violation. In practice, if PH 
assumptions hold then scaled Schoenfeld residuals 95% Confidence Intervals should exclude zero in only 
small and unrelated period of time. This is illustrated below with the mental disturbance status (Figure I.3). 
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Figure I.3: Scaled Schoenfeld residuals over time for the mental disturbance status.
 
 
 
Lin, Wei, and Ying developed graphical and numerical methods for checking the PH assumptions of each 
candidate prognostic factor in a Cox model. The methods are derived from cumulative sums of martingale 
residuals over follow-up times. A martingale is a sequence of random measurements (i.e. a stochastic 
process) for which the knowledge of current and previous events does not help to predict future events. On 
average the future value of the process is equal to the current value of the process. The future is not 
predictable based on the process history. Martingale residuals are defined for each patient as the difference 
at time t between the observed and expected number of events under the PH assumption. They can be 
considered as an estimate of the excess number of events seen in the data but not predicted by the model.  
For each factor, the plot of the standardized score process, a function of the martingale residuals, over time 
of both processes observed from the data and simulated gaussian processes under PH assumption allow 
assessing departure from PH assumptions.
39  
Global statistical significance of this departure is estimated by 
the Kolmogorov-type supremum test. In the example of the mental disturbance, the observed standardized 
score process does not significantly differ from the simulated process under the null hypothesis of PH 
assumptions. This results is confirmed by a non-significant supremum test (p=0.16, figure I.4). 
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Figure I.4: Standardized Score Process and Supremum test for the mental disturbance status. 
 
 
 
This technique also allows to test the functional form of a factor e.g. if the relationship between the factor 
and the outcome is linear or if more sophisticated function should be used. In this thesis, linearity was 
assessed by visual inspection of the Kaplan-Meier curves and the log(-log) plots. 
 
1.7.2 Factor selection and use of bootstrap resampling technique for model building 
 
Being ‘parsimonious’, i.e. selecting only factors which significantly influence patient outcome is a desirable 
property of statistical prognostic models. Several techniques were developed to select factors. In this thesis, 
automated stepwise or backward elimination techniques were used. Backward elimination begins with a 
model in which all candidate variables have been included (the full model). At each step, the variable that is 
the least significant is removed. This process continues until no non-significant variables remain. Stepwise 
elimination starts from a model without factor. A new factor is entered until a prespecified critical 
significance level is reached. The factor with the largest p-value can be removed if the p-value exceeds the 
specified significance level. Though they often do, there is no guarantee that backward and stepwise will 
produce the same final model. Getting different final models can be due to too small sample sizel and/or 
factors strongly correlated. Alternatively, getting the same model does not imply that the “best” model was 
identified. An explanation for these differences might be that none of these automatic procedures do 
preserve the overall significance of the model. P-values provided for each factor are generally too optimistic 
(i.e. too small) because they don’t account for the multiple tests which were performed to obtain the final 
model. As a consequence, some factors of poor importance might still remain in the model (false positives). 
Bootstrap technique can be used to assess the importance of a factor in the model. The bootstrap is a 
simulation technique first described by Bradley Efron.
40
 The idea is that the original dataset is a random 
Introduction  
 
20 
 
sample of patients representative of a general population. Bootstrapping means generating a large number of 
datasets (e.g 1000) each of which with the same sample size as the original by resampling from it with 
replacement (ie. a patient may be selected multiple times, some patients might not be included). Cox model 
is fitted to each bootstrap sample. The percentage of the samples with the factor included in the model by 
stepwise or backward selection is a criterion for the prognostic importance of this factor. It can be 
interpreted in a Bayesian way as an estimate of the posterior probability that the regression coefficients of 
the Cox model are truly different from zero (Figure I.5). The inclusion of a factor at a selection level of 5% 
in the original data is equivalent to a cut-off value of 50% for the bootstrap inclusion fraction using a 
selection level of 5% in each replication. In this work, we used a higher but not too conservative cut-off of 
60%, meaning that for a factor to be included in the final cox model, it needed to be selected in at least 60% 
of bootstrap resampling. 
41
  
 
Figure I.5: The concept of bootstrap. 
 
 
 
1.7.3 Assessing model predictive accuracy 
 
A strong statistical relationship between an outcome and a prognostic factor characterized by small p-values 
in a regression model or large odd or hazard ratios does not necessarily mean that the factor can accurately 
separates patients who are likely to have the event (e.g. have disease progression within 2 years) from those 
who are unlikely to have it (e.g. be free of disease progression at year 2). Pepe et al (2004) showed for a 
binary outcome that in order to obtain reasonable classification accuracy characterized by a False Positive 
Fraction (FPF) equal to 10% and a True Positive Fraction (TPF) equal to 80%, an odd ratio (OR) of 36.0 
was necessary. 
42
 Even with an OR as large as 36.0, one can’t conclude that a marker has a good accuracy as 
a many different values of (FPF, TPF) are consistent with it (see OR formula below). An unacceptably high 
FPF equal 50% and TPF equal 97.3 % also yields to 36.0. These results are indepentent from the study 
sample size.   
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Appropriate methods and indicators must be used to assess biomarker or model performance.  
Table I-1 below summarizes the relationship between an outcome (progression and/or survival status) and a 
binary biomarker (M+ vs M-). It is assumed that M+ predicts for patient who progressed or died.  
 
Table I-1: Definition of accuracy terms 
 
 Progressed or died Free of progression and alive  
 Positive prediction condition Negative prediction condition Total 
M+ True Positive Fraction (TPF) False Positive Fraction (FPF) 
Type I error=1-specificity 
Positive Predictive Value 
PPV =TPF/(TPF+FPF) 
M- False Negative Fraction (FNF) 
Type II error=1-sensitivity 
True Negative Fraction  (TNF) Negative Predictive Value 
NPV = TNF/(FNF+TNF) 
 Sensitivity=TPF/(TPF+FNF) Specificity=TNF/(FPF+TNF)  
Note:  M-  :biomarker negative, M+ biomarker positive,   
 
Sensitivity measures the fraction of true positives which are correctly identified as such (e.g. the percentage 
of patients who progressed or died who are correctly identified as having this condition). Specificity 
measures the fraction of true negatives which are correctly identified (e.g. the percentage of patients free of 
progression and alive who are correctly identified as having this condition). These two measures are closely 
related to the type I and type II errors. A test with a high sensitivity has a low type II error rate (high power). 
A test with a high specificity has a low type I error rate.  The positive predictive value (PPV) is the fraction 
of patients with biomarker M+ that are true positives (progressed or died). The negative predictive value 
(NPV) is the fraction of patients with biomarker M- that are true negatives (free of progression or alive). A 
high PPV (e.g. 90%) indicates that many M+ are true positives. In this situation, the biomarker can precisely 
predict if a patient will progress or die (case). A high NPV indicates that many M- are true negatives. In this 
case, a biomarker can precisely predict if a patient will remain non progressive and alive. PPV/NPV are 
related to sensitivity/specificity by the prevalence of the outcome (total fraction of patients who progressed 
or died).  
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E.g. keeping sensitivity/specificity constant, a lower (higher) prevalence corresponds to a lower (higher) 
PPV.  
 
For continuous biomarkers, Receiver operating characteristic (ROC) curve is a natural generalization of 
(FPF, TPF). In a ROC curve TPF (Sensitivity) is plotted in function of the FPF (1-Specificity) for different 
cut-off points “c” of a biomarker (M+ if  c, M- if < c). Each point on the ROC curve represents a TPF/FPF 
pair corresponding to a particular cut-off. The closer the ROC curve is to the upper left corner, the higher the 
accuracy of the biomarker to predict the outcome. The area under the ROC curve (AUC) is the surface 
between the curve and the diagonal (TPF=FPF) plus 50%. It is a measure of how well a biomarker can 
distinguish between two outcome groups (progressive or dead/free of progression and alive).  Unlike OR, 
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ROC curve or AUC do not depend on the units in which the biomarker was measured. They therefore 
provide natural common scales for comparing different biomarkers. In the example below biomarker N is 
better than M to discriminate between two outcome groups. 
   
Figure I.6: ROC curves for two continuous biomarkers.  
 
 
In survival analysis, the presence of censored times, makes the calculation of AUC more complex. The 
concordance index (C-index) introduced by Harrell (1996) is a natural extension of the ROC curve.
32
 It is 
defined as the probability of concordance given that the pairs considered are usable in which at least one had 
an event. It can be interpreted as the probability that a subject from the event group has a higher predicted 
probability of having an event than a subject from the non-event (censored) group. C-index = 50% implies 
no predictive ability. C-index>0.5 implies some predictive ability, the higher the C-index the better the 
predictive ability. C-index= 100% implies a perfect predictive ability which is rarely observed. Bootstrap 
technique is also used for model internal validition in order to correct the C-index for “optimism”. The 
procedure is straightforward. Using the same selection methods, Cox models are built on each bootstrap 
sample (training set) and evaluated in the full sample (test sets). The difference between the C-index in the 
bootstrap sample and the C-index in the full sample is computed. This process is repeated for each bootstrap 
sample (e.g 1000 times). The “optimism” is computed as the average of all the differences. A C-index 
corrected for overfitting is obtained by subtracting the optimism from the original C-index.   
Both AUC and C-index are often described as measures to assess model “discrimination”. Indeed, these 
measures allow classify or rank different individual patients based on their outcome. Another key statistics 
that describes model predictive accuracy is “calibration”. Calibration refers to the extent of bias of a model. 
It is the degree of correspondence between the estimated probability produced by the model and the actual 
observed probability. If the average predicted probability of progression or death is 40% for a group of 
similar patients and the fraction of patients who actually progressed or died is 40% than the model is well 
calibrated for this group of patients. Poor calibration can occur in highly discriminating models when the 
output is transformed monotonically. Indeed, if all predictions were divided by 10 i.e. if someone with a 
40% risk of progression or death was predicted with a 4% risk, the new model would have the same 
discrimination but would be poorly calibrated. Calibration can be corrected by using a shrinkage parameter 
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but no technique can correct for a lack of discrimination.
32
 Calibration can be assessed by plotting the 
fraction of patients observed with the outcome (i.e. without the event) against the fraction of patients 
predicted with it (dots ). Bootstrap technique can also be used to obtain overfitting-corrected predictions 
(). In a well calibrated model , all ()  should not be too far from the 45° line. This line should be included 
in the ninety five percent confidence intervals of the observed fraction for a particular predicted group of 
patients   (e.g. those with 40% risk of progression or death) (Figure I.7).  
 
Figure I.7: Prognostic model calibration plot. 
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Models with good discrimination and calibration can nevertheless provide survival probability estimates 
which can be highly variable between patients. The proportion of explained variation (PEV), is the amount 
of variation of the outcome variable that is attributable to one or more factors or a full prognostic model, 
relative to the total variation of the outcome variable. In linear regression model, R
2
 is frequently used as a 
measure of explained variation. In Cox regression several methods have been proposed. One of them is the 
measure V by Schemper and Henderson (2000).
43 
 
Let’s assume S(t) is the survival probability function at a time t. S(t|x) is this function conditioned to a factor 
x. f(t) and f(t|x) are the associated density functions i.e. the rates of death or failure events per unit time 
unconditional or conditional to factors x, obtained by computing the first derivative of the function 1-S(t) or 
1-S(t|x)). The marginal and conditional mean absolute deviation are 2 S(t){1-S(t)} and 2 S(t|x){1-S(t|x)} 
respectively. They measure the average absolute distance between the true survival status and the survival 
probability. Taking (0,τ) as the global follow-up period, Schemper et al suggested D(τ) and D(τ|x) as 
measure of marginal and conditional predictive accuracy. 
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marginal and conditional predictive accuracy can be compared to quantify the added value provided by the 
factors. The proportion of variation explained (PEV) by factors x is the ratio 
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For Heinze and Schemper (2000), A PEV of at least 20% is considered a minimum requirement for a model 
to provide “sufficiently precise individual survival predictions”.44 
 
 
1.7.4 Building nomograms and prognostic calculators  
 
According to the Wikipedia definition, a nomogram is a graphical calculating device, a two-dimensional 
diagram designed to allow the approximate graphical computation of a function (sic).
45
  
A nomogram is thus a graphical representation of a function or model but not the model by itself. See 
examples of nomograms for glioblastoma patients in chapter 5. In this thesis, the Cox models were used to 
compute for each patient a linear predictor (LPj) obtained by summing up the products between the 
characteristic i of patient j (xij) and corresponding Cox coefficient (βi):  
 

i
ijij xLP *  
Baseline value LPj  equals 0 and corresponds to the best prognosis patients.  
For each factor, prognostic scores can be computed with the following formula: 
 
100*
*
 i sticcharacteri of each valuefor  score Prognostic


iji x
 
 
Where B is the Cox coefficient corresponding to the factor with the maximum product βi*xij. 
A prognostic score should not be interpreted as if to a high score should correspond a highly influential 
prognostic factors. Nomograms rank the importance of a factor only in the context of other factors. The total 
number of points for each patient is obtained by summing the prognostic scores for each of the individual 
factors included in the nomogram. Summary statistics like median or x-year probabilities are obtained by 
drawing a vertical line from the “total points” axis straight down to the outcome axes. With the advance of 
internet technology, it is now possible to obtain these summary statistics by entering patient individual 
characteristics in online prognostic calculators (see EORTC webpage at http://www.eortc.org/investigators-
area/prognostic-calculators). An advantage of online calculators is that summary statistics can be presented 
with their 95% confidence intervals (CI). Ninety five percent CI are generally not available in statistical 
packages for building nomograms. A disadvantage is that it does not provide an indication of the relative 
importance of each factor. Neither nomograms nor calculators provide an evaluation of the predictive 
performances of prognostic models or the fraction of outcome variation explained by a factor. This 
information is obtained by estimating and interpreting parameters like C-index or PEV (see 1.7.3).   
 
1.7.6 External validation of statistical prognostic models 
 
Validating a statistical prognostic model means assessing its ability to predict the outcome of patients 
different from those used to develop the model. There are different reasons why statistical prognostic model 
might not perform well in other patients. Prognostic modeling unlike properly designed clinical trials are 
non-prespecified and data driven analyses. They generally provide overoptimistic estimation of their true 
predictive performance when it is assessed in the development dataset. As discussed earlier, internal 
validation partially fixes this problem by providing bias corrected model performance estimations. But the 
method fails when sample size of the development dataset is too small. 
46,47 
Simulation studies showed that 
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having 10 to 20 events (e.g. deaths) per factor screened could reduce the risks of both false negative and 
positive factor inclusion, i.e. selecting unimportant factors and failing to include important ones.
32
 Finally, 
patients in the development dataset might not be completely representative of the population with the 
disease. Models are generally developed based on clinical trial data and in selected centers. Their predictions 
might be biased for community patients excluded from clinical studies (e.g. frail patients or presenting with 
comorbidities) or for patients from other centers with a different mix of individual and disease 
characteristics. One can never be sure that the model includes all important factors for all centers. All these 
issues strongly argue to perform an evaluation of model performance on a new series of patients in different 
hospitals, preferably in different locations. Altman and Royston (2000) provides guidelines on how to 
validate a prognostic model which were used in this thesis.
48
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Organization For Research and Treatment of Cancer Trial 26951: assessment of 
consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J 
Neuropathol Exp Neurol. 2007 Jun;66(6):545-51. 
 
2.1 Abstract 
 
The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to 
interobserver variation. The aim of this study was to estimate consensus in typing and grading of these 
tumors using tumor material collected in a large prospective randomized phase III study and to correlate the 
consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome. The available pathology 
material of the first 150 patients, randomized into the European Organization for Research and Treatment of 
Cancer Trial 26951, was reviewed by an independent panel of 9 neuropathologists. The presence of 
deletions of 1p and 19q was assessed by fluorescence in situ hybridization with locus-specific probes. The 
panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by 
the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus. The 
concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%). The survival curves for 
AOD with 1p/19q loss, AOD without these losses, and AOA without 1p/19q loss ran separately in this order. 
The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. 
In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic 
factors. 
 
2.2 Introduction 
 
Following the observation that anaplastic oligodendroglioma (AOD) and anaplastic  oligoastrocytoma 
(AOA) are sensitive to chemotherapy with procarbazine, 1-(2-chloroethyl- 3-cyclohexyl-1-nitrosourea, and 
vincristine (PCV), in 1995 the European Organization for Research and Treatment of Cancer (EORTC) 
Brain Tumor Group initiated a prospective randomized trial in which the effects of the addition of 6 cycles 
of standard PCV chemotherapy to 59.4 Gy radiotherapy in newly diagnosed AOD and AOA were 
investigated. In this trial, in which 368 patients were included, it was shown that the addition of PCV 
chemotherapy increased the progression-free survival, but not the overall survival
1
. A central pathology 
review was part of the design of this trial. Patients were eligible for inclusion if their diagnosis of either 
AOD or AOA had been made in their local hospital. Because the diagnosis of AOD is subject to significant 
inter-observer variation with respect to assessment of tumor lineage and grade, we used this prospective trial 
to assess interobserver variation with regard to classification and grading of oligodendroglial tumors in a 
subset of patients from this trial. For this review, a panel of 9 independent and expert neuropathologists was 
installed, including the central reviewer of the pathologic material for EORTC Trial 26951. The 9 
neuropathologists performed their review of the slides independent of each other and in ignorance of any 
clinical information. No selection of the available pathology material was made before the review; the slides 
were reviewed in just the state they had been received from the local pathologists. We investigated the 
consensus on the overall diagnosis and on individual histologic parameters. The consensus features and 
diagnoses were related to the 1p/19q status of the tumors and the clinical outcome of the patients.
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2.3 Materials and methods 
 
Design of European Organization for Research and Treatment of Cancer Trial 26951 
 
For the design and approvals of EORTC Trial 26951 we refer the reader to Reference 1.  
 
Pathology 
 
For the central pathology review, the centers were required to submit hematoxylin and eosin (H&E)-stained 
slides and either tumor blocks or 10 to 15 unstained slides. Amendment 3 of the study (dated March 21, 
2001) described the assessment of chromosomal loss of 1p and 19q within the study, with the objectives to 
assess the relation of 1p/19q loss with progression-free survival and with overall survival. For the 
assessment of 1p and 19q status, fluorescent in situ hybridization was applied as described previously 
1,2
.  
 
Panel Review 
 
The histopathologic diagnoses made by local pathologists and used to include patients in the trial were AOD 
and AOA. Paraffin-embedded and H&E-stained tumor sections of 114 patients were used for the panel 
review. For the pathology review, a panel of 8 expert neuropathologists (VPC, DF-B, FG, CG, KM, SJM, 
AP, and GR) was formed. The initial central review was done by JMK. The 9 neuropathologists performed 
their review of the slides independent of each other and in ignorance of any clinical information. Further, no 
selection of the slides was made before the review; the H&E-stained slides were reviewed in the state in 
which they had been received from the local pathologist. The original reports or diagnoses of the local 
pathologists were not communicated with the panelists. The reviewers were asked to classify the tumors 
according to the World Health Organization 2000 guidelines 
3
. In addition, they were asked to grade the 
tumors by scoring 5 histologic features (i.e. nuclear pleomorphism, cell density, mitoses, endothelial 
abnormalities, and necrosis) in a simple yes-no fashion. As a result of the review, the diagnostic categories 
that emerged were low-grade glioma (LGG) (including low-grade astrocytoma [LA], low-grade 
oligodendroglioma [LOD], and low-grade mixed oligoastrocytoma [LOA]), anaplastic astrocytoma (AA), 
anaplastic oligodendroglioma (AOD), anaplastic mixed oligoastrocytoma (AOA), glioblastoma (GBM), and 
a category of “other” diagnoses (for instance, ependymoma). Consensus diagnosis of the review panel was 
defined as 6 or more of the 9 reviewers agreeing on a diagnosis of a particular case, a majority diagnosis was 
defined as 4 or 5 reviewers agreeing on a diagnosis of a particular case, and cases were called indeterminate 
if only 3 or fewer reviewers made the same diagnosis. 
 
Statistical Analysis 
 
The distributions of diagnoses and scores of the panelists (including those of the central reviewer) were first 
assessed. Intraclass correlations (ICCs)
4
 were used as chance corrected measures of agreement on the 
diagnosis (coded as AOD or not) and on each feature (coded as present or absent). ICCs and 95% 
confidence intervals were computed on the basis of the variance components of 2-way design general linear 
models, allowing for breaking the global variability into that between patients and between panelists. ICCs 
of 1p/19q loss were also computed separately in each group. ICC80 was considered as an excellent 
agreement. Exact confidence intervals were computed for the proportion of cases with 1p, 19q, and both 
1p/19q loss in each diagnosis. Fisher`s exact test was used for comparison of proportions. The agreement 
between each reviewer (including the initial review made by the local pathologists) and the consensus was 
measured by a  coefficient. A  coefficient < 60 was considered a poor agreement. The Kaplan-Meier 
technique and logrank test were used to assess the prognostic value of the diagnoses and individual 
histologic features. The Cox proportional hazards model was fitted on the consensus diagnosis and features 
as well as available clinical factors to identify independent prognosticators of survival. 
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2.4 Results 
 
Clinical Data 
 
The clinical characteristics and survival outcome of the 114 patients for whom the pathology material was 
available for review were representative of the entire group of 368 patients. There were 60 male patients 
(53%) and 54 female patients (47%). Forty percent of tumors were located in the frontal, 25% in the parietal, 
and 18% in the temporal lobes. Other locations included occipital lobes (3%), basal ganglia and cerebellum 
(1 patient), and corpus callosum (2 patients). Of the patients, 16% had undergone a biopsy only. Enhancing 
tumors were more frequent in the subset of the present study, but tumor enhancement was not found to be of 
prognostic value 
1
 and was therefore not considered as a bias. The local pathologists had diagnosed AOD in 
89 of the 114 cases (78%) and AOA in 25 cases (22%).  
 
Results of Panel Review 
 
Table II-1 shows the distribution of diagnoses made by the 9 reviewers and local pathologists. The 
percentage of AOD as diagnosed by the reviewers varied from 33% to 68% of all cases reviewed and the 
percentage of AOA varied from 7% to 34%. Diagnoses other than AOD or AOA made by the panelists 
included AA (0%-5%), GBM (1%-27%), LOD (1%-11%), LA (0%-2%), and LOA (0%-4%). Other 
diagnoses, such as ependymoma, were made in 1% to 17% of patients (Table II-1). The local pathologists 
had made the diagnosis AOD in 89 of the 114 cases. In 46 of these 89 cases (52%), the panel reached 
consensus and confirmed the diagnosis of AOD (Table II-2). In 9 cases (10%), the AOD diagnosis was 
confirmed with majority agreement. In 22 cases (35%), the reviewers reached a consensus or a majority 
diagnosis that was different from AOD, whereas in the other 12 cases (13%), no consensus or majority 
diagnosis was reached. Overall, consensus and majority diagnoses other than AOD included AOA in 8 
cases, LGG (i.e. LOD, LA, and LOA) in 7 cases, and GBM in 5 cases, and in 2 cases other diagnoses (e.g. 
ependymoma) were made (Table II-2). In 25 of the 114 cases, the diagnosis of AOA was made by the local 
pathologists. In only 2 of these cases (8%), was there consensus among the panelists on this diagnosis (Table 
II-2). In 8 cases (32%), the panel reached a majority diagnosis of AOA. In 2 cases (8%), the diagnosis of 
AOA was mentioned, but only by 3 or fewer reviewers. Panel consensus or majority diagnoses other than 
AOA included AOD in 8 cases; LGG in 1 case, and GBM in 1 case (Table II-2). The agreement of each of 
the individual panelists with the 52 consensus diagnoses of AOD is shown in Table II-3. The  coefficients 
ranged from 46.2 to 72.1. The ICC of the diagnosis AOD was 86.4 (95% confidence interval 80.8-89.0). 
Five reviewers (R2, R4, R6, R7, and R9) had poor agreement with consensus diagnoses (Table II-3). R2, R6, 
and R7 disagreed more often on the non-AOD diagnosis, whereas R9 more frequently disagreed on the 
AOD diagnosis. The  coefficient between consensus and local diagnoses was as low as 18.1, showing 
excellent agreement on the AOD diagnosis but poor agreement on the non-AOD diagnosis (Table II-3). 
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Table II-1: Distribution of the diagnoses made by the 9 reviewers and the local pathologists. 
 
 
 R1 R2 R3 R4 R5 R6 R7 R8 R9 Local 
Pathologist 
AOD (%) 47 62 46 47 54 63 68 54 33 78 
AOA (%) 25 18 7 17 24 15 9 34 18 22 
AA (%) 5 0 3 4 2 2 0 0 11 0 
GBM (%) 6 9 21 4 2 16 1 2 27 0 
LOD (%) 5 6 8 11 5 1 8 3 1 0 
LA (%) 0 0 1 1 2 0 0 1 1 0 
LOA (%) 2 0 1 4 4 0 3 4 2 0 
Other (%) 9 2 7 6 6 3 2 1 17 0 
The diagnosis of AOD, which was made in 78% of cases by the local pathologists, was confirmed in percentages varying 
from 33% to 68%; the diagnosis of AOA made in 22% of cases by the local pathologists was confirmed in only 7% to 34% 
of cases. R5 is the central reviewer of European Organization for Research and Treatment of Cancer Trial 26951. R1YR4 
and R6YR9 are the additional reviewers involved in this study. 
AA, anaplastic astrocytoma; AOA, anaplastic mixed oligoastrocytoma; AOD, anaplastic oligodendroglioma; GBM, 
glioblastoma; LA, low-grade astrocytoma; LOA, low-grade mixed oligoastrocytoma; LOD, low-grade oligodendroglioma. 
 
 
Table II-2: Results of Panel Review. 
 
 
Diagnosis y local 
pathologist 
Panel diagnosis Consensus 
diagnosis 
Majority 
diagnosis 
Intermediate 
diagnosis 
Total 
AOD AOD 46(52) 9(10) 1(1) 56(63) 
 AOA 2(2) 6(7) 3(3) 11(12) 
 LGG 1(1) 6(7) 2(2) 9(10) 
 AA 0(0) 0(0) 0(0) 0(0) 
 GBM 1(1) 4(4) 5(6) 10(11) 
 Other 0(0) 2(2) 1(0) 3(3) 
 Subtotal 50(56) 27(30) 12(16) 89(78) 
AOA AOD 6(24) 2(8) 0(0) 8(32) 
 AOA 2(8) 8(32) 2(8) 12(48) 
 LGG 0(0) 1(4) 1(4) 2(8) 
 AA 0(0) 0(0) 0(0) 0(0) 
 GBM 0(0) 1(4) 2(8) 3(12) 
 Other 0(0) 0(0) 0(0) 0(0) 
 Subtotal 8(32) 12(48) 5(20) 25(22) 
Total  58(51) 39(34) 17(15) 114(100) 
Data are n (%). Although appearing in diagnoses lists of individual panelists, the diagnoses “AA” and “other” were never 
made by consensus or the majority of panelists. 
“Consensus Diagnosis” indicates that 6 or more of the 9 reviewers agreed on the diagnosis. “Majority Diagnosis” 
indicates that 4 or 5 reviewers of the 9 reviewers agreed on the diagnosis. “Indeterminate Diagnosis” indicates that 3 or 
fewer reviewers made the same diagnosis. 
AA, anaplastic astrocytoma; AOA, anaplastic mixed oligoastrocytoma; AOD, anaplastic oligodendroglioma; GBM, 
glioblastoma; LGG, low-grade glioma (i.e. low-grade oligodendroglioma, low-grade mixed oligoastrocytoma, and low-
grade astrocytoma). 
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Table II-3: Agreement of the 9 reviewers with the consensus diagnosis of AOD. 
 
 
 Consensus vs Individual Diagnosis  
 Agreement on positive 
diagnosis of AOD 
Agreement on negative 
diagnosis of AOD 
 
Coefficient 
 (n=52) (%) (n=62) (%)  
R1 87 85 71.8 
R2 92 63 53.6 
R3 83 84 66.5 
R4 77 77 54.2 
R5* 92 77 68.7 
R6 89 59 46.2 
R7 94 55 47.2 
R8 92 81 72.1 
R9 65 94 59.7 
Local 88 31 18.1 
*, R5 is the central reviewer (JMK) of European Organization for Research and Treatment of Cancer Trial 26951. R1Y4 
and R6Y9 are the additional reviewers for this study. Reviewers R2, R4, R6, R7, and R9 had poor agreement with 
consensus diagnoses. 
    
Fluorescence In Situ Hybridization for 1p and 19q 
 
Fluorescence in situ hybridization analysis was not possible in 6% of cases because of lack of available 
material or because the test results could not be interpreted. The frequencies for loss of 1p only, loss of 19q 
only, and combined loss of 1p/19q are listed in Table II-4. For AOD the consensus diagnosis was 
exclusively used, for AOA the consensus and majority diagnosis were used, and for GBM and LGG only 
majority diagnoses were available. Combined loss of 1p/19q was found in 35% of AOD, in 11% of AOA, in 
0% of GBM, and in 50% of LGG. Loss of 1p only was never seen in GBM, whereas loss of 19q was seen in 
one third of these tumors. Loss of 1p and combined loss of 1p/19q was found significantly more often in 
AOD than in AOA or GBM (p = 0.02; p = 0.04). The difference was borderline non-significant for loss of 
19q (p = 0.07) (Table II-4).  
 
Table II-4: Distribution of losses of 1p,19q, combined 1p/19q in the consensus and majority diagnostic. 
 
 AOD (n=50)*† AOA (n=17)†‡ GBM (n=6)‡ LGG (n=8)§  
  95% CI  95% CI  95% CI  95% CI Proportion 
in AOD 
vs in 
AOA or 
GBM (p)¶ 
 n(%) (%)|| n(%) (%) n(%) (%) n(%) (%) 
1p loss 
(irrespective 
of 19q loss) 
27 (52) 38-66 5(28) 10-53 0(0) 0-0 6(75) 35-97 0.02 
19q loss 
(irrespective 
of 1p loss) 
22(42) 29-57 2(11) 1-35 2(33) 4-78 4(50) 16-84 0.07 
Combined 
1p/19q loss 
18(35) 22-49 2(11) 1-35 0(0) 0-0 4(50) 16-84 0.04 
*, Consensus diagnosis. 
†, Two of the 52 (consensus) AODs and 1 of the (consensus and majority) AOAs could not be processed for genotyping.  
‡, Consensus and majority diagnosis. 
§, Majority diagnosis. 
¶, Fisher`s exact test. 
||, Exact 95% confidence interval of the proportion. 
AOA, anaplastic mixed oligoastrocytoma; AOD, anaplastic oligodendroglioma; CI, confidence interval; GBM, 
glioblastoma; LGG, low-grade glioma. 
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Consensus on Individual Histologic Features 
 
The ICCs and 95% confidence intervals for consensus on individual histologic features of AOD are 
summarized in Table II-5. Most reviewers scored the feature of nuclear abnormalities as being present in 
100% of cases, and for that reason this feature was excluded from further analysis. 
The ICC for the feature necrosis was highest, and this was the case for the tumors with and without loss of 
1p/19q. The feature of mitotic count scored lowest, whereas cell density and endothelial abnormalities took 
intermediate positions in the ICC rankings. Except for the feature of endothelial abnormalities, the ICCs for 
all other features were slightly higher in the tumors with retention of 1p/19q, but differences were not 
statistically significant (Table II-5). 
 
Table II-5: Intraclass Correlation for the histologic features in (consensus) AOD. 
 
 
 Intraclass Correlation (95% Confidence Interval) (%) 
 All 1p/19q loss 1p/19q retained 
Diagnosis of AOD 86.4(80.8-89.0) 83.4(70.4-91.3) 86(79.1-89.2) 
Necrosis 92.4(89.6-94.0) 90.0(82.0-94.7) 93.3(90.4-95.0) 
Endothelial abnormalities 86.7(79.8-88.4) 87.5(73.2-92.1) 86.7(79.2-89.2) 
High cellularity 85.1(79.4-88.2) 79.7(60.1-88.3) 87.2(81.8-90.6) 
Mitoses 84.4(78.2-87.5) 77.6(57.5-87.5) 85.1(78.4-88.8) 
 
Prognostic Relevance of Tumor Typing, Tumor Grading, and Individual Histopathologic Features 
 
The survival curves for the respective consensus and majority diagnoses, irrespective of 1p/19q status, are 
shown in Figure II.1. The curve of AOD is separated from the intertwined curves of the AOAs and the 
GBMs. A small group of low-grade gliomas (i.e. LOD, LA, and LOA) showed the best survival (Figure 
II.1). The Kaplan-Meier curves for AOD and AOA with and without 1p/19q loss (the single AOA with 
1p/19q loss is left out) are shown in Figure II.2. The curve for AOD without 1p/19q was intermediate 
between that for AOD with loss of 1p/19q and AOA without loss of 1p/19 (Figure II.2). The p values for the 
differences between the respective survival curves according to the histologic features are listed in Table II-
6. Only features on which consensus existed were used for this analysis. The features were tested 
irrespective of the diagnosis of the tumors. The 2 curves for the feature of cellularity of the tumors ran in the 
expected order but were not significantly different from each other (p = 0.066). The curves for endothelial 
abnormalities and necrosis ran in the expected order and differed significantly (p = 0.028 and p = 0.015, 
respectively) (Table II-6). The feature of nuclear abnormalities was almost univocally scored as present by 
all reviewers and was, therefore, not further analyzed. The curve for the few patients with tumors in which 
no mitoses were found ran steepest, but no significant differences between the curves were obtained. 
Consensus on the features of cell density, endothelial abnormalities, mitoses, and necrosis was reached for 
79 tumors. These tumors were used in multivariate analysis to assess the prognostic value of the individual 
features and patient’s age, extent of surgery, tumor location, and performance status. Patient’s age, the 
presence of tumor necrosis, and 1p/19q status were identified as independent prognosticators (data no 
shown). 
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Figure II.1: OS curves for the respective diagnoses, irrespective of 1p/19q status. 
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LGG
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p<0.0001 (df=3)
 
Note:All curves are based on agreement of 4 or more of the 9 reviewers. The curve of anaplastic oligodendroglioma 
(AOD) is separated from the intertwined curves of anaplastic oligoastrocytoma (AOA), glioblastoma (GBM), and 
anaplastic astrocytoma (AA). O, number of events; N, number of patients. 
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Figure II.2: OS curves according to 1p/19q genotypes for AOD and AOA. 
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Note: All curves are based on agreement of 4 or more reviewers. The patients with AOD with loss of 1p/19q do 
significantly better than those without these losses, and the patients with AOA do significantly worse than those with 
AOD with or without loss of 1p/19q. The majority of consensus AOAs are tumors without loss of 1p/19q. N, number of 
patients; O, number of events. 
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Table II-6: Significances of the differences of survival curves for the histologic features. 
 
 
Histologic feature p 
Cellularity 0.066 
Endothelial abnormalities (proliferation) 0.028 
Necrosis 0.015 
Nuclear abnormalities - 
Mitoses n.s. 
Only consensus features were used for the analysis. 
n.s., not significant. 
 
 
 
2.4 Discussion 
 
Because of optional treatment with alkylating chemotherapy, making the diagnosis of oligodendroglioma 
became highly important
5
. The correlation between the histology of oligodendroglioma, the typical genetic 
signature of combined loss of 1p/19q, and the fair response to alkylating chemotherapy made this type of 
glioma the subject of many clinical and laboratory investigations 
1,6
. In this study, the panelists confirmed 
the diagnosis of AOD made by the local pathologists in just over one half of the cases (range 33%-68%). 
The large discrepancy between the diagnosis made by local pathologists (used for inclusion of the patients 
into the trial) and the experts/panelists shows that central review of pathology material of trials on glial 
tumors is important. For making the diagnosis of oligodendroglioma, one may choose to apply either strict 
or relaxed criteria
7
. Obviously, allowing less strict criteria for making the diagnosis will lead to increased 
interindividual observer variability
8
. Despite the fact that the discriminating microscopic features for 
oligodendrogliomas as originally mentioned by Bailey and Bucy in 1929
9
 are rather ill-defined and 
nonspecific and are thus prone to subjectivity, there was satisfactory concordance on the diagnosis of AOD 
made by the panelists (Table II-5). Because of the large histologic variability and the relatively poor 
definition of oligodendroglial tumors, many studies have focused on the correlation of the genetic signature 
and the histologic particularities of these neoplasms. Combined 1p/19q loss is an early genetic aberration 
that distinguishes AOD as a particular glioma subtype with a protracted clinical course and good response to 
both radiotherapy and chemotherapy
10
. The differences in concordance on the diagnosis of AOD of tumors 
with and without combined loss of 1p/19q were not significant, and the same was true for the scoring of the 
individual features. Taking advantage of the prospective randomized setup of EORTC Trial 26951 we were 
able to correlate the results of the panel review and the status of 1p/19q of the tumors with the parameters of 
outcome. The consensus diagnosis of AOD made by the review panel yielded a survival curve that was 
significantly different from those of consensus or majority diagnosis of AOA and GBM (Figure II.1), and it 
is concluded that there was good correlation of the consensus diagnoses AOD with the outcomes of the 
patients. In addition, AOD with the genetic signature of oligodendroglioma showed significantly better 
survival compared with the AOD without this genotype (Figure II.2), corroborating the notion that loss of 
1p/19q is correlated with better outcome. The present results show that making the diagnosis of AOA is 
more difficult than that of pure AOD: the panel reached consensus in only 8% of cases diagnosed as AOA 
by the local pathologists, and in more than one half of cases the panel agreed that the locally made diagnosis 
was wrong. There was, however, a large range (7%-34%) in the diagnoses of AOA within the panel of 
expert reviewers (Table II-1). Recognition of the classic histology of oligodendroglioma may not be 
difficult, but problems arise when features are only present to some extent. Mixtures of oligodendroglia-like 
cells with astrocytic (tumor) cells may suggest the diagnosis of mixed oligoastrocytoma; there are, however, 
no sensible cutoff percentages for cells with features of the respective lineages in the definition of mixed 
oligoastrocytoma
3
. Proposals for cutoff cell fractions have been invalidated by tumor heterogeneity and 
difficulties in the distinction between reactive and neoplastic glial cells 
3,11,12
. At present, the term “mixed 
oligoastrocytoma” is applicable to a variety of situations. For instance, in up to one half of classic 
oligodendrogliomas gemistocytic cells are seen
13
, and the presence of such cells may also trigger the 
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diagnosis of mixed oligoastrocytoma. Tumors composed of cells with features that are intermediate between 
those of neoplastic oligodendrocytes and astrocytes usually receive the diagnosis of mixed oligoastrocytoma 
as well. In this study, 11% of cases with consensus or majority diagnosis of AOA showed combined 1p/19q 
loss, and thus most consensus or majority AOAs do not show the typical genetic signature found in classic 
oligodendroglioma in the literature 
14, 15
. 
This was in agreement with the survival curve of the patients who did significantly worse than the patients 
with AOD. These findings confirm the experience that 1p/19q status is a powerful prognosticator in glioma 
with oligodendroglial cells. It is questionable to what extent pathomorphology will remain the gold standard 
for classification of gliomas and how far molecular tests will substitute the microscope for identifying 
specific biologic aggressiveness of tumors or relevance to the choice of therapy. In this multivariate analysis 
the presence of necrosis had independent prognostic significance, and the concordance of the reviewers on 
this feature was high (Table II-5). 
Tumor necrosis has been identified as a histologic feature with prognostic value in various retrospective 
studies of oligodendrogliomas and astrocytomas 
16,17
. Tumor necrosis is usually seen in the context of other 
anaplastic features, but when these other features are absent, the impact of necrosis on the biologic behavior 
of oligodendrogliomas should be interpreted with caution 
18,19
. The feature with the second best concordance 
was endothelial abnormalities. The high concordance found for this feature in this panel review indicates 
that it is fairly reproducible. Microvascular proliferation has often emerged from retrospective studies as a 
feature that correlates well with the clinical outcomes 
12,20,21
. Generally, microvascular proliferation 
correlates well with the disruption of the blood-brain barrier, leading to brain edema and tumor enhancement 
on radiologic presentations. Some authors included contrast enhancement of the oligodendrogliomas in their 
grading scheme 
22
, but others argued that this feature is not specific for high-grade oligodendrogliomas 
23
. 
Overall, the biologic link between proliferation of tumor cells, hypoxia-induced necrosis, and proliferation 
of blood vessels underscores the prognostic significance of these features individually 
24
.  
In conclusion, the results show that review of trial related pathology material of glial tumors is an important 
correction of the locally made diagnosis. The concordance on the various histologic features and on the 
overall diagnosis of AOD by expert neuropathologists appeared to be satisfactory. Only one half of the 
tumors with a consensus diagnosis of AOD appeared to harbor loss of 1p/19q. The large discrepancy 
between local pathologists` diagnosis of AOA and the considerable variation in this diagnosis between 
reviewers illustrates the lack of delineators for this diagnosis. Further exploration of molecular abnormalities 
of gliomas with diagnostic, prognostic, or predictive value is indicated.  
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3.1 Abstract  
 
Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 
months in clinical trial populations. However, survival varies greatly among patients. As part of a central 
pathology review, we addressed the question if patients with GBM displaying distinct morphologic features 
respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were 
systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like 
component and respective correlations with outcome and relevant molecular markers. GBM with an 
oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not 
associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, 
significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 
0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT 
methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two 
subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading 
necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was 
present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic 
factors and MGMT status, PPN was borderline non-significant (p = 0.063). Taken together, recognition of 
an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed 
group without prognostic significance. However, the presence of PPN may indicate biological features of 
clinical relevance for further improvement of therapy. 
 
3.2 Introduction 
 
The introduction of combined chemo-radiotherapy adding temozolomide concomitantly and adjuvant to 
radiotherapy has modestly increased outcome of patients with newly diagnosed glioblastoma (GBM) 
32
, in 
particular in patients whose tumors contain an epigenetically inactivated MGMT gene 
11
. However, outcome 
varies dramatically even in a homogenously treated patient population with a median survival of 15 months: 
2- and 5-year survival rates of 27 and 11%, respectively 
7, 19, 21, 32
. Histopathologically, GBM is a 
heterogeneous tumor type and distinct morphologic subtypes may benefit differently from combined chemo-
radiotherapy. Furthermore, unequivocal separation of GBM and anaplastic astrocytomas from anaplastic 
oligo-astrocytic neoplasms is difficult. Previous reports suggested that distinct morphologic features present 
in GBM may have prognostic value, such as the presence of an oligodendroglioma-like component that was 
associated with better outcome in some studies, while the presence of necrosis has been reported as a 
negative prognostic factor 
9, 12, 16, 18, 37
. Here, we addressed the question whether particular morphologic 
features in GBM can identify clinically meaningful subgroups in this patient cohort treated homogenously 
with combined radio-chemotherapy that has become the standard of care. A specific goal was to investigate 
the clinical relevance of recognition of an oligodendroglioma-like component in GBM in tumors that had 
been diagnosed as GBM (all subtypes) by the initial local pathology assessment. The histopathological study 
was carried out as part of the central review performed in the phase III EORTC 26981/22981-NCIC/CE.3 
trial for newly diagnosed GBM 
32, 33
. The results of this detailed histopathological review were correlated 
with outcome and benefit from the new concomitant chemo-radiotherapy and in a subset of cases associated 
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with genetic information  including the MGMT methylation status, copy number aberrations (CNAs) of 
EGFR, CDK4 and MDM2, combined loss of chromosomes 1p and 19q, and mutations of IDH1. 
 
 
3.3 Patients and methods 
 
Patients 
 
Patients were enrolled in the phase III EORTC 26981/22981-NCIC/CE.3 trial 
33
 (ClinicalTrials.gov, number 
NCT00006353) between August 2000 and March 2002. Eligibility criteria have been detailed elsewhere 
32
 
and comprised age between 18 and 70 years, histologically proven newly diagnosed GBM (WHO grade IV) 
and a WHO performance status of 0–2. Patients were randomized to either standard focal radiotherapy (RT) 
with a total dose of 60 Gy or concomitant chemotherapy of oral temozolomide (TMZ) at a daily dose of 75 
mg/m2 given 7 days per week during radiotherapy, followed by up to six cycles of adjuvant TMZ (150–200 
mg/m2) for 5 days every 28 days. All patients had given written informed consent prior to entering the 
study, including for molecular analysis of their tumors. The study was approved by the local ethics 
committees. 
 
Pathology review 
 
Central review was performed jointly by three experienced neuropathologists (RCJ, KM, PW) according to 
WHO 2000 criteria 
15
 using a multiheaded microscope. H&E-stained full sections were used for the 
evaluation. In most cases GFAP-, MIB-1 and a reticulin silver stain were available (collectively performed 
in Lausanne). Morphologic features were systematically recorded in a semiquantitative manner and 
comprised cellular differentiation patterns, types of necrosis (large ischemic type vs. pseudopalisading 
necrosis), microvascular proliferation and MIB-1 labeling index (see evaluation form, Figure III.1, 
Supplementary Figure S1). In line with the WHO classification, pseudopalisading necrosis (PPN) was 
defined as irregular, often serpiginous foci of necrosis surrounded by densely packed, radially oriented 
tumor cells. The agreement between the three pathologists was recorded. For this study, GBM with an 
oligodendroglioma-like component (GBM-O) was defined according to the following histopathological 
criteria: presence of at least one of two ‘‘major criteria’’— ‘diffuse highly cellular and monotonous growth 
at low power magnification’, ‘monomorphous cell population’; and at least two of three ‘‘minor criteria’’—
‘perinuclear halo formation in tumor cells’, ‘rounded tumor cell nuclei with dense chromatin pattern’, 
‘chickenwire architecture of tumor microvasculature’. The extent of these features in the viable tumor tissue 
was recorded (<25, 25–75,>75%). GBM with >25% of the tumor tissue showing oligodendroglioma-like 
component was subclassified as GBM-O (see Figure III.2, for some examples). 
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Table III-1: Pathology review form. 
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Figure III.1: Examples of histology in two tumors diagnosed as GBM with oligo-like component. 
 
 
a Area showing diffuse highly cellular and monotonous 
growth of tumor cells with a dense chromatin pattern, 
perinuclear halo formation and chickenwire architecture of 
the microvasculature. b Highly cellular area showing 
rounded tumor cell nuclei with dense chromatin pattern 
and perinuclear halo formation.  
See ‘‘Patients and methods’’ for the definitions used in the 
present study for recognition of oligodendroglioma-like 
component in glioblastoma. Arrowheads in a mitotic 
figures, arrowhead in b florid microvascular proliferation. 
a,b Hematoxylin and Eosin staining, original 
magnification x200. 
 
Tissue microarray, immunohistochemistry and molecular analysis. 
 
Immunohistochemistry for GFAP and MIB-1, and histochemical reticulin staining were performed 
according to standard procedures on whole sections. A tissue microarray (TMA) was constructed 
comprising 130 patient samples where tumor blocks with sufficient tissue were available as reported 
previously
21
. The TMA was used to screen for the most common IDH1 mutation (R132H) using the 
specific antibody mIDH1R132H (clone H14) 
4
 and for copy number aberrations (CNAs) of selected genes 
by FISH. FISH for EGFR was performed as described 
34
. Two-color FISH assay was performed using a 
mixed 1p36/1q25 and 19p13/19q13 dual color probe set (Cat. No 32-231004, Vysis, Inc., Applied 
Biosystems, Downers Grove, IL, USA) as described 
31
. Samples showing sufficient FISH efficiency 
(~90% nuclei with signals) were evaluated. If possible, signals were scored in at least 200 non-
overlapping, intact nuclei. Deletions of 1p and 19q were scored when at least 50% of tumor nuclei 
contained one signal. The following probes were used for CDK4 and MDM2: KBI-10725 CD4K/SE12 
(12q14); KBI-10717 MDM2/SE12 (12q15) (Kreatech Diagnostics, Amsterdam; The Netherlands). The 
MGMT methylation status has been determined and reported previously 
11, 32
. Expression of the EGFRvIII 
mutant, array comparative genomic hybridization (aCGH) data and gene expression data were available 
for a subgroup of patients 
17, 21
. Additional EGFR amplification data were obtained by quantitative PCR as 
described 
10
. Mutation analysis for IDH1 and IDH2 encompassing codon 132 and 172, respectively, was 
performed by direct Sanger sequencing.  
 
Statistics 
 
The Fisher’s exact test (for binary or nominal categorical data) and the Wilcoxon rank-sum test (for 
continuous or ordinal categorical data) were used in the comparisons of patient and disease characteristics 
between subgroups. Survival analyses were performed with Kaplan–Meier technique with log-rank 
statistics. The Cox regression was used for multivariate analyses. All Cox models were fit with age (≤50, 
51–60,>60), extent of surgery (total, partial, biopsy only), performance status (0, 1, 2), Mini Mental Score 
Examination (<27, 27–30) and MGMT methylation status (unmethylated, methylated).  Pathological 
features significant at a 5% level in univariate analyses were included in the multivariate model. A 
treatment effect was assessed using Peto’s heterogeneity test (predictive value). No adjustment for 
multiple testing was performed in these exploratory analyses. SAS version 9.2 was used for statistical 
analyses. 
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3.4 Results 
 
Histological diagnosis and subclassification. 
 
Central review comprised histological analysis of 360 of 573 patients enrolled (central review of Canadian 
patients was performed independently). Baseline characteristics have been published previously 
32
 and 
sub-cohort patient characteristics are summarized in Table III-1 (Supplemental Table S1). Overall, the 
patient characteristics of this subset did not differ significantly from the overall study population, other 
than molecular markers that could be determined in patients who had undergone tumor resection in 
contrast to biopsy only. From the total of 360 cases reviewed, 6 were considered undiagnosable due to 
insufficient tissue or quality of the sections. Fifteen (4.2%) tumors did not fulfill the criteria for GBM and 
comprised 4 anaplastic astrocytomas (WHO grade III; AA), 4 anaplastic oligoastrocytomas (WHO grade 
III, AOA), 1 anaplastic oligodendroglioma (WHO grade III; AO), 2 anaplastic ependymomas (WHO 
grade III), 2 pilocytic astrocytomas with malignant changes, 1 low grade glioma (WHO grade II) and 1 
meningioma. Of the non-GBM tumors, 6 were in the RT and 9 in the RT/TMZ arm. The remaining 339 
were diagnosed as GBM, of which 3 were subtyped as gliosarcoma and 6 as giant cell GBM. There was a 
95% (338/354) consensus with regard to diagnosis of GBM versus non-GBM among the three 
neuropathologists. The median age of patients with confirmed GBM was 56 years of age (range 19–79) 
(Table III-2, Supplemental Table S2). 
 
Table III-2: Baseline characteristics RT vs TMZ/RT in confirmed GBM.  
 
 
Subsample Characteristics  
 
Treatment 
Total 
(N=339) 
 
RT 
(N=173) 
TMZ/RT 
(N=166) 
P-value 
 N (%) N (%) N (%) Fisher 
CLINICAL CHARACTERISTICS     
Sex                                                                                                                                                                                                                
        Male                                        106 (61.3)                                                                                          110 (66.3)                               216 (63.7)                                0.37
        Female                                         67 (38.7)                                                                                          56 (33.7)                               123 (36.3)                                
Mini mental state evaluation (class)                                                                                                                                                                               
        ≥27                                     102 (59.0)                                                                                          103 (62.0)                               205 (60.5)                                0.64
        <27                                       61 (35.3)                                                                                          55 (33.1)                               116 (34.2)                                
        Missing                                   10 (5.8)                                                                                           8 (4.8)                              18 (5.3)                                
mini mental state evaluation                                                                                                                                                                              
        Median                                                                                                                                                                                           28.0 28.0               28.0              0.64 a 
        Range                                                                                                                                                                                            9.0 - 30.0 7.0 - 30.0 7.0 - 30.0       
        N obs                                                                                                                                                                                            163    158 321      
corticosteroids at entry                                                                                                                                                                                           
        No                                        53 (30.6)                                                                                          62 (37.3)                               115 (33.9)                                0.21
        Yes                                      120 (69.4)                                                                                          104 (62.7)                               224 (66.1)                                
Age (class)                                                                                                                                                                                                        
        ≤50 yrs                                  14 (8.1)                                                                                           17 (10.2)                                31 (9.1)                              0.58 a 
        >50 & ≤60 yrs                           104 (60.1)                                                                                          99 (59.6)                              203 (59.9)                                
        >60 yrs                                   55 (31.8)                                                                                          50 (30.1)                               105 (31.0)                                
Age                                                                                                                                                                                                         
        Median                                                                                                                                                                                           56.0 55.0               56.0              0.62a 
        Mean (SD)                                                                                                                                                                                        54.72 (9.48) 53.94 (10.28) 54.34 (9.87)        
        Range                                                                                                                                                                                            25.0 - 70.0     19.0 - 70.0 19.0 - 70.0        
Extent of surgery                                                                                                                                                                     
        Complete resection                        66 (38.2)                                                                                          68 (41.0)                               134 (39.5)                                0.52
        Partial resection                         84 (48.6)                                                                                          71 (42.8)                               155 (45.7)                                
        Biopsy                                    23 (13.3)                                                                                          27 (16.3)                               50 (14.7)                               
Tumor location (all)                                                                                                                                                                                               
        Frontal                                   50 (28.9)                                                                                          50 (30.1)                               100 (29.5)                                0.11
        Temporal                                  37 (21.4)                                                                                          49 (29.5)                               86 (25.4)                               
        Parietal                                  37 (21.4)                                                                                          25 (15.1)                               62 (18.3)                               
        Occipital                                 12 (6.9)                                                                                           10 (6.0)                               22 (6.5)                               
        Central                                    5 (2.9)                                                                                           10 (6.0)                                15 (4.4)                                
        Multifocal                                28 (16.2)                                                                                          22 (13.3)                               50 (14.7)                                          
        Other                                      4 (2.3)                                                                                           0 (0.0)                               4 (1.2)                                
MIB1     
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Subsample Characteristics  
 
Treatment 
Total 
(N=339) 
 
RT 
(N=173) 
TMZ/RT 
(N=166) 
P-value 
 N (%) N (%) N (%) Fisher 
        Median                                                                                                                                                                                           30.0           30.0               30.0   0.08 
        Mean (SD)                                                                                                                                                                                        32.72 (17.81) 36.40 (18.26) 34.53 (18.10)       
        Range                                                                                                                                                                                            5.0 - 80.0 5.0 - 90.0 5.0 - 90.0       
        N obs                                                                                                                                                                                            156    150 306      
 
TUMOR GENETICS 
MGMT                                           
                                                                                                                                                                   
        Unmethylated                                         44 (25.4)                                                                                          45 (27.1)                               89 (26.3)                               1.00
        Methylated                                         38 (22.0)                                                                                          38 (22.9)                               76 (22.4)                               
        Missing                                   91 (52.6)                                                                                          83 (50.0)                               174 (51.3)                                
IDH1                                                                                                                                                                                                               
        Not mutated                               54 (31.2)                                                                                          67 (40.4)                               121 (35.7)                                0.73
        Mutated                                    5 (2.9)                                                                                           4 (2.4)                               9 (2.7)                                
        Missing                                  114 (65.9)                                                                                          95 (57.2)                              209 (61.7)                                 
EGFR                                                                                                                                                                                                                                            
        Normal                                    27 (15.6)                                                                                          34 (20.5)                               61 (18.0)                               0.73
        Amplified                                 34 (19.7)                                                                                          36 (21.7)                               70 (20.6)                               
        Missing                                  112 (64.7)                                                                                          96 (57.8)                              208 (61.4)                                 
1p/19q                                                                                                                                                                                                             
        No co-deletion                                   65 (37.6)                                                                                          70 (42.2)                               135 (39.8)                                              0.24
        Co-deletion                                       2 (1.2)                                                                                           0 (0.0)                               2 (0.6)                               
        Missing                                  106 (61.3)                                                                                          96 (57.8)                              202 (59.6)                                 
MDM2                                                                                                                                                                                                   
        Normal            55 (31.8)                                                                                          63 (38.0)                               118 (34.8)                                0.39
        Amplified          8 (4.6)                                                                                           5 (3.0)                               13 (3.8)                                 
        Missing          110 (63.6)                                                                                          98 (59.0)                              208 (61.4)                                    
CDK4                                                                                                                                                                                       
        Normal            49 (28.3)                                                                                          58 (34.9)                               107 (31.6)                                0.37
        Amplified         14 (8.1)                                                                                           10 (6.0)                               24 (7.1)                               
        Missing          110 (63.6)                                                                                          98 (59.0)                              208 (61.4)                                 
     
Note: 
a
 Wilcoxon rank sum test 
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Table III-3: Baseline characteristics GBM vs GBM-O. 
 
Subsample Characteristics  
 
Confirmed GBM 
Total 
(N=339) 
 
GBM 
(N=287) 
GBM-O 
(N=52) 
P-value 
 N (%) N (%) N (%)  
CLINICAL CHARACTERISTICS     
Sex                                                                                                                                                                                                                                                                     
        Male                                        186 (64.8)                                                                                          30 (57.7)                                                216 (63.7)                                            0.35
        Female                                        101 (35.2)                                                                                          22 (42.3)                                   123 (36.3)                                                        
Mini mental state evaluation (class)                                                                                                                                                                                                                       
        >=27                                     171 (59.6)                                                                                          34 (65.4)                                   205 (60.5)                                                         0.42
        <27                                      101 (35.2)                                                                                          15 (28.8)                                   116 (34.2)                                                            
        Missing                                   15 (5.2)                                                                                           3 (5.8)                                   18 (5.3)                                                          
mini mental state evaluation                                                                                                                                                                                                 
        Median                                                                                                                                                                                           28.0  29.0            28.0          0.19a 
        Range                                                                                                                                                                                            7.0 - 30.0 10.0 - 30.0 7.0 - 30.0          
        N obs                                                                                                                                                                                            272 49 321                 
Corticosteroids at entry                                                                                                                                                                                                                                  
        No                                       102 (35.5)                                                                                          13 (25.0)                                  115 (33.9)                                                          0.15
        Yes                                      185 (64.5)                                                                                          39 (75.0)                                   224 (66.1)                                                         
Age (class)                                                                                                                                                                                                                                                 
        <=50 yrs                                  23 (8.0)                                                                                           8 (15.4)                                    31 (9.1)                                                         0.04 a
        >50 & <=60 yrs                           170 (59.2)                                                                                          33 (63.5)                                   203 (59.9)                                                        
        >60 yrs                                   94 (32.8)                                                                                          11 (21.2)                                   105 (31.0)                                                                                
Age                                                                                                                                                                                                                          
        Median                                                                                                                                                                                           56.0               53.0              56.0          0.02a 
        Range                                                                                                                                                                                            19.0 - 70.0 25.0 - 69.0 19.0 - 70.0         
Extent of surgery B/PR/CR                                                                                                                                                                                                                                  
        Complete resection                       111 (38.7)                                                                                          23 (44.2)                                   134 (39.5)                                                         0.16a
        Partial resection                        129 (44.9)                                                                                          26 (50.0)                                   155 (45.7)                                                         
        Biopsy                                    47 (16.4)                                                                                          3 (5.8)                                  50 (14.7)                                                         
Tumor location (all)                                                                                                                                                                                                                                                                       
        Frontal                                   84 (29.3)                                                                                          16 (30.8)                                                           100 (29.5)                                          0.22
        Temporal                                  69 (24.0)                                                                                          17 (32.7)                                    86 (25.4)                                                       
        Parietal                                  54 (18.8)                                                                                          8 (15.4)                                  62 (18.3)                                                          
        Occipital                                 22 (7.7)                                                                                           0 (0.0)                                   22 (6.5)                                                          
        Central                                   14 (4.9)                                                                                           1 (1.9)                                   15 (4.4)                                                                     
        Multifocal                                40 (13.9)                                                                                          10 (19.2)                                              50 (14.7)                                              
        Other                                      4 (1.4)                                                                                           0 (0.0)                                    4 (1.2)                                                        
MIB1     
        Median                                                                                                                                                                                           30.0           30.0 30.0          0.24a 
        Mean (SD)                                                                                                                                                                                        34.00 (18.05) 37.16 (18.31)      34.53 (18.10)       
        Range                                                                                                                                                                                            5.0 - 90.0 5.0 - 80.0 5.0 - 90.0          
        N obs                                                                                                                                                                                            255 51  306                 
Note: 
a
 Wilcoxon rank sum test 
 
Frequency of GBM with an oligodendroglioma-like component. 
 
The criteria for GBM-O were met in 52 (15%) samples, at an expected frequency 
12, 29, 37
. Subtyping of 
centrally confirmed GBM, including GBM-O, resulted in a 2:1 agreement for 24 cases, of which 16 
overlapped with the debated cases for GBM versus non-GBM. In the group classified as GBM-O, two of 
five were considered as AOA and two as AO, by one of the neuropathologists. The median age of patients 
with GBM-O was lower than that of the other GBM patients (53 vs. 56 years, p=0.02) (Table III-2 
,Supplemental Table S2).  
 
GBM-O encompass a pathogenetically heterogeneous group.  
 
Evaluation of important prognostic molecular markers revealed the same frequency of MGMT 
methylation in GBM-O (47%, 16/34) versus the remaining GBM (46%, 60/131) (Table III-3). 
Furthermore, combined loss of 1p/19q, a hallmark of oligodendroglial tumors and associated with better 
prognosis in anaplastic glioma 
35
, was a rare event, observed in a single GBM-O, confirmed by aCGH, and 
one GBM (Figure III.3; Table III-3).  
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Table III-4: Tumor genetics of GBM-O versus GBM. 
 
Overall cases in central review Confirmed GBM (%) GBM-O (%) GBM (%) P value 
a
  
Alterations     
methMGMT 76/165 (46) 16/34 (47) 60/131 (46) 1.00 
IDH1 mut 9/130 (7) 6/32 (19) 3/98 (3) 0.007 
Co-del 1p/19q 2/137 (1) 1/31 (3) 1/106 (1) 0.4 
EGFR amp 70/131 (53) 22/31 (71) 48/100 (48) 0.038 
CDK4 amp 24/131 (18) 7/29 (24) 17/102 (17) 0.42 
MDM2 amp 13/131 (10) 4/30 (13) 9/101 (9) 0.49 
Note: Statistically significant values are given in bold. 
a
 Fisher exact test 
 
Next, we investigated if GBM-O exhibit a particular pathogenetic makeup. Mutations of the IDH1 gene 
that are associated with better outcome in GBM 
40
 were significantly enriched in GBM-O (6/32, 19%) as 
compared to the remaining GBM (3/98, 3%; p=0.002). Similarly, EGFR amplification that has been 
associated with older age and potentially worse outcome was present in 71% of GBM-O (22/31) and 48% 
of the remaining GBM (48/100) (p=0.03). IDH1 and EGFR alterations were mutually exclusive as 
reported before 
40
. Intriguingly, of 31 GBMO for which this genetic information was available, 6 carried 
the IDH1R132H mutation, 22 displayed an EGFR amplification, and only three had neither alteration. The 
presence of an IDH1 or IDH2 hot-spot mutation other than IDH1R132H was excluded by direct 
sequencing in these three cases. The notion that the GBM-O phenotype identifies at least two 
pathogenetically distinct subgroups is further supported by classification according to the four gene 
expression-based subtypes proposed by Verhaak et al. 
36
. Of 14 evaluable GBM-O, 5 grouped with the 
proneural, 6 with the classical, 2 with the mesenchymal and 1 with the neural GBM subtypes. In 
accordance with the reported mutation pattern of the four subgroups, all GBMs with an IDH1 mutation 
were in the proneural group, while most EGFR-amplified and EGFRvIII-positive GBMs were in the 
classical subgroup (Figure III.4).  
Presence of an oligo-like component in newly diagnosed GBM identifies a pathogenetically 
heterogeneous subgroup and lacks prognostic value. 
 
50 
 
Figure III.2: Patterns of genetic alterations, diagnosis and outcome.  
 
 
Patient data for 175 cases with 3/6 genetic tests available 
were ordered according to overall survival (OS). Many 
features are rare, such as GBM subtypes, or genetic 
alterations like IDH1 mutations. The visualization allows 
identification of patterns of genetic or clinical features that 
are enriched in either the short survival group or the long 
term survival group. Gene amplification is represented in 
red (CDK4,MDM2, EGFR) and deletions in dark blue 
(co-deletion of 1p/19q). Mutation of IDH1 is represented 
in red, MGMT methylated in gray and unmethylated in 
black. OS in months: light green short survival group (≤9 
months); green intermediate survival group (>9 and 
<24 months); dark green long-term survival group (24 
months). Age<50 years is represented in gray, 50–60 years 
in dark gray, and >60 years in black. Red female, blue 
male. Pink diagnosis as GBM; purple GBM-O; yellow 
Gliosarcoma; orange giant cell GBM (GC-GBM); blue 
AOA; green other non-GBM diagnosis. Concordance of 
reviewers 3:0 for subtype (Con_subT) or diagnosis 
(Con_diagn) in dark blue; blue concordance 2:1; light blue 
diagnosis by Canadian central review. Diagnosis of non-
GBM is indicated in black. White No information for all 
criteria. The associated table below shows the respective 
numbers. EGFRvIII information was available for only 56 
cases and is not included in the upper panel 
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Survival of patients with GBM-O is not different from those with GBM.  
 
Patients with non-GBM pathology (15/354, 4%) were enriched in the patient group with overall survival 
(OS) exceeding 24 months (9/64, 14%), as compared to the short survival group (≤9 months, 1/101), and 
the intermediate group (5/189, 3%) (p<0.001, Chi-square-test) (Figure III.2). Subsequently, only patients 
with confirmed GBM (N = 339) are included for further analysis of morphologic features and outcome. 
There was no difference in OS between GBM and GBM-O (logrank test, p=0.48). Stratification by age 
(≤50, 51–60 or >60) (p = 0.55) or MGMT methylation status (p=0.27) did not differentiate survival in the 
two subgroups. When analyzing the GBM-O separately per randomized treatment arm, survival was not 
different for GBM-O in either arm (TMZ/RT → TMZ arm, p =0.81; RT-only arm, p=0.14) (Figure III.5). 
The respective values for progression-free survival were similar (p=0.97, TMZ/RT → TMZ; p=0.2, RT). 
Likewise, using less strict criteria, just the presence of any oligodendroglioma-like component did not 
show any association with outcome in either of the two treatment arms (Table III-3). The apparent 
enrichment of patients with the presence of any oligodendroglioma-like component in the long survivor 
group as visualized in Figure III.4 was due to inclusion of patients where GBM was not confirmed.  
 
Associations of histopathological features with tumor genetics. 
 
The MIB-1 labeling index was significantly higher in MGMT methylated GBM with a mean index of 38% 
(N = 69) as compared to 30% in MGMT unmethylated tumors (N = 84) (p=0.0015). A trend for a higher 
MIB-1 labeling index was associated with IDH1 mutations and EGFR amplifications (p=0.07, p=0.09). 
No significant association was observed between any morphologic feature and the MGMT methylation 
status.  
 
Associations of tumor genetics and outcome 
 
None of the genetic alterations investigated here was associated with a prognostic or a predictive value 
with the exception of MGMT methylation as previously reported (Table III-4, Supplementary Table 
S5)
32,38
. Mutations of IDH1 were rare in confirmed GBM (9/130; 7%, for which this information was 
available) as expected 
25
 and similarly distributed between the treatment arms (5, RT; 4, RT&TMZ), with 
five of eight assessable cases being MGMT methylated. These small numbers do not allow appropriate 
assessment of the prognostic value of IDH1 mutations (p=0.7, Figure III.6, Supplementary Fig. S2). The 
patterns of genetic alterations and outcome are displayed in Figure III.3.  
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Figure III.3: Gene expression-based classification and GBM subtype.  
 
 
57 patients gene expression data, including for EGFRvIII, 
was available from frozen tumor tissue 
21
. The tumor 
samples were classified according to the algorithm 
proposed by Verhaak et al. 
36
 into classic, mesenchymal, 
neural and proneural GBM. The samples are ordered by 
the gene expression-based classification, followed by 
diagnostic subtype, gliosarcoma (GS), GBM-O and GBM. 
The respective pathogenetic information and clinical 
information is the same as in Figure III.3. The enrichment 
of specific pathogenetic alterations, such as IDH1 
mutations in the proneural and EGFR amplification and 
EGFRvIII expression in the classical subtype, is in 
accordance with the report by Verhaak et al. 
36
 . Gene 
amplification is represented in red (CDK4, MDM2, 
EGFR)  
and deletions in dark blue (co-deletion of 1p/19q). 
EGFRvIII expression determined by qRT-PCR is depicted 
in yellow. Mutation of IDH1 is represented red, MGMT 
methylated in gray and unmethylated in black. OS in 
months: light green short survival group (≤9 months); 
green intermediate survival group (>9 and <24 months); 
dark green long-term survival group (24 months). 
Age<50 is represented in gray, 50–60 in dark gray, and 
>60 years in black. Red female, blue male. Pink diagnosis 
as GBM; purple GBM-O; yellow gliosarcoma (GS). 
Concordance of reviewers 3:0 for subtype (Con_subT) or 
diagnosis (Con_diagn) in dark blue; concordance 2:1 in 
blue; diagnosis by Canadian central review in light blue. 
White no information for all criteria. 
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Figure III.4: Prognostic value of GBM-O for Overall Survival in RT and TMZ/RT→TMZ.  
a. in RT 
(years)
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : GBM-O
146 148 71 13 3 1 1
24 25 15 5 1 1 0
No
Yes
Overall Logrank test: p=0.136
 
b. in TMZ/RT→TMZ 
(years)
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : GBM-O
130 139 82 33 14 5 3
25 27 14 4 3 3 1
No
Yes
Overall Logrank test: p=0.814
 
Note: GBM-O did not have better prognosis than all other GBMs. Kaplan–Meier curves show the OS of GBM versus GBM-O in the RT arm 
(log-rank test p = 0.136) (a) and the TMZ/RT → TMZ arm (p = 0.814) (b) 
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Table III-5: Molecular features of confirmed GBM and OS. 
 
Subsample Characteristics     
 
Treatment 
Total 
(N=450) 
 Prognostic 
value for  
Prognostic 
value for  
Prognostic 
value for  
RT 
(N=229) 
TMZ/RT 
(N=221) 
P-value 
Fisher 
Overal Survival  
P-value 
Overal Survival  
P-value 
Overal Survival  
P-value 
 N (%) N (%) N (%)  Pooled RT TMZ/RT 
MGMT                             
        Unmethylated                  55 (24.0)                                                                                          63 (28.5)                               118 (26.2)                                0.59 <0.0001 0.0003 0.002 
        Methylated                   50 (21.8)                                                                                          46 (20.8)                               96 (21.3)                                 
        Missing             124 (54.1)                                                                                          112 (50.7)                               236 (52.4)                                   
IDH1                                                                                                                                                                                                         
        Not mutated          68 (29.7)                                                                                          77 (34.8)                               145 (32.2)                                0.55 0.70 0.997 0.50 
        Mutated               5 (2.2)                                                                                           4 (1.8)                               9 (2.0)                                   
        Missing             156 (68.1)                                                                                          140 (63.3)                               296 (65.8)                                  
1p/19q                                                                                                                                                                                         
        No loss              79 (34.5)                                                                                          80 (36.2)                               159 (35.3)                                0.50 0.16 0.22 N/A 
        Loss                  2 (0.9)                                                                                           0 (0.0)                               2 (0.4)                                  
        Missing             148 (64.6)                                                                                          141 (63.8)                               289 (64.2)                                 
EGFR                                                                                                                                                                                           
        Normal               36 (15.7)                                                                                          41 (18.6)                               77 (17.1)                               0.88 0.91 0.69 0.92 
        Amplified            41 (17.9)                                                                                          41 (18.6)                               82 (18.2)                                 
        Missing             152 (66.4)                                                                                          139 (62.9)                               291 (64.7)                                   
CDK4                                                                                                                                                                                                  
        Normal               63 (27.5)                                                                                          68 (30.8)                               131 (29.1)                                0.30 0.83 0.09 0.06 
        Amplified            15 (6.6)                                                                                           11 (5.0)                               26 (5.8)                                  
        Missing             151 (65.9)                                                                                          142 (64.3)                               293 (65.1)                                                     
MDM2                                                                                                                                                                                            
        Normal               66 (28.8)                                                                                          73 (33.0)                               139 (30.9)                                0.08 0.73 0.35 0.20 
        Amplified            11 (4.8)                                                                                           5 (2.3)                              16 (3.6)                                                  
        Missing             152 (66.4)                                                                                          143 (64.7)                               295 (65.6)                                  
 
Presence of pseudopalisading necroses (PPN) is associated with a treatment effect of TMZ.  
 
Correlation of the distinct morphologic features assessed, such as type of necrosis, vascular pattern and 
cell differentiation, and including the MIB-1 (Ki67) labeling index (Figure III.1, Supplementary Fig. S1), 
identified PPN as the only morphologic feature associated with outcome (Table III-3). PPN was present in 
63% of all GBM (212/339) and associated with a treatment effect (Figure III.7; Table III-3). Addition of 
TMZ to RT was beneficial in the patient cohort exhibiting PPN (p = 0.0002), while no such effect was 
present in the absence of PPN (p = 0.86; Figure III.7a). Peto’s interaction test was significant (p = 0.026; 
Figure III.7b) and borderline nonsignificant in a Cox interaction model adjusted for known clinical 
prognostic factors (p = 0.087, Table III-5, Supplemental Table S3) not accounting for MGMT that was 
available only for a subset of 165 mostly resected tumors (Table III-1,Supplementary Table S1). This 
suggests that indeed PPN may identify a subgroup of chemo-sensitive GBM. The incidence of PPN was 
lower in patients with biopsy only (46 vs. 65.4%, p = 0.01), while no association with age was observed (p 
= 0.15). To exclude a bias of potential underestimation of PPN in stereotactic biopsies resulting from the 
small sample size, and the fact that biopsy only by itself is an unfavorable prognostic factor, the analyses 
were repeated in patients who underwent a tumor resection. Peto’s test was significant (p = 0.040, 
Supplementary Fig. S3) and the adjusted Cox interaction model including MGMT was borderline 
nonsignificant (p = 0.063, Table III-5, Supplementary Table S4). A similar treatment effect of PPN was 
observed for PFS (p<0.0001) in the TMZ arm, while there was a trend in the RT arm (p = 0.078). 
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Figure III.5: Prognostic value of IDH1 for OS.  
 
(years)
0 1 2 3 4 5 6 7
0
10
20
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40
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O N Number of patients at risk : IDH1
136 145 89 32 12 8 3 1
8 9 6 1 1 1 1 0
Not mutated
Mutated
Overall Logrank test: p=0.701
 
 
 
Table III-6: Predictive value of PPN for TMZ/RT effect on OS – all confirmed GBM. 
 
Summary of the Number of Event 
and Censored Values 
Total Event Censored 
Percent 
Censored 
321 307 14 4.36 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square p 
Hazard 
Ratio 
Treatment 1 0.16014 0.18903 0.7177 0.3969 . 
PPN 1 -0.33989 0.17527 3.7606 0.0525 . 
Treatment*PPN 1 0.41465 0.24238 2.9267 0.0871 . 
Age 1 0.19407 0.09932 3.8182 0.0507 1.214 
Extent of surgery 1 0.37024 0.08471 19.1035 <.0001 1.448 
MMSE 1 0.24354 0.13187 3.4107 0.0648 1.276 
WHO PS 1 0.24945 0.08816 8.0068 0.0047 1.283 
Note: in all confirmed GBM. Cox interaction model with adjustment excluding MGMT status 
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Table III-7: Predictive value of PPN for TMZ/RT effect on OS – resected GBM. 
 
 
Summary of the Number of Event and 
Censored Values 
Total Event Censored 
Percent 
Censored 
153 144 9 5.88 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square p 
Hazard 
Ratio 
Treatment 1 -0.12946 0.33802 0.1467 0.7017 . 
PPN 1 -0.38704 0.27127 2.0357 0.1536 . 
Treatment*PPN 1 0.72863 0.39195 3.4559 0.0630 . 
Age 1 0.20497 0.16359 1.5699 0.2102 1.227 
Extent of surgery 1 0.16113 0.17634 0.8349 0.3609 1.175 
MMSE 1 0.35953 0.20542 3.0631 0.0801 1.433 
WHO PS 1 0.24902 0.14123 3.1090 0.0779 1.283 
MGMT 1 -0.82561 0.18569 19.7682 <.0001 0.438 
 
 
Figure III.6: Predictive value of PPN for TMZ/RT Effect on Overall Survival – all confirmed GBM 
 
a Kaplan Meier Curve 
(years)
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b Forest Plot 
 
Note:The presence of Pseudopalisading  necrosis is associated with a treatment effect. a The  Kaplan–Meier curves visualize the overall outcome of 
the patients in the presence or absence of pseudo-palisading necrosis (PPN). In the presence  of PPN, there is a treatment effect (RT vs. TMZ/RT → 
TMZ p = 0.002), while in the absence of PPN, no such difference is observed (RT vs. TMZ/RT → TMZ, p = 0.86).  b Forest Plot and Peto’s test of 
interaction between PPN and treatment for OS in all confirmed GBMs. Peto’s test was significant (p = 0.03) indicating that  reatment effects differ 
significantly as a function of PPN. 
 
 
Figure III.7: Predictive value of PPN for TMZ/RT Effect on Overall Survival – resected GBM 
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3.5 Discussion 
 
The present study was performed to assess prognostic significance of morphological features of GBM in 
the registration trial for temozolomide, with a focus on GBMO. Classification of GBM was in high 
concordance (>95%) between the 59 centers and central review. Expectedly, reclassification as a non-
GBM histology was significantly enriched among long-term survivors (Figure III.3). The trial analyses 
and respective reports were on an intention-to-treat basis 
32
, and hence include patients with non-GBM 
histology.  
Identification of unambiguous morphologic features with a prognostic or predictive value within GBM 
would be clinically valuable, as such markers could be easily implemented in routine histopathologic 
diagnostics. The recognized phenotypical GBM variants, giant cell GBM  and gliosarcoma are rare 
(6,<2% and 3,<1% in this study)
15
, precluding reliable assessment of a potential prognostic significance 
when patients are treated with the current standard of care. Evaluation of the prognostic value of an 
oligodendroglioma-like component in an otherwise classic GBM revealed no association with a more 
favorable disease course in either of the two treatment arms, in contrast to previous studies on GBM-O 
9, 
12, 16, 18, 29
. This discrepancy might be explained by the fact that most studies were performed in the pre-
TMZ chemotherapy era. GBM-O, as defined in this report, seems to benefit similarly from 
chemoradiotherapy, in line with the identical MGMT methylation frequency compared to other GBMs 
that differ from frequencies reported for AO and AOA of over 70% 
5, 20, 27, 39
. Further, the delineation of 
‘‘pure’’ GBM versus GBM-O, and AOA and AO is difficult, as reflected in variable frequencies of 
reported 1p/19q codeletions in these studies ranging from 0 to over 20% for the GBM-O subgroup 
9, 12, 13, 
16, 18, 29
. This study uncovered that GBM-O encompasses at least two distinct pathogenetic subgroups, 
characterized either by EGFR amplifications or IDH1 mutations, and further supported by respective 
expression-based classification (Figure III.3). GBM-O, as defined here, may in part overlap with the small 
cell variant of GBM with high cellularity, diffuse more or less monotonous growth and relatively small, 
partly rounded nuclei that is known for increased EGFR amplification frequencies 
12,18
. Conversely, GBM 
with IDH mutations are now recognized as a distinct subtype with a different pathogenetic/epigenetic 
origin, evolving from lower grade glioma with high frequencies of IDH mutations, characteristic of 
secondary GBM 
1,23,40
. Interestingly, IDH mutant gliomas are associated with a DNA hypermethylation 
phenotype 
24
. This association has recently also been reported in leukemia, identifying a new prognostic 
subtype, and mechanistically linking aberrant metabolism (onco-metabolite) with epigenetic deregulation 
6,26
. Our finding that recognition of an oligodendroglioma-like phenotype in otherwise classic GBM 
associates two completely different genetic/epigenetic GBM subtypes is a surprise and questions the 
clinical utility of morphologic identification of GBM-O. The introduction in the 2007 WHO classification 
of high-grade malignant oligoastrocytic tumors with necrosis as GBM-O 
14
 has led to substantial 
controversy among pathologists 
30
 and will certainly have to be re-visited given the recently discovered 
distinct pathogenetic/epigenetic evolution. Determination of oncogenetic events such as IDH status and 
1p/19q co-deletions provide a more promising tool for robust and reproducible (sub) classification of 
malignant gliomas 
8
. Evaluation of distinct morphologic features in this homogenously treated patient 
population identified PPN as potentially associated with benefit from combined chemoradiotherapy. 
Presence of PPN may reflect the tumor milieu including the tumor vascularization type, which may have 
an effect on drug perfusion and thereby on response to chemotherapy. Pseudopalisades are enriched for 
hypoxic and apoptotic tumor cells, with a lower relative proliferation index, and are frequently associated 
with a central degenerating or thrombosed vascular lumen 
2, 28
. Tumor-associated vascular injury has been 
associated with factors released from glioma cells after genetic alterations such as EGFR amplifications or 
cellular stress conditions such as hypoxia 
3, 28
. Based on a comprehensive analysis of PPN in human GBM 
and experimental models, it has been hypothesized that pseudopalisades comprise hypoxic tumor cells 
migrating away from dysfunctional vessels 
2, 28
. However, the presence of PPN does not directly correlate 
with hypoxia as suggested by gene expression profiles available for 50 patients of this cohort 
21, 22
. No 
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correlation was observed with the previously identified hypoxia-induced gene expression signature, while 
the EGFR expression signature (G25) was significantly associated with the presence of PPN (p = 0.02). 
Evaluation of associations of PPN with previously identified expression signatures in appropriately 
powered studies may indicate underlying molecular mechanisms that merit further analysis for 
improvement of therapy. The respective hypotheses may be tested in the database of ‘The Cancer Genome 
Atlas’ (TCGA) once the morphologic information is publicly available 36. In contrast to our study, Homma 
et al. 
12
 reported an association of the presence of any type of necrosis with worse outcome. This 
discrepancy may be explained by the fact that all these patients were treated before the TMZ era (before 
1994) and likely received RT alone. This study has shown that systematic combined morphologic and 
molecular characterization of tumor samples of patients enrolled in clinical trials is instrumental for 
validating and identifying new prognostic and predictive factors that will have an impact on clinical 
practice. This was an exploratory study requiring validation in an independent data set of a homogenous 
patient population treated with combined chemo-radiotherapy. The limited numbers of samples available 
for molecular analyses unfortunately reduced the power of the study, once more emphasizing the 
importance of collecting sufficient tissues for all patients enrolled in clinical trials.  
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4.1 Abstract  
 
Recent studies have shown that the clinical outcome of anaplastic oligodendroglial tumors is variable, but 
also that the histological diagnosis is subject to interobserver variation. We investigated whether the 
assessment of 1p/19q codeletion, polysomy of chromosome 7, epidermal growth factor receptor (EGFR) 
gene amplification (EGFR
amp
), and loss of chromosome 10 or 10q offers additional prognostic information 
to the histological diagnosis and would allow molecular subtyping. For this study, we used the clinical 
data and tumor samples of the patients included in multicenter prospective phase III European 
Organisation for Research and Treatment of Cancer (EORTC) study 26951 on the effects of adjuvant 
procarbazine, chloroethyl cyclohexylnitrosourea (lomustine), and vincristine chemotherapy in anaplastic 
oligodendroglial tumors. Fluorescence in situ hybridization was used to assess copy number aberrations of 
chromosome 1p, 19q, 7, 10, and 10q and EGFR. Three different analyses were performed: on all included 
patients based on local pathology diagnosis, on the patients with confirmed anaplastic oligodendroglial 
tumors on central pathology review, and on this latter group but after excluding anaplastic 
oligoastrocytoma (AOA) with necrosis. As a reference set for glioblastoma multiforme (GBM), patients 
from the prospective randomized phase III study on GBM (EORTC 26981) were used as a benchmark. In 
257 of 368 patients, central pathology review confirmed the presence of an anaplastic oligodendroglial 
tumor. Tumors with combined 1p and 19q loss (1p
loss
19q
loss
) were histopathologically diagnosed as 
anaplastic oligodendroglioma, were more frequently located in the frontal lobe, and had a better outcome. 
Anaplastic oligodendroglial tumors with EGFR
amp
 were more frequently AOA, were more often localized 
outside the frontal lobe, and had a survival similar to that for GBM. Survival of patients with AOA 
harboring necrosis was in a similar range as for GBM, while patients with AOA with only endothelial 
proliferation had better overall survival. In univariate analyses, all molecular factors except loss of 10q 
were of prognostic significance, but on multivariate analysis a histopathological diagnosis of AOA, 
necrosis, and 1p
loss
19q
loss
 remained independent prognostic factors. AOA tumors with necrosis are to be 
considered WHO grade IV tumors (GBM). Of all molecular markers analyzed in this study, especially loss 
of 1p/19q carried prognostic significance, while the others contributed little prognostic value to classical 
histology.  
 
4.2 Introduction 
 
Over the last 15 years, oligodendroglial tumors have been recognized as treatment-sensitive tumors with a 
favorable survival.
1,2
 Molecular studies have shown that this is of particular concern in the subgroup with 
an unbalanced translocation of 19p to 1q, der(1;19)(p10;q10), resulting in the 1p/19q codeletion. 
3–7
 The 
favorable outcome even after radiotherapy (RT) only has recently been further confirmed by two 
randomized prospective studies on (neo)adjuvant procarbazine, chloroethyl cyclohexylnitrosourea 
(CCNU; lomustine), and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors, which 
showed a more favorable survival in tumors with combined 1p
loss
19q
loss
.
8,9
 However, not all tumors with 
an oligodendroglial phenotype have such favorable outcome: up to 20% of patients died within 1 year 
after diagnosis, an outcome that is more consistent with glioblastoma multiforme (GBM). European 
Organisation for Research and Treatment of Cancer (EORTC) study 26951 investigated the benefit of six 
cycles of adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors.
8
 We used this study to 
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investigate the correlation between clinical outcome and specific histological and molecular features. We 
were particularly interested to learn whether necrosis and endothelial proliferation have   
similar prognostic significance in mixed anaplastic oligoastrocytoma (AOA) and pure anaplastic 
oligodendroglioma (AOD), and whether the assessment of specific molecular aberrations usually 
associated with GBM (epidermal growth factor receptor [EGFR] gene amplification, loss of chromosome 
10 or of 10q) contributes to histological diagnosis and clinical prognosis. While this research was ongoing, 
in 2007 a revised WHO classification for glioma was published.
10
 Because this WHO 2007 classification 
of brain tumors classifies AOA with necrosis (previously considered grade III) as grade IV GBM, in a 
further analysis of prognostically important factors AOA with necrosis as diagnosed by the central review 
pathologist were left out. The first level of this analysis considered only the factors directly related to the 
analysis of the tissue samples; in the subsequent level of analysis, clinical information was introduced to 
explore factors with independent prognostic significance. 
 
4.3 Materials and Methods  
 
Patients were eligible for EORTC study 26951 if they had been diagnosed by the local pathologist with 
AOD or AOA with at least 25% oligodendroglial elements according to the 1994 edition of the WHO 
classification of brain tumors,11 had at least three of five anaplastic characteristics (high cellularity, 
mitoses, nuclear abnormalities, endothelial proliferation, and necrosis), were between 16 and 70 years of 
age, had an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2, and had not 
undergone prior chemotherapy or RT to the skull. The clinical details of these studies have been published 
elsewhere.
12
 Since no statistically significant differences in overall survival were observed between the 
patients assigned to RT and those assigned to RT followed by six cycles of adjuvant PCV chemotherapy, 
the patients in both arms were studied together. After inclusion and randomization, central pathology 
review took place (J.M.K.). Patients were then regrouped in three data sets: (1) all patients as diagnosed 
by the local pathologist using the local diagnosis of both histology and anaplastic features (“local 
diagnosis”), (2) centrally confirmed AOD and AOA according to the WHO 1994 classification (“WHO 
1994”), and (3) all centrally confirmed AOD and only the centrally confirmed AOA without necrosis 
(“WHO 2007”). In groups 2 and 3, the central review diagnosis of anaplastic features was used. For 
comparison, a group of patients with GBM obtained from EORTC 26981 was used.
13
  
 
Fluorescence In Situ Hybridization 
 
Probes to 1p36 (D1S32), centromere 1 (pUC1.77), 19p (equivalent amounts of bacterial artificial 
chromosome [BAC] RPCI 11-959O6, 11-957I1, and 11-153P24), 19q (BAC 426G3), PTEN (PAC 
190P6), CEP10 (CEP10; D10Z1), EGFR (BAC RPCI 11-148p17, a kind gift of Dr. A. Perry), centromere 
7 (CEP7; P7t1), and CEP12 (CEP12; Pa12H8) were labeled with biotin-16-dUTP (pUC1.77; Roche 
Diagnostics, Mannheim, Germany), digoxigenin-16-dUTP (D1S32, 959O6, 957I1, 153P24, 190P6, 
148p17; Roche Diagnostics), Spectrum Green (P7t1; Vysis Inc., Downers Grove, IL, USA), Spectrum 
Orange (D10Z1; Vysis Inc.), or Cy5 (Amersham Biosciences, Piscataway, NJ, USA). Tumor sections 
were deparaffinized, dehydrated, and microwave treated in citrate buffer (pH 6.0) and then digested in 
0.4% pepsin solution (Sigma-Aldrich, St. Louis, MO, USA) in 0.9% NaCl (pH 1.5–2.0), as previously 
described.
14 
Subsequently, slides were dehydrated, and probe solutions were applied. Tumor sections and 
probes were codenaturated on a slide moat preheated to 80°C for 5 min, and then cooled on ice and 
incubated at 37°C for 48 h in a moistened chamber. After incubation, slides were washed in 1.5 M urea 
saline–sodium citrate (SSC) at 45°C for 30 min and rinsed in 2xSSC. Probes were detected using 
antirhodamine-conjugated digoxigenin (426G3, 148p17; Roche Diagnostics, Mannheim, Germany), 
antidigoxigenin-conjugated with fluorescein isothiocyanate (D1S32, 959O6, 957I1, 153P24, 190P6; 
Roche Diagnostics), or Cy3-conjugated avidin (pUC1.77; Brunschwig Chemie, Amsterdam, the 
Netherlands) antibodies at a concentration of 4 and 15 μg/ml diluted in phosphate-buffered saline. Nuclei 
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were counterstained with diamidinophenylindole in antifade solution (Vector Laboratories, Burlingame, 
CA, USA). Locus-specific fluorescence in situ hybridization (FISH) probes were enumerated in 60 
nonoverlapping nuclei per hybridization utilizing a Leica DM-RXA fluorescence microscope (Leica, 
Wetzlar, Germany). Images were captured using a COHU 4910 series monochrome CCD camera (Cohu 
Inc., San Diego, CA, USA) attached to the fluorescence microscope equipped with a PL Fluotar 3100, 
numerical aperture 1.30–0.60 objective, I3 and N2.1 filters (Leica), and Leica QFISH software (Leica 
Imaging Systems, Cambridge, UK). Ratios were calculated for 1p versus CEP1, 19q versus 19p, or 10q 
versus CEP10 (10qloss) by dividing the number of signals of the marker by the number of signals of the 
reference; a ratio of less than 0.80 was considered allelic loss. If a borderline ratio was obtained (0.75–
0.90), spots in 200 nuclei were counted. For ratios of EGFR versus CEP7, CEP7 versus CEP12, or CEP10 
versus CEP12, different cutoff levels were used. A ratio of EGFR/CEP7.2 was considered EGFR 
amplification (EGFR
amp
), a ratio of CEP7/CEP12 > 1.1 displayed polysomy of chromosome 7 (7
poly
), and 
a ratio < 0.85 for CEP10/CEP12 was indicative of monosomy 10 (10
loss
). These cutoff values were 
determined in a set of nontumoral controls that displayed <10% nuclei with more than two signals for the 
investigated marker/nucleus. 
 
Statistical Analysis 
 
The prognostic significance of the tissue variables (diagnosis, anaplastic features, and molecular features) 
were first analyzed without taking any nontissue (clinical) factors into account. For the multivariate 
analysis, the following major prognostic clinical variables were used: WHO PS (0, 1, 2), age (,50, >50), 
type of surgery (biopsy or resection), and type of adjuvant treatment (none or PCV). For the histological 
factors, the diagnosis (AOD or AOA) and the five anaplastic features were used, diagnosed either by the 
local pathologist for the local diagnosis or by the central review pathologist for centrally confirmed 
tumors. For the molecular factors, 1p
loss
, 19q
loss
, 1p
loss
19q
loss
, EGFR
amp
, 7
poly
, 10
loss
, and 10q
loss
 were used. 
Association between factors was assessed by the Spearman correlation coefficient (SCC); Fisher’s exact 
test was used for inference. Survival analyses in the three populations were performed with the log-rank 
test and the Cox regression analysis stratified by the treatment, with and without backward selection. 
Internal validation was performed by bootstrap resampling technique (5% confidence) to assess the 
generalizability of the models. Factors with a probability of inclusion (PI) in regression models of less 
than 60% based on 1,000 bootstrap samples were considered not confirmed as independent prognostic 
factors. Patients with missing values in at least one factor were removed from the analyses. No formal 
adjustment for multiple testing was performed; nevertheless, a conservative significance level of 1% was 
considered for all comparisons.  
 
4.4 Results 
 
In this study, 368 patients were randomized; 265 had been diagnosed by the local pathologist with an 
AOD and 100 with an AOA (three missing). At central pathology review, in 257 patients the diagnosis of 
an anaplastic oligodendroglial tumor was confirmed (175 AOD, 82 AOA). Other frequent diagnoses at 
central review were low-grade tumors (39 patients) and high-grade astrocytic tumors (anaplastic 
astrocytoma or GBM, 39 patients); for 22 patients no material was received for review. Table IV-1 
specifies the pathology findings, presence of necrosis, and endothelial proliferation in each of the three 
data sets. 
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Table IV-1: Main pathological findings. 
 
Finding Locally diagnosed AOD or 
AOA 
Diagnosis at Central 
Pathology Review 
WHO Definition 2007 
N 368 346 202 
Histology    
 AOD 265 175 175 
 AOA 100 82 27 
 Missing 3 22  
 HGA  39  
 LGG  39  
 Other  11  
Presence of necrosis    
AOD:total 148:265 119:175 119:175 
AOA:total 51:100 55:82 0:27 (definition) 
Endothelial proliferation    
AOD:total 211:265 166:175 166:175 
AOA:total 69:100 80:82 25:27 
Abbreviations: AOD, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; HGA, high-grade astrocytoma; LGG, 
low-grade glioma. 
 
Molecular Alterations 
 
Table IV-2 shows the distribution of molecular characteristics and Table IV-3 the correlations between the 
molecular characteristics. 1p
loss
 and 19q
loss
 were highly correlated with each other (SCC = 0.51). EGFR
amp
 
was correlated with 7
poly
 (SCC = 0.40) and with 10
loss
 (SCC = 0.48). EGFR
amp
 and 1p
loss
19q
loss
 were 
poorly anticorrelated (SCC = –0.24): of the 227 patients with both measures, 59 patients had 1ploss19qloss, 
50 had EGFR
amp
, 3 had both, and 121 had neither (p = 0.0001).  
 
Table IV-2: Presence or absence of chromosomal findings and numbers without test results. 
 
 1p loss 19q loss Combined 
1p and 19q 
loss 
EGFR 
Amplification 
7 Polysomy 10q Loss 10 Loss 
Absent 186 (51%) 198 (54%) 217 (59%) 182 (50%) 162 (44%) 211 (57%) 199 (54%) 
Present 131 (36%) 98 (27%) 76 (21%) 51 (14%) 68 (19%) 37 (10%) 39 (11%) 
Missing 51 (14%) 72 (20%) 75 (20%) 135 (37%) 138 (38%) 120 (37%) 130 (35%) 
 
Table IV-3: Spearman correlation coefficients between the various molecular parameters. 
 
 Spearman Correlation Coefficient (p Value) and Number of Patients  
Molecular Parameter 1p and 19q loss EGFR 
Amplification 
7 Polysomy 10q Loss 10 Loss 
1p and 19q loss 1 -0.24 -0.10 -0.15 -0.19 
  (0.0002) (0.15) (0.02) (0.003) 
 293 227 224 241 231 
EGFR amplification  1 0.40 0.26 0.48 
   (<0.0001) (0.0001) (<0.0001) 
  233 230 213 207 
7 polysomy   1 0.07 0.26 
    (0.31) (0.0001) 
   230 211 206 
10q loss    1 -0.18 
     (0.006) 
    248 238 
10 loss     1 
     238 
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Necrosis but not endothelial proliferation discriminates a subgroup of AOA with similar survival profile 
as GBM.  
 
Of the 82 AOA tumors, 55 (67%) showed necrosis. Endothelial proliferation was present in almost all 
AOA tumors (80 of 82) and in all 55 AOA tumors with necrosis. Table IV-4 shows the survival of patients 
with AOD and AOA with or without necrosis, and the reference group of GBM patients treated with RT 
only, and Figure IV.1 shows the survival curves of these patients in the RT arms of both studies. After 
correction for extent of resection, PS, and age, in the patients treated with RT alone survival for AOA with 
necrosis was in a similar range as the survival for GBM (hazard ratio [HR] = 1.53; 95% confidence 
interval [CI], 1.02–2.31; p = 0.042). Survival in the 25 patients with AOA showing endothelial 
proliferation but no necrosis was better than in patients with GBM (p = 0.007). The outcome of AOD 
patients without tumor necrosis was better than for those without tumor necrosis, but in the latter category 
survival was still much more favorable than for patients with GBM or with AOA without necrosis (Figure 
IV.1). 
 
Table IV-4: Two-year OS rates in confirmed AOD and AOA in relation to the presence of necrosis. 
 
Diagnosis Median Survival 
[Range (months)] 
Two-Year Survival Rate 
AOA with necrosis 15.9 [12.7-18.0] 27.3 [16.4-39.4] 
AOA without necrosis
a
 21.9 [16.0-33.5] 48.0 [27.8-65.6] 
AOD with necrosis 34.7 [24.2-59.4] 59.32 [49.9-67.6] 
AOD without necrosis NR [NR-NR] 82.1 [69.4-90.0] 
Glioblastoma EORTC 26981 12.1 [11.2-13.0] 10.4 [6.8-14.1] 
Abbreviations: AOA, anaplastic astrocytoma; AOD, anaplastic oligodendroglioma; NR, not reached; EORTC, European 
Organisation for Research and Treatment of Cancer 
a
AOA with endothelial proliferation but no necrosis; two patients with AOA lacking both necrosis and endothelial proliferation 
have been left out. 
 
Molecular alterations are distinct in subgroups of oligodendroglial tumors.  
 
Table IV-5 shows the molecular findings in the centrally confirmed AOA without necrosis, AOD, and 
AOA with necrosis. Combined 1p
loss
19q
loss
 was more frequent in AOD or AOA without necrosis; AOA 
with necrosis more often had EGFR
amp
, 7
poly
, and 10
loss
. Despite the observed differences in frequencies, 
none of the items clearly separated both subgroups. Frontal tumors and previous resection for a low-grade 
tumor were more frequently observed in tumors with combined 1p
loss
19q
loss
 (p = 0.0021 and p = 0.0087) 
and less frequent in tumors with EGFR
amp
 (p = 0.0004 and p = 0.0045). No other clinical factor, including 
age, was related to any of the molecular factors (data not shown). 
 
Table IV-5: Molecular findings in tumors with central review diagnosis of AOD and AOA. 
 
Molecular Parameter AOD All AOA AOA with Necrosis AOA without Necrosis 
1p and 19q loss 53/145 (37%) 5/69 (7%) 5/46 (11%) 0/23 (0%) 
EGFR amplification 20/113 (18%) 25/59 (42%) 17/39 (44%) 8/20 (40%) 
7 polysomy 28/110 (25%) 22/59 (37%) 18/39 (46%) 4/20 (25%) 
10q loss 16/130 (12%) 14/56 (25%) 10/38 (26%) 4/18 (22%) 
10 loss 17/124 (14%) 16/53 (30%) 12/35 (34%) 4/18 (22%) 
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Prognostic significance of tissue characteristics only (including molecular characteristics).  
 
Table IV-6 shows the univariate analysis of all histological and molecular factors in all patients. All 
molecular factors except for loss of 10q were correlated with outcome (p < 0.01). Outcome for AOA with 
EGFR
amp
 was similar to that for AOD with EGFR
amp
 (p = 0.354). Except for combined 1p
loss
19q
loss
, in all 
three data sets, multivariate analysis using tissue (molecular and histological) factors showed none of the 
other molecular factors to be of prognostic significance. The presence of necrosis was of significance, 
when assessed by the local pathologist or by the central reviewing pathologist. Furthermore, the central 
review histopathological diagnosis (AOD, AOA with or without necrosis) was of significance. 
 
Table IV-6: Univariate survival analysis of all histological and molecular factors in all patients. 
 
Factor p Hazard Ratio 
(95% Confidence Interval) 
High cellularity <0.0001 2.82 (1.81-4.40) 
Nuclear abnormalities 0.0009 4.49 (1.85-10.91) 
Mitoses 0.0001 2.20 (1.47-3.31) 
Endothelial abnormalities <0.0001 3.44 (2.03-5.83) 
Necrosis <0.0001 2.66 (1.94-3.64) 
1p loss <0.0001 0.27 (0.19-0.38) 
19q loss <0.0001 0.31 (0.21-0.45) 
Combined 1p and 19 loss <0.0001 0.25 (0.16-0.40) 
EGFR amplification <0.0001 2.68 (1.86-3.86) 
7 polysomy 0.0002 1.94 (1.37-2.75) 
10q loss 0.1 1.43 (0.93-2.19) 
10 loss <0.0001 2.47 (1.67-3.65) 
 
Local diagnosis—all patients.  
Selected were 1p
loss
, combined 1p
loss
19q
loss
, necrosis, 7
poly
, and 10
loss
. With bootstrap resampling, not 
confirmed were 7
poly
 (PI = 52%) and 10
loss
 (PI = 49%). 1p
loss
 was borderline not confirmed (PI = 58%).  
 
Centrally confirmed AOD and AOA (WHO 1994). 
Selected were 1p
loss
, combined 1p
loss
19q
loss
, AOA, and necrosis. With bootstrap resampling, 1p
loss
 was not 
confirmed (PI = 52%).  
 
Central diagnosis—confirmed AOD and AOA but not AOA with necrosis (WHO 2007).  
Selected were 1p
loss
 and combined 1p
loss
19q
loss
; both were confirmed with bootstrap resampling. 
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Figure IV.1: OS curves of patients split by diagnosis and presence of necrosis compared to GBM. 
 
Note: Only patients randomized to the radiotherapy control arm of European Organisation for Research and Treatment of 
Cancer trials 26951 and 26981 are represented. 
 
Prognostic significance of tissue characteristics adjusted for main clinical factors. 
 
Local diagnosis—all patients.  
Selected were PS, age, 1p
loss
, 1p
loss
19q
loss
, necrosis, 7
poly
, and 10
loss
 (Table IV-7). With bootstrap 
resampling, 1p
loss
 (PI = 56%) and 10
loss
 (PI = 38%) were not confirmed. The PI of 7
poly
 was of 
borderline significance (59.7%); the other factors were confirmed. 
 
Centrally confirmed AOD and AOA (WHO 1994). 
Selected were PS, age, 1p
loss
19q
loss
, AOD diagnosis, and necrosis (Table IV-7). All factors were confirmed 
by bootstrap resampling. 
 
Central diagnosis—confirmed AOD and AOA but not AOA with necrosis (WHO 2007).  
Selected were PS, age, 1p
loss
, 1p
loss
19q
loss
, and 10
loss
 (Table IV-7). With bootstrap resampling, PS  and 
1p
loss
19q
loss
 were confirmed. The other factors had PIs<60%. 
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Table IV-7: Multivariate analyses in confirmed AOD or AOA including or excluding AOA with necrosis. 
 
 
 
Locally diagnosed  
AOD or AOA 
Centrally confirmed  
AOD or AOA, WHO 1994 
Centrally confirmed  
AOD or AOA (Excluding AOA 
with Necrosis), 
WHO 2007 
Factor HR 
(95% CI) 
p 
(% inclusion) 
HR 
(95% CI) 
p 
(% inclusion) 
HR 
(95% CI) 
p 
(% inclusion) 
Extent of surgery       
Partial/total resection 1.00 NS (53) 1.00 NS (23) 1.00 NS (16) 
Biopsy 1.80 (0.99-3.27)  1.25 (0.62-2.53)  0.85 (0.35-2.07)  
WHO performance 
statusa 
      
0       
1 1.45 (1.09-1.92 0.01 (66) 1.84 (1.29-2.64) 0.0009 (83) 1.90 (1.25-2.89) 0.003 (84) 
2       
Age       
<50 1.00 0.002 (84) 1.00 0.0080 (72) 1.00 NS (20) 
50 1.85 (1.27-2.71)  1.78 (1.16-2.73)  1.73 (1.04-2.88) 0.04 (57) 
1p loss only       
No 1.00 0.04 (56) 1.00 NS (39) 1.00 0.04 (52) 
Yes 0.57 (0.33-0.97)  0.59 (0.30-1.17)  0.49 (0.25-0.96)  
19q loss only       
No 1.00 NS (24) 1.00 NS (33) 1.00 NS (20) 
Yes 0.63 (0.30-1.29)  0.47 (0.18-1.25)  0.57 (0.18-1.77)  
Combined 1p/19q loss       
No 1.00 <0.0001 (100) 1.00 <0.0001 (100) 1.00 <0.0001 (100) 
Yes 0.12 (0.06-0.25)  0.16 (0.08-0.33)  0.10 (0.04)-
0.22) 
 
AOD       
No 1.00 NS (9) 1.00 0.0003 (66) 1.00 NS (18) 
Yes 1.06 (0.67-1.68)  0.43 (0.27-0.68)  0.80 (0.29-2.17)  
High cellularity       
No 1.00 NS (14) 1.00 NS (23) 1.00 NS (18) 
Yes 1.48 (0.66-3.30)  0.72 (0.26-2.0)  1.08 (0.32-3.69)  
Nuclear abnormalities       
No 1.00 NS (17) 1.00 NS (3) 1.00 NS (4) 
Yes 1.03 (0.46-2.30)  1.27 (0.12-
13.39) 
 0.58 (0.05-7.50)  
Mitoses       
No 1.00 NS (18) 1.00 NS (30) 1.00 NS (38) 
Yes 1.51 (0.70-3.24)  0.67 (0.34-1.32)  0.48 (0.21-1.09)  
Endothelial 
abnormalities 
      
No 1.00  1.00 NS (10) 1.00 NS (12) 
Yes 1.49 (0.87-2.57) NS (26) 1.48 (0.42-5.24)  1.49 (0.40-5.55)  
Necrosis       
No 1.00 0.0004 (92) 1.00 0.0006 (80) 1.00 NS (41) 
Yes 2.00 (1.36-2.94)  2.34 (1.44-3.81)  1.77 (0.81-3.86)  
EGFR amplification       
No 1.00 NS (29) 1.00 NS (36) 1.00 NS (29) 
Yes 1.24 (0.68-2.26)  1.36 (0.72-2.58)  1.24 (0.50-3.08)  
7poly       
No 1.00 0.02 (59) 1.00 NS (30) 1.00 NS (35) 
Yes 1.65 (1.09-2.49)  1.29 (0.74-2.24)  1.48 (0.73-2.98)  
10loss       
No 1.00 0.03 (38) 1.00 NS (27) 1.00 0.04 (31)b 
Yes 1.68 (1.06-2.68)  1.17 (0.63-2.19)  1.93 (1.02-3.65)  
10qloss       
No 1.00 NS (24) 1.00 NS (28) 1.00 NS (16) 
Yes 0.73 (0.38-1.38)  0.65 (0.33-1.32)  0.79 (0.35-1.79)  
Abbreviations: HR, hazard ratio; CI, confidence interval; NS, not significant. 
a
 For ordered categorical factors, the first value is 
the reference. HR=1 X x means the risk of death is increased by x% between patients belonging to adjacent groups. 
b
 Selected 
by backward selection but not kept in the final model because the percentage of inclusion in bootstrap simulations was less than 
60% 
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4.5 Discussion 
 
In the present study, losses of 1p (41%) and/or 19q (33%) were the most common genomic alterations. In 
addition, no less than 22% of cases displayed EGFR
amp
, which was inversely related to the 1p/19q 
codeletion. Loss of 10q and/or copy number aberrations of chromosomes 7 (gain) and 10 (loss) were also 
observed in a substantial number of anaplastic oligodendroglial tumors, predominantly in tumors with 
EGFR
amp
. The molecular, histological, and clinical properties identified two subgroups of tumors with 
distinct prognostic characteristics: (1) oligodendroglial tumors with 1p
loss
19q
loss
, mainly located in the 
frontal lobe, with a predominant AOD histology and a favorable prognosis, and (2) tumors with EGFR
amp
, 
often with copy number alterations of chromosomes 7 and/or 10, located outside the frontal region, with a 
mixed oligoastrocytoma phenotype and with a less favorable prognosis. The subgroup with EGFR
amp
 and 
loss of chromosome 10 resembles the previously described “GBM with oligodendroglial phenotype.” 15–21 
The same genetic lesions (and often also with EGFRvIII mutations) have been described in the small-cell 
GBM variant, which is characterized by monomorphous, deceptively bland nuclei and is often 
misdiagnosed as AOD.
22,23
 Together with PTEN (phosphatase and tensin homolog) mutations and 
deletions, EGFR
amp
, 7 
poly
, and 10
loss
 are the most common genotypic alterations in GBM.
24
 As expected, 
after correction for prognostic variables, comparison of this subset of patients with tumors with EGFR
amp
 
to a group of GBM patients from EORTC study 26981 shows no statistically significant difference in 
survival.
25
 Clearly, despite the intent of the EORTC study 26951 to include chemosensitive 
oligodendroglioma, this analysis shows that a large number of less sensitive GBM with some 
oligodendroglial features was entered into this clinical study. The EORTC study on anaplastic 
oligodendroglial tumors was initiated because studies on recurrent disease showed anaplastic 
oligodendroglial tumors as opposed to GBM to be sensitive to chemotherapy. Over the past years, it has 
become clear that the diagnosis of WHO grade III, including classical AOD, is subject to a considerable 
interobserver disagreement, and the exact delineation of AOD and AOA from GBM with oligodendroglial 
features is unclear.
26,27
 During the conduct of the clinical study, the strong relationship between 
1p
loss
19q
loss
 and response to chemotherapy was discovered, limiting the subset of chemotherapy-sensitive 
tumors to the 1p19q codeleted tumors. The poor clinical outcome observed in some of the patients made 
us hypothesize that the use of molecular diagnostics aiming at genetic abnormalities associated with GBM 
could identify tumors with some oligodendroglial morphology but with an outcome similar to GBM (and 
to be treated like GBM). Our results show that molecular diagnostics can indeed serve this purpose, 
although the added benefit is less than anticipated. Simultaneously, retrospective studies have shown that 
survival of AOD differs from the survival of AOA, and that the presence of necrosis identifies a subgroup 
of AOA with unfavorable outcome.
28,29
 Because of the latter finding, by simply leaving out the word 
“necrosis” in the section on AOA, the 2007 edition of the WHO classification of brain tumors considers 
the presence of necrosis no longer consistent with the diagnosis of AOA.
30,31
 In the present prospective 
setting, the outcome of AOA with necrosis is in a similar range and clinically more or less equivalent to 
the outcome of GBM with a risk-adjusted p-value that did not meet preset levels of statistical significance 
(p= 0.04). The GBM-like nature of “AOA with necrosis” is further corroborated by the presence of 
EGFR
amp
 in 44% and 10
loss
 in 35% of the tumors, which is similar to the incidence of these genetic 
aberrations in studies of GBM. On the other hand, AOA patients with only endothelial abnormalities have 
a somewhat better outcome, justifying the inclusion of this population in the present WHO definition of 
AOA. Similarly, although for AOD necrosis had a prognostic impact, the outcome was much better than 
for GBM. In another review series, “grade IV” AOA (the diagnosis of which required necrosis) had a 
better survival than GBM, but median survival in the AOA grade IV group was 15.6 months, compared to 
10.9 months in the GBM group.
32
 Our findings (see Table IV-4) are also consistent with that conclusion, 
and the limited number of AOA with necrosis (55 patients) may have affected the power to reach 
statistically significant differences with the GBM group. In two previous studies, necrosis did affect 
outcome of AOA (or non classic oligodendroglioma) but not that of AOD (or classical 
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oligodendroglioma).
27,33
 In the pathology review of Radiation Therapy Oncology Group study 94-02, age, 
multifocal disease, histology (classical vs. non classical), and 1p/19q status were independent prognostic 
factors but not necrosis. In our analysis, necrosis was of prognostic significance in locally diagnosed 
tumors and also in the WHO 1994 data set and in centrally confirmed AOD. In multivariate analysis of the 
entire study population, necrosis remained an independent prognostic factor (data not shown). With 
changing views on the diagnosis of oligodendroglial tumors, it will be interesting to repeat this analysis 
based on a repeated pathology review with stricter criteria for oligodendroglioma. 
 
Our findings show that 1p
loss
19q
loss
 is the most powerful molecular predictor of outcome. Although highly 
correlated to outcome in univariate analyses, the other molecular factors have little additional value when 
considered together with all other available information, in particular, the histological diagnosis and the 
histological features (the presence of necrosis). Both clinically and molecularly, the WHO 1994 “AOA 
with necrosis” classification indeed equals GBM, and previous studies have shown that in GBM the 
presence of EGFR amplification has no additional prognostic significance.
34
 Of note, in the local 
diagnosis polysomy of chromosome 7 and loss of chromosome 10 were selected in multivariate analysis 
but not confirmed. This suggests that molecular studies may be more relevant when the pathological 
diagnosis is less certain (e.g., in a setting where the diagnosis is not made by an experienced 
neuropathologist or when only small biopsies are available for histopathological diagnosis). 
Retrospectively, the inclusion criteria of the EORTC phase III study on adjuvant PCV chemotherapy 
failed to reach its objective: to enter a subset of chemotherapysensitive tumors into the study. The 
inclusion of many GBM-like tumors is likely to have affected the power of this study, and thus the 
outcome of the study. Of note, the analysis of the pathology review within the similar North American 
Intergroup Radiation Therapy Oncology Group Trial 9402 suggests that adjuvant PCV treatment may be 
beneficial in the so-called classical AOD as diagnosed by microscopy.
27
 In that study, it was suggested 
that inclusion based on central review is pivotal to keep the study population homogeneous. It is of note, 
however, that in that study the interobserver agreement was also moderate, and it remains unclear how a 
study population based on inclusion by central review reflects the patients locally diagnosed (and treated) 
in everyday clinical practice with such a tumor. 
 
There are a number of potential shortcomings of the present study. First, FISH has a limited sensitivity 
and specificity. In particular, GBM may have partial deletions of 1p, which is picked up by FISH for 
1p36.6.
35–37
 This may explain why we observed 1p/19q codeletions together with EGFR
amp
 in some 
patients. Also, FISH for 19q can be troublesome due to the often weak fluorescence signals that are 
obtained. Second, limitations in available material may have caused sample bias. More advanced 
techniques using better conserved tissue samples are likely to yield better results. In a comparable project 
including 60 patients also treated within EORTC study 26951 and from whom frozen tumor samples were 
available, BAC array-based comparative genomic hybridization (aCHG) was performed (Ibdaih et al., 
unpublished observations). This analysis revealed four genomic subgroups with prognostic information 
(combined 1p/19q 
loss
, EGFR
amp
, loss of chromosome 21, and neither of these). Multivariate analysis with 
all relevant prognostic factors identified age (p= 0.0002) and genomic profile (p<, 0.0001) as independent 
prognostic factors. The interobserver variation between the aCHG data from that study and the FISH data 
used in the present study was considered good for both EGFR
amp
 (=0,796) and 1p/19q codeletion 
(=0,612). Still, a few samples were classified differently by these techniques. The two studies suggest 
that, in addition to pathological features (notably necrosis), molecular data are of interest for anaplastic 
oligodendroglial tumors. Both studies confirmed the 1p/19q codeletion as a strong biomarker in anaplastic 
oligodendroglial tumors and identified additional biomarkers requiring further investigations as candidates 
in the non-1p/19q-codeleted anaplastic oligodendroglial tumors. 
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Methylation status of the MGMT (O
6
-methylguanine–DNA methyltransferase) promoter gene was no part 
of this analysis; with the limited amount of tissue available (usually slides only) and stored for many 
years, this was not yet possible at the time of this study, although it is currently being studied in a subset 
of patients. This is likely to be an additional prognostic or predictive factor, especially in patients treated 
with chemotherapy (although the recent German NOA4 study suggests it may also be of prognostic value 
in patients managed with RT only).
38,39
 In conclusion, this study shows that, at the molecular level, 
EORTC study 26951 of anaplastic oligodendroglial tumors included a heterogeneous group of tumors, 
with almost 25% of tumors more resembling GBM, which should not have entered the study. Particularly, 
combined 1p
loss
19q
loss
 contained additional prognostic significance, while most of the additional 
prognostic information of the other investigated molecular characteristics was already covered by the 
histopathology. Our study confirms that AOA with necrosis should indeed be considered GBM (WHO 
grade IV). The clinical outcome of patients with EGFR amplification was similar to that of a control group 
with GBM. 
 
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study. 
 
 
74 
 
4.6 References 
 
1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J 
Clin Oncol. 1994;12:2013–2021.  
 
2. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent 
oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 
1998;51: 1140–1145.  
 
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic 
response and survival in patients with anaplastic oligodendrogliomas. J Natl Canc Inst. 
1998;90:1473–1479.  
 
4. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors 
shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175–1190.  
 
5. van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in 
oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97:1276–1284.  
 
6. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19) (q10;p10) in five 
oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp 
Neurol. 2006;65:988–994.  
 
7. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p 
and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 
2006;66:9852–9861.   
 
8. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant PCV improves progression free 
survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and 
oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol. 2006;24:2715–2722.  
 
9. Cairncross JG, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy (RT) 
versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup 
trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol. 2006;24:2707–2714. 
 
10.  Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the 
Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007.  
 
11. Sobin LH, ed. Histological Typing of Tumours of the Central Nervous System. New York: 
Springer-Verlag; 1993. 
 
12. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and 
vincristine improves progression-free survival but not overall survival in newly diagnosed 
anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for 
Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–2722.  
 
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.  
 
 
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study. 
 
 
75 
 
14. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive 
for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42:2499–
2503.   
 
15. Jeuken JWM, Sprenger SHE, Wesseling P, et al. Identification of subgroups of high-grade 
oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. 
1999;58:606–612. 
 
16. Jeuken JWM, Nelen MR, Vermeer H, et al. PTEN Mutation analysis in two genetic subtypes of 
high-grade oligodendroglial tumors: PTEN is only occasionally mutated in one of the two genetic 
subtypes. Cancer Genet Cytogenet. 2000;119:42–47.  
 
17. Jeuken JW, Sprenger SH, Boerman RH, et al. Subtyping of oligoastrocytic tumours by 
comparative genomic hybridization. J Pathol. 2001;194:81–87.  
 
18. Zlatescu MC, Tehrani Yazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with 
genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;18:6713–6715.  
 
19. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, et al. Correlations between molecular profile 
and radiologic pattern in oligodendroglial tumors. Neurology. 2004;63:2360–2362.  
 
20. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates 
with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002;161:313–319.  
 
21. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a 
pathological and molecular study. J Neuropathol Exp Neurol. 2001;60:863–871. 
 
22. Perry A, Aldape KD, George DH, et al. Small cell astrocytoma: an aggressive variant that is 
clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 
2004;101:2318–2326.  
 
23. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture—a histological equivalent of EGFR 
amplification in glioblastoma multiforme? J Neuropathol Exp Neurol. 2001;60:1099–1104.  
 
24. Wiltshire RN, Rasheed BK, Friedman HS, et al. Comparative genetic patterns of glioblastoma 
multiforme: potential diagnostic tool for tumor classification. Neuro-Oncology. 2000;2:164–173. 
 
25. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed 
glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III 
randomized trial. J Clin Oncol. 2006;24:2563–2569.  
 
26. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from 
EORTC trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and 
correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545–551.  
 
27. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the 
correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation 
Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360–369.  
 
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study. 
 
 
76 
 
28. Smith SF, Simpson JM, Brewer JA, et al. The presence of necrosis and/ or microvascular 
proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: 
review of 98 patients. J Neurooncol. 2006;80:75–82.  
 
29. Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of 
oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade 
gliomas. J Clin Oncol. 2006;24:5419–5426.  
 
30. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. Anaplastic oligoastrocytoma. In: 
Kleihues P, Cavenee WK, eds. Anaplastic Oligoastrocytoma. Lyon, France: IARC Press; 2000:68–
69.  
 
31. von Deimling A, Reifenberger G, Kros JM, Louis DN, Collins VP. Anaplastic oligoastrocytoma. 
In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, ed. Anaplastic Oligoastrocytoma. Lyon, 
France: International Agency for Research on Cancer; 2008:66–67.  
 
32. Buckner JC, O’Fallon JR, Dinapoli RP, et al. Prognosis in patients with anaplastic 
oligoastrocytoma is associated with histologic grade. J Neurooncol. 2007;84:279–286.  
 
33. Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of 
oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade 
gliomas. J Clin Oncol. 2006;24:5419–5426.  
 
34. Quan AL, Barnett GH, Lee SY, et al. Epidermal growth factor receptor amplification does not 
have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol 
Phys. 2005;63:695–703.  
 
35. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite 
significance in gliomas. Ann Neurol. 2005;58:483–487.  
 
36. Idbaih A, Kouwenhoven M, Jeuken J, et al. Chromosome 1p loss evaluation in anaplastic 
oligodendrogliomas. Neuropathology. 2008;28: 440–443.  
 
37. Ichimura K, Vogazianou AP, Liu L, et al. 1p36 is a preferential target of chromosome 1 deletions 
in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 
2008;27:2097–2108.  
 
38. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in 
glioblastoma. N Engl J Med. 2005;352:997–1003.  
 
39. Wick W, Weller M. NOA-04 randomized phase III study of sequential radiochemotherapy of 
anaplastic glioma with PCV or temozolomide [abstract]. Proc Am Soc Clin Oncol. 2008;26:1008s.
 
 
 77 
 
Chapter V.  Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross 
JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. 
Nomograms for predicting survival of patients with newly diagnosed 
glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-
22981/CE.3. Lancet Oncol. 2008 Jan;9(1):29-38. 
 
5.1 Abstract 
 
Background  
A randomised trial published by the European Organisation for Research and Treatment of Cancer 
(EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial 26981-
22981/CE.3) showed that addition of temozolomide to radiotherapy in the treatment of patients with 
newly diagnosed glioblastoma significantly improved survival. We aimed to undertake an exploratory 
subanalysis of the EORTC and NCIC data to confirm or identify new prognostic factors for survival in 
adult patients with glioblastoma, derive nomograms that predict an individual patient’s prognosis, and 
suggest stratification factors for future trials.  
Methods 
Data from 573 patients with newly diagnosed glioblastoma who were randomly assigned to radiotherapy 
alone or to the same radiotherapy plus temozolomide in the EORTC and NCIC trial were included in this 
subanalysis. Survival modeling was done in three patient populations: intention-to-treat population of all 
randomised patients (population 1); patients assigned temozolomide and radiotherapy (population 2, 
n=287); and patients assigned temozolomide and radiotherapy who had assessment of MGMT promoter 
methylation status and who had undergone tumour resection (population 3, n=103). Cox proportional 
hazards models were fitted with and without O
6
-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status. Nomograms were developed to predict an individual patient’s median and 2-
year survival probabilities. No nomogram was developed in the radiotherapy-alone group because 
combined treatment is now the new standard of care.  
Findings  
Independent of the MGMT promoter methylation status, analysis in all randomised patients (population 1) 
identified combined treatment with temozolomide, more extensive tumour resection, younger age, Mini-
Mental State Examination (MMSE) score of 27 or higher, and no corticosteroid treatment at baseline as 
independent prognostic factors correlated with improved survival outcome. In patients assigned 
temozolomide and radiotherapy (population 2), younger age, better performance status, more extensive 
tumour resection, and MMSE score of 27 or higher were associated with better survival. In patients who 
had tumours resected, who were assigned temozolomide and radiotherapy, and who had available MGMT 
promoter methylation status (population 3), methylated MGMT, better performance status, and MMSE 
score of 27 or higher were associated with improved survival. Nomograms were developed and are 
available at http://www.eortc.be/tools/gbm calculator.  
Interpretation  
MGMT promoter methylation status, age, performance status, extent of resection, and MMSE are 
suggested as eligibility or stratification factors for future trials in patients with newly diagnosed 
glioblastoma. Stratifying by MGMT promoter methylation status should be mandatory in all glioblastoma 
trials that use alkylating chemotherapy. Nomograms can be used to predict an individual patient’s 
prognosis, and they integrate pertinent molecular information that is consistent with a paradigm shift 
towards individualised patient management. 
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5.2 Introduction 
 
A randomised trial published by the European Organisation for Research and Treatment of Cancer 
(EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial 26981-
22981/CE.3) showed that addition of temozolomide to radiotherapy for the treatment of patients with 
newly diagnosed glioblastoma significantly improved survival.
1
 Radiotherapy plus concomitant and 
adjuvant temozolomide has rapidly become the new standard of care in Europe and North America. New 
strategies are now being developed that build on this treatment of glioblastoma. Despite this progress, the 
overall outcome of patients with glioblastoma remains unsatisfactory, and prognosis is highly variable in 
various categories of patients. Previous studies have identified several clinical factors that help to explain 
the variability of outcome in patients with glioblastoma. Age, performance status, and extent of surgical 
resection are the most consistently reported prognostic factors.
2–7
 In particular, a recursive partitioning 
analysis (RPA) undertaken by the Radiation Therapy Oncology Group (RTOG) has identified four risk 
classes for glioblastoma (classes III, IV, V, and VI) based on patients’ ages, Karnofsky performance 
status, neurological function, mental status, and extent of surgery.
2,3
 Additionally, the effect of tumour 
location has been described in several published studies, and includes, in particular, the unfavourable 
effect of midline cranial shift involvement and of deep seated tumours, and the possible favourable 
prognosis of a frontal location.
4–10
 The unfavourable prognostic effect of an abnormal mental status was 
first reported by Curran and colleagues
2
 in the original report of the RPA classification, although a formal 
definition of abnormal mental status was not provided. In a study of prognosis in high-grade gliomas, the 
Folstein Mini-Mental State Examination (MMSE) was retained in an RPA together with age and grade.
11
 
Similarly, Brown and co-workers
12
 identified MMSE as a prognostic factor in patients with low-grade and 
high grade gliomas. In another study,
13
 the group also suggested increased fatigue as an independent 
predictor of poorer survival. Decreased expression of the O
6
-methylguanine-DNA methyltransferase 
(MGMT) repair enzyme makes tumours sensitive to alkylating chemotherapy. Molecular analysis of the 
tumour tissue of a large subgroup of patients showed that the benefit of temozolomide chemotherapy 
might be restricted to patients who have a silenced MGMT gene by promoter methylation.
14,15
 The main 
aim of this study was to confirm or identify new prognostic factors for survival in patients with 
glioblastoma and to derive nomograms, i.e., graphical representations of statistical models that predict 
patient prognosis. Nomograms have been used for other cancer sites, especially urological cancers, but so 
far have not been applied to neuro-oncology. 
 
5.3 Methods 
 
Patients and procedures 
 
Five hundred seventy three patients with newly diagnosed glioblastoma (WHO astrocytoma grade IV) 
were randomly assigned treatment in the EORTC and NCIC trial.
1
 Eligibility criteria were: age 18 to 70 
years; WHO performance status less than or equal to 2; no more than 6 weeks since diagnostic surgery or 
biopsy; adequate haematological, renal, and hepatic function (absolute neutrophil count of ≥1500×10⁶ 
cells per L, platelet count of ≥100×10⁹ cells per L, serum creatinine concentration ≤1.5 times the upper 
limit of normal (ULN) in the laboratory where it was measured, total serum bilirubin concentration ≤1.5 
times the ULN, and liver-function values <3 times the ULN for the laboratory); and patients who were 
receiving corticosteroids had to receive a stable or decreasing dose for at least 14 days before 
randomisation. Patients were assigned standard radiotherapy alone or the same radiotherapy plus daily 
temozolomide followed by up to six cycles of adjuvant temozolomide. Patients were stratified by centre, 
age, performance status, and extent of surgical resection. Other available baseline clinical factors were 
sex, tumour location, ongoing corticosteroid treatment, MMSE score, and haemoglobin concentration. 
Age was categorised into three groups of almost equal size (≤50 years, 51–60 years, and >60 years). The 
cut-off for MMSE, i.e., normal (27–30) versus impaired (<27), was used as previously reported.11 
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Haemoglobin concentrations of 120 g/L or higher in women and 130 g/L or higher in men were deemed 
normal. Assessment of tumour characteristics was based on local interpretation of preoperative MRI 
images. Extent of surgical resection was ascertained perioperatively by the neurosurgeon (macroscopically 
complete vs partial vs biopsy only). Survival was calculated as time from randomisation to death from 
cancer or any other cause, or censored at the date of last follow-up. All patients provided written informed 
consent and the study was approved by the ethics committees of the participating centres. 
 
Statistical analyses 
 
Compared with previous publications that used data up to May, 2004, 
1,14,16 
this study is based on survival 
data updated in September, 2006. Univariate screening was done by use of Kaplan-Meier curves,
17
 log-
rank test for binary variables, and log-rank trend test for ordered categories. To identify subgroups of 
patients with potentially different survival if assigned temozolomide and radiotherapy compared with 
those assigned radiotherapy alone, treatment by factor interaction tests were computed. From these tests, p 
values less than an arbitrarily chosen significance level of 10% were candidates for the multivariate 
analyses. Since many factors were ordinal, the association between them was estimated by the Spearman 
rank correlation coefficient (rho).
18
 A coefficient less than 0.30 was deemed a poor correlation. The Cox 
proportional hazards model was used with forward stepwise model selection with a significance level of 
5%.
19
 The probability of inclusion of a factor in the multivariate model, a criterion for the prognostic 
importance of the factor, was estimated by use of the bootstrap resampling technique (see webappendix).
20
 
Variables with a probability of inclusion higher than 60% based on 1000 bootstrap samples were included 
in the final model. Methylation status of the MGMT promoter was ascertained retrospectively in a 
representative subset of 206 (36%) patients for whom sufficient tumour material was available.
14
 The 
subgroup of patients in which the MGMT promoter methylation status was assessed was not different from 
the group of patients without MGMT promoter methylation status assessment with respect to known 
prognostic factors, except for extent of resection. MGMT promoter methylation status could not usually be 
assessed in patients whose tumours were only biopsied because of absence of sufficient tumour tissue. 
Survival modelling was done in three patient populations: the intention-to-treat population of all 
randomised patients (n=573); a subgroup of patients assigned temozolomide and radiotherapy (n=287); 
and a subgroup of patients who underwent partial or complete resection and were assigned temozolomide 
and radiotherapy in the presence of an MGMT promoter methylation assessment (n=103). The reasons for 
doing the analyses in three different populations were the following: to identify the main clinical 
prognostic factors taking into account that the treatment was important; the strength and importance of 
some prognostic factors might differ according to the treatment assigned, especially in patients assigned 
temozolomide and radiotherapy; and the effect of MGMT promoter methylation status on the prognosis of 
patients assigned temozolomide and radiotherapy needed to be evaluated further. For the three 
populations, the R “Design” package was used to develop nomograms that predict median survival and 
probability of survival at 2 years taking into account patients’ characteristics. The accuracy of predictions 
was assessed by estimating the models’ calibration and discrimination measured by the Concordance 
index corrected for optimism (C-index). The C-index is the probability that for two patients chosen at 
random, the patient who had the event first had a higher probability of having the event according to the 
model. C-index=0.50 represents agreement by chance; C-index=1.0 represents perfect discrimination.
21
 
Ideally, the accuracy of a model should be assessed in an independent dataset. However, an independent 
dataset was not available, therefore, the C-index needed to be corrected for “optimism”. In this analysis, 
the bootstrap technique was used to estimate this correction (webappendix). 
Calibration and discrimination of Cox models based on the RPA classification were also assessed and 
compared with those of our models. These prognostic factor analyses were exploratory. Their findings 
were therefore restricted by their small sample sizes, low power, and possible selection biases.  
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Table V-1: Patient demographics and baseline characteristics. 
 
 Population 1 * 
n (%) 
(n=573) 
Radiotherapy 
alone, n (%)   
(n=286) 
Population 2 ‡ 
n (%) 
(n=287) 
Population 3 ‡ 
n (%) 
(n=103) 
 
Patients not in 
population 3 ¶  
n(%) (n=470) 
Extent of surgery 
Biopsy  
Partial 
Complete 
 
93 (16.2) 
254 (44.3) 
226 (39.4) 
 
45 (15.7) 
128 (44.8) 
113 (39.5) 
 
48 (16.7) 
126 (43.9) 
113 (39.4) 
 
0 (0.0) 
56 (54.4) 
47 (45.6) 
 
93 (19.8) 
198 (42.1) 
179 (38.1) 
Age  
≤50 years 
51-60 years  
>60 years 
 
183 (31.9) 
220 (38.4) 
170 (29.7) 
 
88 (30.8) 
111 (38.8) 
87 (30.4) 
 
95 (33.1) 
109 (38.0) 
83 (28.9) 
 
44 (42.7) 
40 (38.8) 
19 (18.4) 
 
139 (29.6) 
180 (38.3) 
151 (32.1) 
WHO performance status     
0 
1 
2 
223(38.9) 
277 (48.3) 
73 (12.7) 
110 (38.5) 
141 (49.3) 
35 (12.2) 
113 (39.4) 
136 (47.4) 
38 (13.2) 
42 (40.8) 
49 (47.6) 
12 (11.7) 
181 (38.5) 
228 (48.5) 
61 (13.0) 
Sex 
Male 
Female 
Not recorded 
 
360 (62.8) 
212 (37.0) 
1 (0.2) 
 
175(61.2) 
110 (38.5) 
1 (0.3) 
 
185 (64.5) 
102 (35.5) 
0 (0.0) 
 
65 (63.1) 
38 (36.9) 
0 (0.0) 
 
295 (62.8) 
174 (37.0) 
1 (0.2) 
Corticosteroids at randomization    
 No 
Yes 
Missing 
164 (28.6) 
408 (71.2) 
1 (0.2) 
70 (24.5) 
215 (75.2) 
1 (0.3) 
94 (32.8) 
193 (67.2) 
0 (0.0) 
31 (30.1) 
72 (69.9) 
0 (0.0) 
133 (28.3) 
336 (71.5) 
1 (0.2) 
MMSE 
27-30 
<27 
Missing 
 
167 (29.1) 
384 (67.0) 
22 (3.8) 
 
86 (30.1) 
188 (65.7) 
12 (4.2) 
 
81 (28.2) 
196 (68.3) 
10 (3.5) 
 
24 (23.3) 
75 (72.8) 
4 ( 3.9) 
 
143 (30.4) 
309 (65.7) 
18 ( 3.8) 
Lobe 
Frontal 
Temporal 
Parietal 
Occipital 
Central 
Multifocal 
Other 
Missing 
 
169 (29.5) 
160 (27.9) 
101 (17.6) 
37 (6.5) 
20 (3.5) 
79 (13.8) 
4 (0.7) 
3 (0.5) 
 
82 (28.7) 
79 (27.6) 
54 (18.9) 
17 (5.9) 
7 (2.4) 
40 (14.0) 
4 (1.4) 
3 (1.0) 
 
87 (30.3) 
81 (28.2) 
47 (16.4) 
20 (7.0) 
13 (4.5) 
39 (13.6) 
0 (0.0) 
0 (0.0) 
 
42 (40.8) 
30 (29.1) 
10 ( 9.7) 
8 ( 7.8) 
1 ( 1.0) 
12 (11.7) 
0 ( 0.0) 
0 ( 0.0) 
 
127 (27.0) 
130 (27.7) 
91 (19.4) 
29 ( 6.2) 
19 ( 4.0) 
67 (14.3) 
4 ( 0.9) 
3 ( 0.5) 
Hemisphere 
Right 
Left 
Both 
Missing 
 
297 (51.8) 
269 (46.9) 
5 (0.9) 
2 (0.3) 
 
146 (51.0) 
135 (47.2) 
3 (1.0) 
2 (0.7) 
 
151 (52.6) 
134 (46.7) 
2 (0.7) 
0 (0.0) 
 
57 (55.3) 
46 (44.7) 
0 ( 0.0) 
0 ( 0.0) 
 
240 (51.1) 
223 (47.4) 
5 ( 1.1) 
2 ( 0.4) 
Hemoglobin level 
Anemia 
Normal 
Missing 
 
140 (24.4) 
429 (74.9) 
4 (0.7) 
 
72 (25.2) 
214 (74.8) 
0 (0.0) 
 
68 (23.7) 
215 (74.9) 
4 (1.4) 
 
24 (23.3) 
77 (74.8) 
2 (1.9) 
 
116 (24.7) 
352 (74.9) 
2 ( 0.4) 
MGMT promoter methylation status     
Methylated 
Unmethylated 
Unknown 
92 (16.1) 
114 (19.9) 
367 (64.0) 
46 (16.1) 
54 (18.9) 
186 (65.0) 
46 (16.0) 
60 (20.9) 
181 (63.1) 
45 (43.7) 
58 (56.3) 
0 ( 0.0) 
47 (10.0) 
56 (11.9) 
367 (78.1) 
Abbreviations: MMSE=Mini-Mental Examination. MGMT=O
6
-methylguanine-DNA methyltransferase. * All randomized 
patients (intent-to-treat population). † All patients assigned temozolomide and radiotherapy. ‡ Patients who underwent partial 
or complete resection and were assigned temozolomide and radiotherapy who had MGMT promoter methylation status 
available. ¶ Patients who were assigned to radiotherapy alone, or radiotherapy and temozolomide who did not have assessment 
of MGMT promoter methylation status or who underwent biopsy. Percentages might not add up to 100% because of rounding.  
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5.4 Results 
 
Data from 573 patients with newly diagnosed glioblastoma who were randomised in the EORTC and 
NCIC trial were included in this subanalysis. Table V-1 shows the characteristics of the patients. In the 
population of all randomised patients (population 1), overall, MMSE was missing in 22 patients (4%). 
Except for the MGMT promoter methylation status, fewer than six patients (1%) had data missing for the 
other factors. The dataset was found to be representative of the population of patients with glioblastoma, 
therefore, no imputation technique was used and patients with missing data were excluded from analysis. 
Table V-2 summarises the univariate survival analyses of each factor by presenting the log-rank test p 
value. Apart from hemisphere (left or right), all factors passed the 10% statistical significance criterion. 
Patients with anaemia showed a better outcome compared with patients with normal haemoglobin 
concentrations (p=0.04). Nonetheless, the haemoglobin concentration by treatment interaction test was not 
significant (p=0.11). Absence of treatment with corticosteroids at baseline and more extensive surgery 
were correlated positively with survival. We did not note significant survival difference between frontal, 
temporal, occipital, and parietal locations (data not shown). Tumours with central location or that were 
multifocal (i.e., present on more than one lobe) had worse prognoses than unilobar tumours; patients with 
such tumours also underwent complete resection less often (25 of 103 [24%] vs 201 of 470 [43%] 
patients), and more often had impaired MMSE (42 of 96 [44% ] vs 125 of 455 [27%] patients). The last 
column of table V-2 shows p values of the treatment by factor interaction tests. Treatment by WHO 
performance status was the only interaction test that passed the 10% statistical significance criterion 
(p=0.06). Kaplan-Meier survival estimates for the most important factors are available at 
http://www.eortc.be/tools/gbmcalculator/kmcurves.htm. Significant but poor correlations (rho<0.30) 
between various factors were noted. More extensive resection was positively correlated with: better 
performance status (rho=0.15); absence of treatment with corticosteroids (rho=0.24); monofocal location 
(rho=0.17); and normal mental status (rho=0.16). Younger age was positively associated with better 
performance status (rho=0.17) and normal mental status (rho=0.25). Better performance status was 
positively correlated with absence of corticosteroids treatment (rho=0.13) and normal mental status 
(rho=0.25). A negative correlation was recorded between normal MMSE and multifocal or central tumour 
location (rho=–0.13). Anaemic patients received corticosteroids at randomisation less frequently than did 
patients with normal haemoglobin concentrations (81 of 140 [58%] patients vs 323 of 429 [75%] patients), 
and these patients more often underwent complete resection (69 of 140 [49%] patients vs 154 of 429 
[36%] patients). Therefore, in these patients, anaemia might be due, in part, to the preceding surgery. 
Table V-3 shows findings of the multivariate Cox proportional hazards analyses. Factors selected in the 
final model for population 1 were treatment, age, extent of surgical resection, MMSE score, and use of 
corticosteroids at baseline. Probabilities of inclusion (ie, of being selected in the Cox model) were 99.6% 
for treatment, 82% for age, 96% for extent of surgical resection, 98% for MMSE score, and 85% for use 
of corticosteroids at baseline. The C-index corrected for optimism was 65%. Accuracy was not improved 
when age and MMSE score were entered as continuous factors (C-index corrected for optimism equals 
65%). Performance status was not selected and its probability of inclusion was 48%. However, 
performance status was selected in the absence of MMSE score in the Cox model (data not shown). Figure 
V.1 shows the nomogram for all randomized patients (population 1). Median survival and probability of 
survival at 2 years are obtained by drawing a vertical line from the “total points” axis straight down to the 
outcome axes. The total number of points for each patient is obtained by summing the points for each of 
the individual factors in the nomogram. Alternatively, prognosis can be obtained by summing the points 
for each factor in table V-4 and reading the median survival and probability of survival at 2 years from 
figure V.2. For example, a patient in population 1 who is treated with radio therapy alone, disregarding 
MGMT promoter methylation and performance status, who is aged 40 years, with a partially resected 
tumour, an MMSE score of 30, and who did not receive corticosteroids at baseline has a total prognostic 
score of 132 and is predicted to have a 15-month median survival and 24% probability of surviving 2 
years. Baseline characteristics of patients assigned temozolomide and radiotherapy (population 2) were 
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similar to those assigned radiotherapy alone (table V-1). Table V-2 summarises the univariate analyses of 
each factor by showing the medians with 95% CI, p values, and hazard ratios (HR) with 95% CI in each of 
the two treatment groups. For example, in population 2, patients with an MMSE less than 27 and who 
were assigned temozolomide and radiotherapy had a risk of death of 1.87 times that of patients with an 
MMSE in the range of 27–30. Apart from hemisphere (left or right) and sex, all factors passed the 10% 
statistical significance criterion. Also, patients with anaemia who were assigned temozolomide and 
radiotherapy showed a better outcome compared with patients with normal haemoglobin concentrations 
(p=0.023). Table V-3 summarises the multivariate analyses. For patients assigned temozolomide and 
radiotherapy (population 2), factors that were selected and included in the final model were age (p=0.008, 
probability of inclusion 80%), performance status (p=0.006, 78%), extent of surgery (p=0.0004, 75%), and 
MMSE score (p=0.0009, 79%). In this subset, corticosteroids were not selected (p>0.05, 33%). Sex was 
selected, but had a percentage of inclusion in bootstrap simulations of less than 60% (p=0.03, 55%) and, 
therefore, was excluded from the final model. The C-index corrected for optimism was 63%. Since the 
performance status by treatment interaction test was significant and this factor was selected for the 
patients assigned temozolomide and radiotherapy (population 2), but not for the group of all randomized 
patients (population 1), a Cox model was also fitted for patients assigned radiotherapy alone. In this 
subset, extent of surgery (p=0.007, 80%), MMSE score (p<0.0001, 89%), and corticosteroid treatment at 
baseline (p=0.005, 81%) were selected, but not age (p>0.05, 29%) or performance status (p>0.05, 8%). In 
this subgroup, patients with anaemia did not show better outcomes compared with patients with normal 
haemoglobin concentrations (p>0.05). Figure V.3 shows the nomogram for patients who were assigned 
temozolomide and radiotherapy (population 2). Prognosis can also be obtained from table V-4 and figure 
V.4. For example, if the same patient used in the example for population 1 had a performance status of 0 
and a total prognostic score of 50, their predicted median survival would be 21 months and probability of 
survival at 2 years would be 43%. Patients in population 3 (those assigned temozolomide and 
radiotherapy, and who had resected tumours and known MGMT promoter methylation status) were 
younger than those not in this subgroup (median age 53 years [range 19–70] vs 56 years [range 18–70]), 
and had more frontal tumours (42 of 103 [41%] patients) than those not in this subgroup (127 of 470 
[27%] patients; table V-1). MGMT promoter methylation status was missing in 64% of patients. With such 
a high percentage of missing data, no substantial benefit was expected from imputation techniques and, 
therefore, analyses were done only for the dataset with complete data. MGMT promoter methylation status 
was not correlated with age or with any of the other prognostic factors tested. Due to the small sample size 
and low power of the analyses in population 3, factors selected in the univariate analyses of patients 
assigned temozolomide and radiotherapy were also considered for the multivariate analysis in this 
population. The final multivariate Cox model shown in table V-3 included MGMT promoter methylation 
status (p<0.0001, probability of inclusion 92%), performance status (p=0.003, 82%), and MMSE score 
(p=0.008, 81%). The C-index corrected for optimism was 66%. Figure V.5 shows the resulting nomogram 
for population 3. Prognosis can also be obtained from table V-4 and figure V.6. For example, the patient 
mentioned in the previous populations would have a median survival of 48.0 months compared with 16.9 
months and a probability of survival at 2 years of 66% compared with 32.5%, in MGMT promoter 
methylated versus unmethylated tumours, respectively. The nomogram for the population of all 
randomized patients (population 1) was well calibrated but could not make an accurate prediction for 
patients with a probability of survival at 2 years better than 40%. The nomograms in the two other  
populations could  predict patients with a survival probability at 2 years greater than 40% but were less 
well calibrated and predictions were less accurate. We show in the webtable that predictions of our 
nomograms are more accurate than those of models based on the RPA classification. C-index of RPA-
based models is 58% in population 1, 59% in population 2, and 56% in population 3 (webtable). Accuracy 
was especially low for RPA classes III and V.  
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Table V-2: Univariate analyses of potential survival prognostic factors. 
 
 
RT alone patients 
(n=286) 
Population 2 * 
(n=287) 
Population 1 † 
(n=573) 
Treatment 
Interaction test 
 Median, mo 
(95% CI) 
HR 
(95%CI) 
p Median, mo 
(95% CI) 
HR-95%CI p HR 
(95%CI) 
p p 
Treatment assignment         
Temozolomide and 
radiotherapy 
NA NA  NA NA  1.00 <0.0001 NA 
Radiotherapy NA NA  NA NA  1.57 
(1.32-1.87) 
  
Extent of surgery‡         
Complete resection 14.2  
(13.0-16.2) 
 <0.0001 18.8 
(16.4-22.9) 
 <0.0001  <0.0001 0.41 
Partial resection 11.7 
(9.7-13.1) 
1.45 
(1.22-1.73) 
 13.5 
(11.9-16.4) 
1.46 
(1.22-1.74) 
 1.44 
(1.27-1.63) 
  
Biopsy 7.9 
(6.4-10.6) 
  9.4 
(7.5-13.6) 
     
Age (years) ‡          
≤50 years 13.6 
(11.6-15.6) 
 0.054 17.4 
(15.3-21.5) 
 0.0004  <0.0001 0.17 
51-60 years 12.0 
(10.0-14.2) 
1.16 
(1.00-1.36) 
 14.6 
(13.6-17.9) 
1.34 
(1.14-1.57) 
 1.26 
(1.13-1.41) 
  
>60 years 11.8 
(10.5-12.8) 
  11.3 
(9.4-15.1) 
     
WHO performance status ‡         
0 13.3 
(11.8-15.7) 
 0.050 17.4 
(15.7-21.2) 
 0.0001  <0.0001 0.06 
1 11.9 
(10.0-13.2) 
1.19 
(1.00-1.42) 
 14.1 
(12.5-17.0) 
1.47 
(1.21-1.79) 
 1.33 
 (1.17-1.51) 
  
2 10.5 
(8.5-13.0) 
  9.9 
(6.9-12.1) 
     
Sex          
Female 12.6 
(11.9-16.1) 
1.00 0.08 16.3 
(13.4-20.4) 
1.00 0.26 1.00 0.09 0.87 
Male 11.4 
(10.5-12.9) 
1.24 
(0.97-1.59) 
 14.4 
(12.4-16.4) 
1.16 
(0.89-1.51) 
 1.17 
(0.98-1.40) 
  
Corticosteroids at randomization        
No 16.3 
(14.4-17.3) 
1.70 
(1.29-2.25) 
0.0002 19.7 
(16.4-24.9) 
1.00 0.005 1.00 <0.0001 0.92 
Yes 11.0 
(9.7-12.1) 
  13.6 
(11.9-14.9) 
1.47 
(1.12-1.94) 
 1.60  
(1.32-1.95) 
  
MMSE score          
27-30 13.3 
(12.2-14.8) 
1.00 <0.0001 17.1 
(15.3-19.1) 
1.00 <0.0001 1.00 <0.0001 0.41 
<27 9.3 
(7.9-11.7) 
1.78 
(1.37-2.31) 
 10.3 
(8.6-12.9) 
1.87 
(1.43-2.46) 
 1.81  
(1.50-2.19) 
  
Tumour location          
Unilobal 12.5 
(12.0-14.1) 
1.00 0.03 16.3 
(14.4-18.3) 
1.00 0.0004  <0.0001 0.20 
Central and  multilobal 9.5 
(7.5-11.7) 
1.40 
(1.02-1.91) 
 11.3 
(9.2-14.0) 
1.76 
(1.28-2.42) 
 1.58 
(1.26-1.96) 
  
Hemisphere          
Right 13.0 
(11.9-14.4) 
1.00 0.28 15.7 
(13.9-18.1) 
1.00 0.92 1.00 0.62 0.89 
Left 11.4  
(10.0-12.3) 
1.07  
(0.84-1.36) 
 14.4 
(12.4-17.0) 
1.00 
(0.80-1.30) 
 
 
1.05  
(0.88-1.24) 
  
Hemoglobin level          
Low (anaemia) 11.4 (10.0-
13.3) 
1.00 0.71 18.6 
(15.7-25.9) 
1.00 0.023 1.00 0.04 0.11 
Normal 12.2  
(11.4-13.5) 
1.05  
(0.80-1.39) 
 13.5 
(12.2-15.5) 
1.41 
(1.05-1.89) 
 1.24  
(1.01-1.52) 
  
MGMT promoter methylation status        
Methylated 15.3 (13.0-
20.9) 
1.00 0.0001 21.7 
(18.6-N) 
1.00 0.0003 1.00 <0.0001 0.31 
Unmethylated 11.8  
(10.0-14.4) 
2.40  
(1.53-3.78) 
 12.4 
(11.6-14.4) 
2.24  
(1.43-3.51) 
 2.10  
(1.54-2.85) 
  
NA=not available. MMSE=Mini-Mental State Examination. N=not enough events to calculate upper 95% CI boundary. 
MGMT=O
6
-methylguanine-DNA methyltransferase. Age, performance status, and extent of surgery are treated as ordinal 
variables. *All patients assigned temozolomide and radiotherapy. †All randomised patients (intention-to-treat population). ‡For 
ordered categorical factors, the fi rst value is the reference. HR=1·x means hat the risk of death is increased by x% between 
patients belonging to adjacent groups—e.g., for the category of age in population 1, HR=1.16 indicates the risk of death 
increases by 16% between age ≤50 years and 51–60 years and by the same increase between groups 51–60 years and >60 years. 
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Table V-3: Cox proportional hazards analyses of survival prognostic factors. 
 
 Population 1 * 
(n=573, 547used=547,  
498 deaths) 
RT alone patients 
(n=286, 274 used,  
263 deaths) 
Population 2 † 
(n=287, 273 used, 235  
deaths) 
Population 3 ‡ 
(n=103,97 used=97,  
77 deaths) 
 HR  
(95% CI) 
p 
(% inclusion) 
HR 
(95% CI) 
p 
(% inclusion) 
HR  
(95% CI) 
p 
(% inclusion) 
HR  
(95% CI) 
p 
(% inclusion) 
Treatment assignment        
Temozolomide and 
Radiotherapy 
1  NI NI NI NI NI NI 
Radiotherapy  1.60  
(1.34-1.91) 
<0.0001 
(99.6) 
NI NI NI NI NI NI 
MGMT promoter methylation status        
Methylated NI NI NI NI NI NI 1.00 <0.0001 (92) 
Unmethylated NI NI NI NI NI NI 2.75  
(1.68-4.49) 
 
Age (years) §         
≤50 years  0.003 (82)  NS (29)  0.008(80)  NS(37) 
51-60 years 1.19 
(1.06-1.34) 
 1.12  
(0.95-1.32) 
 1.26  
(1.06-1.48) 
 1.32  
(0.95-1.84) 
 
>60 years         
WHO Performance status §        
0  NS(48)  NS (8)  0.006(78)  0.003(82) 
1 1.12  
(0.98-1.28) 
 0.98  
(0.82-1.19) 
 1.32  
(1.08-1.60) 
 1.76  
(1.21-2.55) 
 
2  
 
   
 
 
 
   
Interaction term 
between performance 
status and treatment  
0.99  
(0.82-1.19) 
NS(40) NI NI NI NI NI NI 
Extent of surgery §         
Complete resection  <0.0001(96)  0.007 (80)  <0.001(75)  NS(7) ¶ 
Partial resection 
 
1.33 (1.17-
1.52) 
 1.29 (1.07-
1.55) 
 1.37 (1.14-
1.63) 
 1.03 [0.64-
1.64] 
 
Biopsy  
 
       
 
Tumor location         
Unilobal 1.00 NS(30)  NS (13)  NS(52)  NS(41) 
Central and multilobal 1.17  
(0.92-1.50) 
 0.94  
(0.66-1.33) 
 1.40  
(0.99-1.97) 
 1.62  
(0.80-3.29) 
 
MMSE score         
27-30  <0.0001(98)  <0.0001 (89)  <0.001 (79)  0.008(81) 
<27 1.63  
(1.34-1.98) 
 1.71 
(1.31-2.24) 
 1.66  
(1.25-2.19) 
 1.98  
(1.20-3.28) 
 
Corticosteroids at randomisation        
No 1.00 0.003(85) 1.00 0.005 (81)  NS(33)  NS(12) 
Yes 1.36  
(1.11-1.67) 
 1.52  
(1.13-2.03) 
 1.19  
(0.89-1.59) 
 1.17  
(0.70-1.97) 
 
Sex         
Female 1.00 NS(51)  NS (22)  0.03|| (55)  NS(10) 
Male  1.16  
(0.97-1.40) 
 1.13  
(0.88-1.46) 
 
 1.30  
(0.99-1.70) 
 1.10  
(0.69-1.77) 
 
Hemoglobin         
Low (anaemia) 1.0 NS(9)  NS (9)  NS(36)  NS(21) 
Normal 1.06  
(0.86-1.31) 
 0.96  
(0.72-1.28) 
 1.33  
(0.98-1.81) 
 1.44  
(0.85-2.46) 
 
     
C-Index corrected for 
optimism 
65% NI 63% 65.5% 
Note: MGMT=O
6
-methylguanine-DNA methyltransferase. NI=not included in Cox model. NS=not significant. MMSE=Mini-
Mental State Examination. Percentages might not add up to 100% because of rounding. *All randomised patients (intention-to-
treat population). †All patients assigned temozolomide and radiotherapy. ‡Patients who underwent partial or complete resection 
and were assigned temozolomide and radiotherapy who had MGMT promoter methylation status available. §For ordered 
categorical factors, the first value is the reference. HR=1·x means that the risk of death is increased by x% between patients 
belonging to adjacent groups - e.g., for the category of age in population 1, HR=1.19 indicates the risk of death increases by 
19% between age ≤50 years and 51–60 years and by the same increase between groups 51–60 years and >60 years. ¶ Partial vs 
complete resection. || Sex was selected by stepwise selection but was not kept in the final model because the percentage of 
inclusion in bootstrap simulations was below 60%. 
Nomograms for predicting survival of patients with newly diagnosed glioblastoma.  
 
85 
 
Table V-4: Prognostic scores of each factor in the three nomograms.  
 
 Population 1* (n=573) Population 2† (n=287) Population 3‡ (n=103) 
Treatment assignment    
Temozolomide and  
radiotherapy 
0 NA NA 
Radiotherapy 82 NA NA 
MGMT promoter methylation status   
Methylated NI NI 0 
Unmethylated NI NI 90 
Age, years    
≤50 0 0 NI 
51-60 31 35 NI 
>60 61 71 NI 
Extent of surgery    
Total 0 0 NI 
Partial 50 50 NI 
Biopsy 100 100 NI 
WHO performance status    
0 NI 0 0 
1 NI 41 50 
2 NI 82 100 
MMSE score    
27-30 0 0 0 
<27 85 78 61 
Corticosteroids at randomisation   
No 0 NI NI 
Yes 54 NI NI 
NA=not applicable. MGMT=O6-methylguanine-DNA methyltransferase. NI=not included in fi nal model. MMSE=Mini-
Mental State Examination. Points were summed to obtain a total prognostic score. Patients with good a prognosis have a low 
total prognostic score. *All randomised patients (intention-to-treat population). †All patients assigned temozolomide and 
radiotherapy. ‡Patients who underwent partial or complete resection and assigned temozolomide and radiotherapy who had 
MGMT promoter methylation status available. 
 
Nomograms for predicting survival of patients with newly diagnosed glioblastoma.  
 
86 
 
Figure V.1: Nomogram for predicting survival in all randomised patients (population 1) 
 
 
 
Figure V.2: Prognostic plots in all randomised patients (population 1)  
 
 
 
Note: Median survival in months (blue line, left y-axis) and probability of survival at 2 years (red line, right y-axis) are plotted 
as a function of the total prognostic score. 
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Figure V.3: Nomograms for predicting survival in patients assigned TMZ/RT (population 2) 
 
 
 
Figure V.4: Prognostic plots in patients assigned TMZ/RT (population 2). 
 
 
Note: Median survival in months (blue line, left y-axis) and probability of survival at 2 years (red line, right y-axis) are plotted 
as a function of the total prognostic score. 
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Figure V.5: Nomogram in patients resected, assigned TMZ/RT and MGMT assessed (population 3) 
 
 
 
 
Figure V.6: Prognostic plots in patients resected, assigned TMZ/RT and  MGMT assessed (population 3) 
 
 
Note: Median survival in months (blue line, left y-axis) and probability of survival at 2 years (red line, right y-axis) are plotted 
as a function of the total prognostic score. 
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5.5 Discussion 
 
A proper understanding of prognostic factors is important for the counselling of individual patients, to 
select patients for specific treatments, and for the design and interpretation of clinical trials. The EORTC 
and NCIC trial 26981-22981/CE.3 showed that treatment with concurrent and adjuvant temozolomide in 
addition to radiotherapy improved the overall outcome compared with treatment with radiotherapy alone.
1
 
The companion prognostic factor analysis reported here has identified treatment with radiotherapy, and 
concomitant and adjuvant treatment with temozolomide, age, extent of surgical resection, MGMT 
promoter methylation status, WHO performance status, neurological function expressed by the MMSE, 
and the need for corticosteroids administration after surgery or biopsy as the most relevant independent 
prognostic factors for the outcome of patients with glioblastoma. Although the prognostic significance of 
some of these factors has been discussed before, our finding in this study that the presence of 
corticosteroid treatment at baseline in patients assigned radiotherapy alone, but not in those assigned 
temozolomide and radiotherapy, has a substantial negative prognostic effect, deserves further 
investigation. Addition ally, our findings that WHO performance status and age are significantly 
correlated with survival in patients assigned temozolomide and radiotherapy, but not those assigned 
radiotherapy alone need further study. Corticosteroid use was identified as a poor prognostic factor in a 
small study published in 1989,
22
 which had a heterogeneous patient population, but has not been assessed 
in many more recent trials. Use of corticosteroids might identify patients with more severe clinical signs 
and symptoms before surgery, or those with larger tumours or tumours that were amenable to biopsy only. 
Also, efficacy of corticosteroid treatment seems to be enhanced in patients with a good performance 
status. For both situations, confirmations in future trials are needed. The findings from our trial confirm 
the presence of a strong correlation between better outcome and completeness of tumour resection; 
however, interpretation of the findings is restricted by the fact that the extent of resection was based on 
perioperative assessment by a neurosurgeon, without a mandatory postoperative radiological confirmation. 
This restricts the reliability of the distinction between partially and completely resected patients. Patients 
in the study were not stratified according to the extent of surgery and we could not identify the relevance 
of the extent of resection in the subset of patients with known MGMT promoter methylation status. 
Therefore, the relative contribution from attempting maximum resection cannot be assessed. 
Consequently, whether more extensive resection improves outcome remains unclear from these data. 
However, in view of the better outcome of resected patients in many studies, all patients with glioblastoma 
should undergo resections that are as extensive as safely possible.
1
 Our findings show that combined and 
adjuvant temozolomide treatment improves outcome, and they suggest that—although not reaching 
statistical significance—patients with a methylated MGMT promoter benefit especially from the addition 
of temozolomide to their treatment. Even patients who were not treated with concomitant and adjuvant 
chemotherapy presented with a better outcome in the presence of a methylated MGMT promoter, probably 
due to a greater efficacy of salvage chemotherapy with alkylating drugs administered at the time of 
recurrence.
14
 Earlier studies in which all patients received adjuvant carmustine in addition to radiotherapy 
also noted that alkyltransferase expression was of prognostic importance.
23,24
 We have discussed 
elsewhere the effect of stratifying by this molecular marker in the development of new therapeutic 
strategies for patients with glioblastoma.
15
 The current analysis did not show any correlation between age 
and MGMT promoter methylation status, which implies that the poor prognosis of elderly patients cannot 
be explained by a lower frequency of MGMT promoter methylation. By contrast, in the presence of 
information on MGMT promoter methylation, age was no longer retained in the model and the nomogram. 
This observation suggests that older patients with methylated MGMT promoter might benefit from the 
new combination treatment, despite their age. However, the reason for this might be the absence of power 
in this subgroup analysis. Additional data will be necessary to assess the effect of temozolomide and 
radiotherapy in this subgroup. In an RPA, RTOG identified six prognostic classes of anaplastic gliomas 
based on clinical factors, in which classes III to VI are applicable to glioblastomas. However, this system, 
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developed and validated in the early 1990s, is based on data collected from 1974 to 1994. During the three 
decades since 1974, not only have diagnostic methods, radiotherapy planning, and treatment techniques 
dramatically changed, but also histopathological classification systems have been revised, and molecular 
factors relevant for outcome have been identified. Within the current clinical context, we have previously 
shown that RPA prognostic classes still separate prognostic groups after combined chemo radiotherapy 
with temozolomide in patients with newly diagnosed glioblastoma.
16,25
 Our analysis adds a new dimension 
to the previous studies, in that it approaches prognosis from the individual patient’s perspective: the 
nomogram offers a more tailored approach for individual patients taking into account their individual 
prognostic factors. Investigators might want to use their prediction in groups of patients from small phase 
II trials that assess innovative adjuvant treatment strategies to assess whether improved outcome is not a 
consequence of patient selection. Since formal comparisons are not possible in phase II trials, this use of 
nomograms should be limited to guide further research only. We claim that nomogram predictions are 
more accurate than those based on the RPA classification and, therefore, are better adapted to study 
tailored therapeutic options for individual patients. This study is exploratory and a limitation of these 
nomograms is that no validation is possible yet in a large independent set of patients.
3,26
 Currently, no 
other large datasets are available on patients treated with radiotherapy with concurrent and adjuvant 
temozolomide chemotherapy, who also have MMSE scores and MGMT promoter methylation status. 
Some analyses have been undertaken in subgroups of patients, especially in those with sufficient 
biological material for assessment of MGMT promoter methylation. Validity and application of these 
nomograms need to be assessed in prospectively acquired data. In future trials of patients with newly 
diagnosed glioblastoma, MGMT promoter methylation status, age, performance status, extent of resection, 
and MMSE score should be considered as eligibility criteria or stratification factors, or both. Stratifying by 
MGMT promoter methylation status should be mandatory in adjuvant and recurrent glioblastoma trials that 
include the administration of alkylating drugs. When MGMT promoter methylation status cannot be 
assessed before randomisation, it should be ascertained after inclusion of patients and used as a correction 
factor in the survival analyses.  
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6.1 Abstract  
 
Background:  
Prognostic models have been developed to predict survival of patients with newly diagnosed glioblastoma 
(GBM). To improve predictions, models should be updated with information at the recurrence. We 
performed a pooled analysis of European Organization for Research and Treatment of Cancer (EORTC) 
trials on recurrent glioblastoma to validate existing clinical prognostic factors, identify new markers, and 
derive new predictions for overall survival (OS) and progression free survival (PFS).  
 
Methods:  
Data from 300 patients with recurrent GBM recruited in eight phase I or II trials conducted by the EORTC 
Brain Tumour Group were used to evaluate patient’s age, sex, World Health Organisation (WHO) 
performance status (PS), presence of neurological deficits, disease history, use of steroids or anti-
epileptics and disease characteristics to predict PFS and OS. Prognostic calculators were developed in 
patients initially treated by chemoradiation with temozolomide. 
 
Results:  
Poor PS and more than one target lesion had a significant negative prognostic impact for both PFS and 
OS. Patients with large tumours measured by the maximum diameter of the largest lesion (42 mm) and 
treated with steroids at baseline had shorter OS. Tumours with predominant frontal location had better 
survival. Age and sex did not show independent prognostic values for PFS or OS. 
 
Conclusions:  
This analysis confirms performance status but not age as a major prognostic factor for PFS and OS in 
recurrent GBM. Patients with multiple and large lesions have an increased risk of death. With these data 
prognostic calculators with confidence intervals for both medians and fixed time probabilities of survival 
were derived. 
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6.2 Introduction 
 
The prognosis of patients with glioblastoma (GBM) remains dismal despite substantial therapeutic 
improvement provided by chemoradiation with temozolomide (TMZ) at the initial diagnosis.
1
 As yet, 
there is still no universally accepted standard treatment at the first recurrence, many patients being treated 
with nitrosoureas (e.g. lomustine [CCNU]) or with bevacizumab or considered for experimental therapy 
within clinical trials.
2
 Clinical trials of new treatments or novel approaches aiming at improving outcome 
after disease recurrence are urgently needed. In order to identify a real sign of activity of investigational 
treatments, reliable end-points for phase II trials are required. Probabilities of progression-free survival at 
6 months (PFS6) and of overall survival at 1 year (OS12) are both recognised end-points for clinical trials 
to assess the outcome of patients with recurrent GBM.
3
 The identification of accurate prognostic factors is 
an important issue to guide therapeutic decisions and patient management.
4
 In a previous report, we 
reviewed the prognostic importance of clinicobiological factors for predicting survival in newly diagnosed 
GBM. We showed that combined and concomitant radio and TMZ chemotherapy (TMZ/Radiotherapy 
(RT) → TMZ), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, extent 
of primary surgery, age, World Health Organization (WHO) performance status (PS), Mini-Mental State 
Examination (MMSE) and administration of corticosteroids at the baseline strongly impacted on patient’s 
survival.
5
 At the time of tumour progression other prognostic factors may be relevant. Patients commonly 
have an altered performance status, and will require more frequent corticosteroids administration. 
Furthermore, treatment specific molecular alterations may be selected for in the recurrent tumour, such as 
inactivation of mismatch repair pathway constituents in TMZ treated patients.
6
 The New Approaches to 
Brain Tumor Therapy Central Nervous System (NABTT CNS) Consortium performed a Recursive 
Partitioning Analysis (RPA) for overall survival in recurrent high-grade gliomas. They identified 
histology, age, Karnofsky’s index (KPS), tumour localisation and corticosteroids at the baseline as 
important prognostic factors.
7
 Joint North Central Cancer Treatment Group (NCCTG) and North America 
Brain Tumor Coalition (NABTC) analyses found grade, age, PS, baseline steroids and time since initial 
diagnosis (Wu et al., 2010) as most influential factors for survival.
8
 Dempsey et al. showed that a large 
tumour by volumetric measurement had a detrimental effect on survival in a group of malignant gliomas. 
They also identified older age and male sex as risk factors for survival.
9
 Age was not identified as an 
independent prognostic factor for survival in two previous reports.
10,11
 We have pooled the data from 
phase I and phase II clinical trials on recurrent GBM conducted by the European Organization for 
Research and Treatment of Cancer (EORTC) Brain Tumour Group (BTG) in order to further assess 
prognostic factors for clinical outcome and to develop prognostic models. We have derived prognostic 
calculators providing estimates with confidence intervals for both medians and fixed time probabilities of 
survival. 
 
6.3 Patients and methods 
 
Patient selection 
 
Between 1999 and 2010, the EORTC has conducted eight prospective multicentre phase 1 and phase 2 
clinical trials investigating safety and activity of novel therapeutic agents in recurrent malignant glioma.
12–
19
 Agents under study in dose finding phase I trials were SCH66336 (lonafarnib) and LY317615 
(enzastaurin). The phase II trials involved XR5000 (DACA, Xenova_), D19575 (glufosfamide), RFS 
2000, STI571 (imatinib, Glivec_), OSI 774 (erlotinib, Tarceva_) and ZK219477 (sagopilone). Table VI-1 
(Supplemental Table 1) presents a description of trial characteristics. None of the experimental agents 
showed clinically relevant activity. In all studies, eligibility criteria were similar. Patients were at least 18 
years of age, with WHO PS 0-2 or KPS 70–100%, adequate haematological, renal and hepatic functions. 
Corticosteroid doses, if applicable, were to be stable or decreasing for at least 1 week. In three studies, 
newly diagnosed patients with multifocal disease not amenable to radiotherapy were allowed. In the two 
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phase I trials, measurable disease was not mandatory but at least one bi-dimensional lesion was 
recommended. In phase II trials, prior radiotherapy had to be completed more than 3 months before 
registration in order to reduce the chance of treating a pseudoprogression. Three of the trials included 
patients who had received prior chemotherapy for a disease recurrence or progression. In two trials 
patients using enzyme inducing anti epileptic drugs (EIAED) were excluded. In one trial a higher dose of 
the investigational drug (erlotinib) in patients under EIAED was to be prescribed. Each trial was approved 
by the EORTC Protocol Review Committee as well as by the participating institutions local ethical 
committee and the respective national regulatory authorities. Written informed consent was obtained prior 
to enrolment into the trial. In order to determine whether our pooled patient population was representative 
of a standard patient population, the survival of the patients in the pooled dataset was compared to the 
survival from the date of first disease progression of patients recruited in the EORTC 
26981/22981/National Cancer Institute of Canada (NCIC) CE.3 trial who were treated with TMZ/RT → 
TMZ and subsequently received another line of chemotherapy after first progression.
1
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Table VI-1: Description of trials characteristics and main eligibility criteria. 
Trial 
characteristics 
16991G 16994G 16996G 16011 16027 26034 26061 26054 
ClinicalTrials.go
v Identifier 
NCT0000493
7 
NCT0001430
0 
NCT0000582
6 
NCT0003936
4 
NCT0008309
6 
NCT0008687
9 
NCT0042406
0 
NCT0051660
7 
Agents XR5000 
(DACA, 
Xenova ®) 
D19575 
(glufosfamide
) 
RFS 2000 STI571 
(imatinib, 
Glivec ®) 
SCH66336 
(lonafarnib) 
OSI 774 
(erlotinib, 
Tarceva ®) 
ZK219477 
(sagopilone) 
LY317615 
(enzastaurin) 
Phase II II II II I II II I 
Activation year 1999 2001 2000 2002 2004 2004 2006 2007 
Sample size 16 32 17 51 19 110 38 17 
Primary 
endpoint 
Objective 
Response 
Objective 
Response 
Objective 
Response 
Objective 
Response + 
PFS 6 months 
DLT & MTD PFS 6 months Objective 
Response + 
PFS 6 months 
DLT& MTD 
Publication Twelves et al, 
Ann Oncol. 
2002 
van den Bent  
et al, Ann 
Oncol. 2003 
Raymond et 
al, Eur J 
Cancer. 2002 
Raymond et 
al, J Clin 
Oncol. 2008 
Stupp et 
al,2011 
van den Bent 
et al, J Clin 
Oncol. 2009 
Stupp R et al. 
Ann. Oncol. 
2011 
Rampling et 
al. In press. 
Eligibility 
criteria 
        
Histology GBM GBM GBM Any primary 
gliomas  
Any primary 
glioma 
GBM or 
GBM-O 
(<25% oligo 
component) 
GBM or 
GBM-O 
(<25% oligo 
component) 
Grade 3 or 4 
primary 
glioma  
Recurrent 
disease 
documented by 
MRI 
Yes CT or MRI CT or MRI CT or MRI CT or MRI MRI MRI CT or MRI 
Patients not 
amenable to 
radiotherapy can 
enter the trial 
Not specified Not specified Not specified Not specified Yes Not specified Yes Yes 
Measurable 
disease, at least 
one 
bidimensionally 
measurable 
target lesion 
Yes Yes Yes Yes 
 
Not 
mandatory, 
but 
recommended 
Yes Yes Not 
mandatory, 
but 
recommended 
PS≤2 or KPS>70 Yes Yes Yes Yes Yes Yes Yes Yes 
Age 18 yrs Yes Yes Yes Yes Yes Yes Yes Yes 
On stable or 
decreasing dose 
of 
corticosteroids 
for 2 weeks prior 
to registration 
Yes Yes, for 1 
week prior to 
start of 
treatment 
Yes Yes Yes Yes, for 2 
weeks prior to 
start of 
treatment 
Yes, for 1 
week prior to 
registration 
Yes, for 1 
week prior to 
registration 
Initial surgery 
occurred within 
3 months of 
registration 
No No No No Allowed No No Allowed 
Surgery at 
recurrence 
 
No No No Yes, within 3 
months 
measurable 
disease 
confirmed on 
a post 
operative 
imaging made 
within 72 
hours from 
surgery 
Not  specified Yes, within 3 
months 
measurable 
disease 
confirmed on 
a post 
operative 
imaging made 
within 72 
hours from 
surgery 
Yes, within 3 
months 
measurable 
disease 
confirmed on 
a post 
operative 
imaging made 
within 72 
hours from 
surgery 
Not specified 
Last dose of 
radiotherapy 
administered 
within 3 months 
of registration 
No No No No Not specified No No Not specified 
One line of prior 
chemotherapy 
completed 
within 6 weeks 
Yes, adjuvant 
only  
Yes, adjuvant 
or for the 
recurrence  
Yes, adjuvant 
only 
Yes, adjuvant 
or for the 
recurrence 
completed 
within 4 
weeks (6 for 
nitrosoureas) 
Yes, adjuvant 
or for the 
recurrence 
completed 
within 4 
weeks (6 for 
nitrosoureas) 
Yes, adjuvant 
only 
completed 
within 4 
weeks (6 for 
nitrosoureas)* 
Yes, adjuvant 
only 
completed 
within 4 
weeks (6 for 
nitrosoureas)* 
Yes, adjuvant 
or for the 
recurrence 
completed 
within 4 
weeks (6 for 
nitrosoureas)*
* 
Administration Not specified Not specified Not specified Switched to Switched to Both EIAED EIAED EIAED 
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of Anti-epileptic non EIAED 
recommended
. 
non EIAED 
recommended
. 
and non 
EIAED 
allowed. 
Erlotinib dose 
was increased 
in case of 
EIAED.  
switched to 
non EIAED 
after  a wash-
out period 
of at least one 
month prior 
to start of 
treatment. 
switched to 
non EIAED 
after  a wash-
out period 
of at 2 weeks 
prior to start 
of treatment 
Note: MTD: Maximum Tolerated Dose.  DLT: Dose Limiting Toxicities.  MacDonald Criteria were used to assess response and 
progression in all trials. PS= WHO Performance Status, KPS, Karnofski Performance Scale, *: Patients who received 
concomitant/adjuvant Temozolomide at first presentation were eligible and randomized to Tarceva or BCNU, **: Patients 
previously exposed to temozolomide were allowed (except patients progressing during temozolomide treatment or progressing 
within 6 weeks of temozolomide treatment completion). 
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Candidate prognostic factors 
 
Factors screened for their prognostic value were sex, age, WHO PS, time from initial surgery or biopsy, 
prior chemotherapy, time since last dose of chemotherapy, time since last day of irradiation, surgery for 
recurrent disease, use of corticoids, administration of anti-epileptic drugs, United Kingdom Medical 
Research Council (MRC) neurological evaluation score (available in six studies), tumour load as assessed 
by the number of target lesions (defined as MRI contrast enhancing lesions with the largest diameter of at 
least 2 cm) and tumour size measured by the maximum diameter of the largest lesion. The effect of the 
presence of non-targeted lesions was also evaluated. Tumour localisation could be retrieved in five trials. 
The effect on prognosis of any concomitant chronic disease was also assessed. Table VI-2 (Online 
Supplemental Table 2) lists the factors screened and the coding conventions.  
 
Table VI-2: List of factors screened and coding conventions. 
 Coding convention 
Screened prognostic factors  
Prior chemotherapy no/without/with temozolomide 
Prior surgery for recurrence no/yes 
Age Per quartile or 
<median/>=median 
WHO performance status 0/1/2 or 
0/>0 
Sex male/female 
Neurological deficit (MRC score) no/some/moderate or major or 
no/yes 
Baseline steroids administration  no/yes 
Baseline anti-epileptic therapy no/yes or 
no/EIAED/Non EIAED only 
Number of target lesions 0-1/>1 
Presence of non target lesions no/yes 
Largest lesion area (mm²)  
 
Per quartile or 
<median/>=median 
 
Largest lesion diameter (mm) 
Time since last chemotherapy 
Time since last radiotherapy 
Time since initial surgery 
Time since initial histological diagnosis 
Frontal location no/yes 
Presence of chronic disease no/yes 
 
 
Patient outcome measurements 
 
In all trials, Macdonald’s criteria were used to assess tumour response.20 Follow-up assessments were 
obtained every 8 weeks until disease progression. Progression free survival was computed as the time 
between the date of registration or randomization and the date of progression or death, whichever occurred 
first. Patients alive without evidence of progression were censored at the date of the last visit. Overall 
survival was calculated from the date of registration or randomization until date of death for any cause. 
Surviving patients were censored at date of last visit. In the EORTC/NCIC 26981/22981 trial residual 
survival was computed from the date of start of a new chemotherapy for recurrence after chemoradiation 
with TMZ until date of death. Patients alive at the date of last visit were censored.  
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Statistical considerations 
 
Categorical data were tabulated with frequencies and percentages. Medians and ranges (minimum–
maximum) were used to summarise continuous variables. The significance of the association between 
categorical factors was assessed by the Fisher Exact test (nominal) or the Jonckheere-Terpstra test 
(ordinal). Between continuous variables, significance was computed based on a specific student’s statistic 
for testing the null hypothesis of no association. For the association between continuous and categorical 
(nominal) factors, the Wilcoxon rank sum test (two levels) or the Kruskall Wallis test (more than two 
levels) was used. In all analyses, p-values lower than 1% (p < 0.01) have been reported. Survival analyses 
were carried out in two patient populations: all GBM patients and the subset of patients who were treated 
for first progression after chemoradiation with TMZ. Kaplan Meier curves and logrank tests were 
computed stratified by category of treatment for the recurrence (an experimental agent, a cytotoxic agent, 
and a combination of both). Multivariate Cox models were fit of a significant difference between the 
different categories of treatment, non-stratified multivariate Cox models were fitted. Factors with a p-
value less than 10% in univariate analysis were considered for Cox multivariate analyses. Proportional 
hazards (PH) assumptions were tested with the Supremum Test and by graphical method (LLS plot). PH 
assumptions were considered strongly violated if the p-values were less than 1%. The stepwise forward 
method was used for factors selection. The model’s internal validity was assessed by the bootstrap 
method. Factors with an importance (PI: posterior probabilities that the regression coefficients are 
different from zero) lower than 60% were excluded from the final models. A significance level of 5% was 
applied to all multivariate analyses. Model’s discrimination was assessed by the Harrel’s C-index 
corrected for optimism by the bootstrap technique.
21,22
 The model’s goodness of fit was assessed by the 
Schemper’s percentage of explained variation (PEV).23 A PEV of at least 20% is considered a minimum 
requirement for a model to provide sufficiently precise individual survival predictions.
24 
Prognostic 
calculators were developed for each final model in the population pre-treated with TMZ/RT → TMZ and 
the model calibration was assessed. Predictions for median PFS, OS, 6-month PFS (PFS6) and 1-year OS 
(OS12) were derived. SAS version 9.2 (SAS Institute Inc., Cary, NC, United States of America (USA)) 
was used for all statistical analyses except the computation of the C-index and calibration plots which 
were obtained from the R ‘Design’ and ‘Hmisc’ Packages. The percentage of explained variation was 
computed using the SAS macro RELIMPCR (Comparing the importance of prognostic factors in Cox 
regression using SAS).
24
 The reflected method was used to estimate median survival with 95% confidence 
interval.
25
 The loglog transformation was used for the 95% confidence intervals of PFS6 and OS12.  
 
6.4 Results 
 
Patients characteristics and correlation analyses 
 
Four hundred eleven patients were recruited in the eight trials, 300 had a local histopathological diagnosis 
of GBM (astrocytoma grade IV according to WHO). Central pathology review was available for 155 
patients (52%), in 149 patients (96%) GBM was confirmed. Baseline characteristics are summarised in 
Table VI-3. One hundred thirty eight patients had received TMZ/RT → TMZ as first-line therapy. One 
hundred fifty eight patients received standard fractionated RT to the equivalent of approximately 60 Gy 
alone or with another chemotherapy, four were treated without previous radiotherapy. Patients who 
received TMZ/RT → TMZ were significantly less often under baseline steroids (57% versus 73%, p = 
0.004). At progression, patients in this subgroup received Carmustine (BCNU) (11%) or TMZ (7%) or 
various other therapies (36%, including Procarbazine, Lomustine, and Vincristine (PCV), Lomustine 
(CCNU), Irinotecan (CPT11), Etoposide (VP16), Natulan). No patient received Bevacizumab after 
protocol treatment. Eight percent of the patients were re-operated at the time of progression. Table VI-4 
(Supplemental Table 3) shows the results of correlation analyses.  
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Table VI-3: Characteristics of all GBM patients and of patients (non) pre-treated by TMZ/RT→TMZ.  
 
Patient and disease characteristics  p-value 
 Prior administration of TMZ/RT→TMZ  
 No(N=162) Yes (N=138) Total (N=300)  
 N (%) N (%) N (%)  
Central review                                                                                                                                                                                                                                                                         
        No                                    76 (46.9)                                                                                          69 (50.0)                                      145 (48.3)                                                                                        0.64
        Yes                                   86 (53.1)                                                                                          69 (50.0)                                       155 (51.7)                                                       
Central Diagnosis                                                                                                                                                                                                                                                               
        GBM                                   85 (52.5)                                                                                          64 (46.4)                                      149 (49.7)                                                                                        0.10
        OA                                     0 (0.0)                                                                                           2 (1.4)                                       2 (0.7)                                                         
        AA                                     1 (0.6)                                                                                           1 (0.7)                                       2 (0.7)                                                                         
        Other                                  0 (0.0)                                                                                           2 (1.4)                                                 2 (0.7)                                                
        Missing                               76 (46.9)                                                                                          69 (50.0)                                       145 (48.3)                                                        
Disease Status                                                                                                                                                                                                                                                                       
        First progression                    142 (87.7)                                                                                          138 (100.0)                                           280 (93.3)                                                      N/A 
        Second progression                      20 (12.3)                                                                                          0 (0.0)                                     20 (6.7)                                                         
Presence of measurable disease                                                                                                                                                                                                                           
        No                                     2 (1.2)                                                                                           5 (3.6)                                       7 (2.3)                                                        0.25 
        Yes                                  160 (98.8)                                                                                          133 (96.4)                                       293 (97.7)                                                        
Sex                                                                                                                                                                                                                                                 
        Male                                 101 (62.3)                                                                                          95 (68.8)                                      196 (65.3)                                                       0.27 
        Female                                61 (37.7)                                                                                          43 (31.2)                                       104 (34.7)                                                                                  
WHO Performance Status                                                                                                                                                                                                                                                                 
        0                                     44 (27.2)                                                                                          40 (29.0)                                       84 (28.0)                                                     0.20 
        1                                     88 (54.3)                                                                                          84 (60.9)                                      172 (57.3)                                                                                        
        2                                     30 (18.5)                                                                                          14 (10.1)                                       44 (14.7)                                                       
Neurological deficit                                                                                                                                                                                                                                                                        
        No            50 (30.9)                                                                                          50 (36.2)                                      100 (33.3)                                                                                        0.09
        Some     47 (29.0)                                                                                          54 (39.1)                                        101 (33.7)                                                       
        Moderate   38 (23.5)                                                                                          20 (14.5)                                       58 (19.3)                                                        
        Major            5 (3.1)                                                                                           2 (1.4)                                       7 (2.3)                                                                          
        Missing                               22 (13.6)                                                                                          12 (8.7)                                                 34 (11.3)                                                 
Age  (years)                                                                                                                                                                                                     
        Median                                                                                                                                                                                           53.5 53.5 53.5               0.72
        Range                                                                                                                                                                                            19.0 - 75.0        18.0 - 78.0  18.0 - 78.0
        N  162                138                300                 
Associated chronic disease                                                                                                                                                                                                                                                       
        No                                   110 (67.9)                                                                                          73 (52.9)                                      183 (61.0)                                                                                        0.78
        Yes                                   49 (30.2)                                                                                          30 (21.7)                                       79 (26.3)                                                       
        Missing                                3 (1.9)                                                                                           35 (25.4)                                         38 (12.7)                                                                  
Time since initial diagnosis (weeks)        
                
   
        Median                                                                                                                                                                                           42.3 47.1 44.1              0.16
        Range                                                                                                                                                                                            2.0 - 319.6        6.4 - 393.1        2.0 - 393.1
        N  162                138                300                 
Extent of initial surgery     
        Biopsy                                 6 (3.7)                                                                                           4 (2.9)                                       10 (3.3)                                                                                   1.00
        Resection                             57 (35.2)                                                                                          36 (26.1)                                          93 (31.0)                                                       
        Missing                               99 (61.1)                                                                                          98 (71.0)                                       197 (65.7)                                                      
Time since initial surgery (weeks)                                                                                                                                                                                         
        Median                                                                                                                                                                                           40.1 45.0 41.9               0.06
        Range                                                                                                                                                                                            2.0 - 222.4        11.7 - 393.1       2.0 - 393.1
        N  157                131                288                 
Prior radiotherapy                                                                                                                                                                                                                                                                     
        No                                     4 (2.5)                                                                                           0 (0.0)                                       4 (1.3)                                                     0.13 
        Yes                                  158 (97.5)                                                                                          138 (100.0)                                        296 (98.7)                                                                                         
Time since  last dose of irradiation (weeks)                                                                                                                                                                            
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Patient and disease characteristics  p-value 
 Prior administration of TMZ/RT→TMZ  
 No(N=162) Yes (N=138) Total (N=300)  
 N (%) N (%) N (%)  
        Median                                                                                                                                                                                           30.1 35.7 31.9 0.16
        Range                                                                                                                                                                                            4.9 - 308.6        13.0 - 221.6       4.9 - 308.6
        N 156                138                294                 
Prior chemotherapy                                                                                                                                                                                                                                                                 
        No    89 (54.9)                                                                                          0 (0.0)                                    89 (29.7)                                                                                         N/A
        Yes, without temozolomide                55 (34.0)                                                                                          0 (0.0)                                     55 (18.3)                                                          
        Yes, with temozolomide                  18 (11.1) †                                                                                         138 (100.0)                                       156 (52.0)                                                                             
Time since last chemotherapy (weeks)                                                                                                                                                                                      
        Median                                                                                                                                                                                           12.1 8.1 9.6                0.02*
        Range                                                                                                                                                                                            3.4 - 128.6        3.9 - 171.3        3.4 - 171.3
        N                                                                                                                                                                                       73                 138                211
Surgery for recurrence                                                                                                                                                                                                                              
        No                                   145 (89.5)                                                                                          118 (85.5)                                       263 (87.7)                                                      0.38 
        Yes                                   17 (10.5)                                                                                          20 (14.5)                                       37 (12.3)                                                                           
Baseline steroids                                                                                                                                                                                                                                                                 
        No                                    44 (27.2)                                                                                          60 (43.5)                                       104 (34.7)                                                       0.004** 
        Yes                                  118 (72.8)                                                                                          78 (56.5)                                     196 (65.3)                                                                                        
Baseline anti-epileptic                                                                                                                                                                                                                                                                   
        No AED                                     56 (34.6)                                                                                          51 (37.0)                                       107 (35.7)                                                   0.72 
        EIAED                                     43 (26.5)                                                                                          31 (22.5)                                      74 (24.7)                                                                                        
        Non EIAED only                                     63 (38.9)                                                                                          56 (40.6)                                       119 (39.7)                                                       
Number of target lesions                                                                                                                                                                                                                                                               
        0                                      2 (1.2)                                                                                           5 (3.6)                                                     7 (2.3)                                                  0.22 
        1                                    132 (81.5)                                                                                          114 (82.6)                                       246 (82.0)                                                      
        2                                     24 (14.8)                                                                                          17 (12.3)                                      41 (13.7)                                                                                        
        3                                      3 (1.9)                                                                                           2 (1.4)                                       5 (1.7)                                                         
        4                                      1 (0.6)                                                                                           0 (0.0)                                       1 (0.3)                                                      
Presence of non target lesions                                                                                                                                                                                                                       
        No                                   137 (84.6)                                                                                          116 (84.1)                                       253 (84.3)                                                      1.00 
        Yes                                   25 (15.4)                                                                                          22 (15.9)                                       47 (15.7)                                                                 
Frontal location                                                                                                                                                                                                            
        No                                    50 (30.9)                                                                                          75 (54.3)                                       125 (41.7)                                                      1.00 
        Yes                                   27 (16.7)                                                                                          42 (30.4)                                       69 (23.0)                                                                 
        Missing                               85 (52.5)                                                                                          21 (15.2)                                         106 (35.3)                                                     
Largest lesion area  (mm²)                                                                                                                                                                                                        
        Median                                                                                                                                                                                           1483.5 1134.0 1289.0 0.02*
        Range                                                                                                                                                                                            125.0 - 8000.0     80.0 - 4950.0      80.0 - 8000.0
        N obs                                                                                                                                                                                            160 132 292         
Largest lesion diameter (mm)                                                                                                                                                                                              
        Median                                                                                                                                                                                           43.0 41.5 42.0            0.07
        Range                                                                                                                                                                                            19.0 - 100.0       10.0 - 94.0 10.0 - 100.0
        N obs                                                                                                                                                                                            160 132 292
† Temozolomide administered at first progression after radiotherapy. * p<0.05  ** p<0.01. 
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Table VI-4: Correlation analyses. 
  
 PS Age Sex Ster AED NeuroD TarL Tsize InitD Lrad Psurg Front 
PS NA            
Age NS NA           
Sex NS NS NA          
Ster P<0.0001 NS NS NA         
AED P=0.008 NS NS P=0.002 NA        
NeuroD P<0.0001 P=0.001 NS P<0.0001 P=0.002 NA       
TarL NS NS NS P=0.001 NS NS NA      
Tsize P=0.006 NS P=0.009 P<0.0001 NS P=0.005 NS NA     
InitD NS NS NS P<0.0001 NS NS NS NS NA    
Lrad NS NS NS P<0.0001 NS NS NS NS NS NA   
Psurg NS P=0.007 NS NS NS NS NS NS NS P=0.008 NA  
Front NS NS NS NS NS P=0.006 NS NS NS NS NS NA 
Legend: NA: Not applicable, NS: p>1%, Patients under steroids (Ster) were more often under anti-epileptic drugs (AED, 
p=0.002), had a worse performance status (PS,p<0.0001) and more often neurological deficits (NeuroD p<0.0001). They had 
more often more than one target lesion (TarL,p=0.001). Times since their initial diagnosis (InitD,54 vs 40 weeks, p<0.0001) 
and last radiotherapy (Lrad,44 vs 29 weeks, p<0.0001) were shorter and they  more often had larger tumors (Tsize,median 49 vs 
31 mm, p<0.0001). Male patients had larger tumors (Sex,45 vs 38 mm for females, p=0.009). Patients with prior surgery for 
recurrence were younger (Psurg,median 48 vs 55 years, p=0.007) and had a longer time since radiotherapy (41 vs 30 weeks, 
p=0.008). Patients treated with AED more often had a poor performance status (p=0.008) and had more often and more severe 
neurological deficits (p=0.002). Patients with frontal involvement had less often or less severe neurological deficits 
(Front,p=0.006). Tumor area was larger in patients with a poorer performance status (p=0.006). They had more often or more 
severe neurological deficits (p<0.0001). Neurological deficits were also associated with older age (p=0.001) and a larger tumor 
(p=0.005). Older age was not significantly associated with a deteriorated performance status (p=0.053). The percentages of 
patients with PS 2 were 14.4% for age>54 and 15.2% for age ≤ 54.   
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Outcome description and prognostic factor analyses 
 
Table VI-5 and VI-6 (Supplemental Table 4a & b) summarise the univariate analyses of PFS and OS for 
each candidate prognostic factor and each category of treatment at recurrence in the two populations by 
presenting median PFS, 6-month PFS rate (PFS6), median OS, 1-year OS rate (OS12), hazard ratios and 
p-values. Table VI-7 displays the results of the final multivariate Cox analyses. For both PFS and OS, the 
results of the proportional hazards assumptions analyses can be found at http://www.eortc.be/tools/ 
recgbmcalculator/Sensitivity.aspx. No strong PH assumption violation was observed in all analyses. 
 
Table VI-5: Univariate screening of prognostic factors for PFS 
  GBM pre-treated with TMZ/RTTMZ  
(n=138) 
 all GBM   
(n=300) 
 N Median PFS  
(95% CI) 
6-month PFS 
probability  
(95% CI) 
HR 
(95% CI) 
p N Median PFS 
(95% CI) 
6-month PFS 
probability 
 (95% CI) 
HR  
(95% CI) 
p 
All patients 138 1.84  
(1.74, 2.14) 
18.25  
(12.31,25.13) 
N/A N/A 300 1.81  
(1.74, 1.91) 
14.72 
(10.98,18.98) 
N/A N/A 
Treatment at the 
recurrence 
          
16011: 
Imatinib 
15 1.71  
(1.64, 5.82) 
20.00  
(4.89, 42.39) 
1.00                 0.12 
df=7   
51 1.81 
(1.71, 2.43) 
15.69 
(7.34, 26.88) 
1.00 <1E-4 
df=9 
16027: 
TMZ+Lonafarnib 
15 2.04  
(1.64, 5.32) 
13.33  
(2.19, 34.57) 
1.01  
(0.49, 2.08)    
 19 2.04  
(1.77, 5.32) 
15.79  
(3.92, 34.94) 
1.00  
(0.59, 1.70) 
 
16991: 
XR5000 
0 N/A N/A N/A  16 1.30 
 (1.38, 2.96) 
0.00 ( ,  ) 3.02  
(1.71, 5.36) 
 
16994G: 
Glufosfamide 
3 1.77  
(1.68, 9.79) 
33.33  
(0.90, 77.41) 
0.83  
(0.24, 2.88)    
 32 1.41  
(1.35, 2.63) 
3.13  
(0.24, 13.72) 
1.72  
(1.10, 2.70) 
 
16996G: 
RFS 2000 
2 1.36  
(N, N) 
0.00 
 ( ,  ) 
5.01  
(1.10, 22.8)   
 17 1.45 
 (1.38, 2.56) 
5.88  
(0.39, 23.50) 
1.44  
(0.83, 2.50) 
 
26054: 
TMZ+Enzastaurin 
11 5.52  
(5.09, 7.39) 
36.36  
(11.18, 62.68) 
0.66  
(0.30, 1.45)    
 17 5.52 
 (4.47, 8.77) 
41.18 
(18.58, 62.64) 
0.59 
(0.34, 1.03) 
 
26061: 
Sagopilone 
35 1.58  
(1.38, 2.04) 
8.57  
(2.20, 20.57) 
1.48  
(0.80, 2.73)    
 38 1.58 
(1.38, 1.84) 
7.89  
(2.04, 19.10) 
1.49 
(0.97, 2.29) 
 
26034: 
TMZ 
0 N/A N/A N/A  27 3.75  
(2.30, 6.05) 
29.63  
(14.06, 47.03) 
0.76  
(0.47, 1.21) 
 
26034: 
BCNU 
29 2.02  
(1.84, 5.49) 
21.43  
(8.71, 37.83) 
0.93  
(0.50, 1.75)    
 29 2.02 
 (1.84, 5.49) 
21.43 
(8.71, 37.83) 
0.92  
(0.58, 1.46) 
 
26034: 
Erlotinib 
28 1.92  
(1.74, 5.13) 
21.43  
(8.71, 37.83) 
0.91  
(0.49, 1.71)    
 54 1.81 
(1.71, 1.94) 
12.96  
(5.70, 23.30) 
1.18  
(0.80, 1.73) 
 
Category of 
treatment 
          
No cytotoxic 
(targeted agent only) 
83 1.71  
(1.61, 1.91)              
15.66  
(8.83, 24.26)  
1.00                 0.35 
df=2   
208 1.68 
(1.54, 1.74)              
9.62  
(6.09, 14.08)   
1.00                 0.0005 
df=2   
Cytotoxic (BCNU or 
TMZ) 
29 2.02  
(1.74, 3.29)              
21.43 
(8.71, 37.83)  
0.83 
(0.54, 1.28)    
0.40 
df=1   
56 2.37 
(1.84, 3.75)              
25.45  
(14.89, 37.41) 
0.63  
(0.47, 0.86)    
0.003 
df=1  
Combination (TMZ 
+ targeted agent) 
26 4.42  
(1.94, 5.45)              
23.08 
(9.38, 40.31)  
0.74 
(0.47, 1.15)    
0.18 
df=1   
36 3.68  
(2.04, 5.45)              
27.78 
(14.48, 42.78) 
0.58  
(0.40, 0.82)    
0.0025 
df=1   
Sex                                                  
        Male                                95 1.74 
(1.68, 2.10)              
15.96 
(9.41, 24.04)  
1.00                  0.66 
df=1 
196 1.77 
(1.71, 1.87)              
12.31 
(8.17, 17.34)  
1.00                 0.41 
df=1 
        Female                              43 2.04 
(1.77, 5.32)              
23.26  
(12.05, 36.60) 
0.92  
(0.64, 1.33)    
 104 1.84  
(1.71, 2.07)              
19.23 
(12.32, 27.30) 
0.90  
(0.71, 1.15)    
 
Performance Status                                    
        0                                   40 2.04 
(1.71, 5.52) 
30.00  
(16.80, 44.37) 
1.42  
(1.06, 1.90)    
0.02 
df=1   
84 2.04  
(1.77, 3.75) 
27.38  
(18.36, 37.16) 
1.41  
(1.17, 1.69)    
0.0003 
df=1   
        1                                   84 1.84 
(1.71, 2.14) 
13.25 
 (7.04, 21.46) 
  172 1.77 
(1.71, 1.94) 
11.11 
(6.96, 16.34) 
  
        2                                   14 1.68 
(1.02, 5.45) 
14.29  
(2.32, 36.55) 
  44 1.69  
(1.41, 1.84) 
4.55  
(0.83, 13.61) 
  
           
        0 40 2.04  
(1.71, 5.52) 
30.00 
 (16.80,44.37) 
1.00                 0.04 
df=1 
84 2.04  
(1.77, 3.75) 
27.38  
(18.36, 37.16) 
1.00                 0.003 
df=1 
        >0 98 1.81  
(1.71, 2.07) 
13.40  
(7.54, 20.96) 
1.50  
(1.01, 2.22)    
         216 1.74 
(1.71, 1.84) 
9.77  
(6.27, 14.18) 
1.50 
(1.15, 1.97)    
         
Neurological deficit                                          
        No          50 1.77  
(1.58, 2.86) 
20.00  
(10.32, 31.97) 
1.06  
(0.83, 1.36)    
0.61 
df=1   
100 1.84  
(1.74, 2.37) 
20.00 
(12.83, 28.32) 
1.16  
(0.99, 1.37)    
0.06 
df=1   
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        Some   54 1.81  
(1.71, 2.10) 
9.43  
(3.47, 19.05) 
  101 1.74  
(1.68, 1.94) 
8.00 
(3.74, 14.35) 
  
        
Moderate/major 
22 1.82  
(1.64, 6.18) 
27.27  
(11.12, 46.37) 
  65 1.74  
(1.51, 1.87) 
13.85  
(6.81, 23.34) 
  
Age (quartiles)                                                                                                                                                                                                      138 N/A N/A 0.93
(0.80, 1.08)    
0.36 
df=1   
300 N/A N/A 0.99  
(0.90, 1.09)    
0.86 
df=1   
Age (median)                                                                                                                                                                                                         
        < 54 yrs                                                                                                                                                                                            69 1.81
(1.71, 2.14) 
15.94
(8.49, 25.49) 
1.00                 0.54
df=1 
150 1.74  
(1.68, 1.94) 
16.00  
(10.66, 22.31) 
1.00                  0.60 
df=1 
        54 yrs 69 1.99  
(1.71, 3.75) 
20.59  
(11.96, 30.84) 
0.90 
(0.64, 1.27)    
         150 1.84  
(1.74, 2.10) 
13.42  
(8.54, 19.41) 
0.94  
(0.75, 1.18)    
         
Associated chronic 
disease                  
          
        No                                  73 1.94  
(1.74, 3.29) 
23.29  
(14.38, 33.45) 
1.00                 0.98 
df=1 
183 1.84  
(1.77, 2.30) 
16.39  
(11.45, 22.11) 
1.00                 0.51 
df=1 
        Yes                                 30 2.10  
(1.91, 5.45) 
17.24  
(6.29, 32.73) 
0.99 
(0.64, 1.55)    
         79 1.87  
(1.77, 2.60) 
14.10  
(7.50, 22.74) 
0.91  
(0.70, 1.20)    
         
Time since initial 
diagnosis (quartiles)                                                                                                                                                                 
138 N/A N/A 1.06 
(0.91, 1.24)
0.46 
df=1
300 N/A N/A 0.95  
(0.86, 1.05)    
0.32 
df=1   
Time since initial 
surgery (quartiles)                                                                                                                                                                                 
131 N/A N/A 1.04 
(0.89, 1.21)
0.62 
df=1   
288 N/A N/A 0.96  
(0.86, 1.06)    
0.38 
df=1   
Time since  last  
irradiation 
(quartiles)                                                                                                                                                                            
138 N/A N/A 1.10 
(0.94, 1.28)    
0.23 
df=1   
294 N/A N/A 0.96  
(0.86, 1.06)    
0.42 
df=1   
Prior chemotherapy                              
        No  0 N/A N/A N/A N/A 89 1.84  
(1.74, 2.14) 
14.61  
(8.23, 22.73) 
1.00                 0.54 
df=2   
        Yes, without 
temozolomide                
0 N/A N/A N/A N/A 55 1.58  
(1.38, 1.84) 
9.09  
(3.34, 18.41) 
1.11  
(0.78, 1.58)    
0.57 
df=1   
        Yes, with 
temozolomide                  
138 1.84  
(1.74, 2.14) 
18.25  
(12.31, 25.13)      
N/A N/A 156 1.84  
(1.74, 2.10) 
16.77  
(11.39, 23.06) 
0.93  
(0.71, 1.22)    
0.60 
df=1   
Time since last 
chemotherapy 
(quartiles)                                                                                                                                                                                
138 N/A N/A 1.01 
(0.85, 1.19)    
0.95 
df=1   
211 N/A N/A 1.00  
(0.87, 1.13)    
0.94 
df=1   
Surgery for 
recurrence                      
          
        No                                  118 1.81  
(1.71, 2.10) 
18.80  
(12.33, 26.34) 
1.00                 0.43 
df=1 
263 1.81  
(1.74, 1.94) 
14.89  
(10.89, 19.47) 
1.00                 0.30 
df=1 
        Yes                                 20 1.91  
(1.71, 3.29) 
15.00  
(3.73, 33.47) 
1.21  
(0.75, 1.97)    
         37 1.84  
(1.71, 2.76) 
13.51  
(4.94, 26.40) 
1.21  
(0.85, 1.71)    
         
Baseline steroids                               
        No                                  60 1.77  
(1.68, 2.76) 
22.03  
(12.52, 33.24) 
1.00                 0.82
df=1 
104 1.84  
(1.74, 2.79) 
23.30  
(15.68, 31.81) 
1.00                 0.08 
df=1 
        Yes                                 78 1.87  
(1.74, 2.56) 
15.38  
(8.44, 24.23) 
0.96  
(0.67, 1.38)    
         196 1.81  
(1.71, 1.91) 
10.20  
(6.47, 14.92) 
1.25  
(0.97, 1.62)    
         
Baseline anti-
epileptic                     
          
        No AED                                   51 2.04  
(1.71, 4.04) 
22.00  
(11.80, 34.21) 
1.00                 0.17 
df=2   
107 1.86  
(1.71, 2.30) 
16.98  
(10.56, 24.70) 
1.00 0.39 
df=2 
        EIAED                                   31 1.77  
(1.68, 1.94) 
6.45  
(1.15, 18.62)   
1.56  
(0.97, 2.50)    
0.06 
df=1   
74 1.71  
(1.64, 1.94) 
8.11  
(3.31, 15.70) 
1.22  
(0.90, 1.65) 
0.20 
df=1 
        Non EIAED 
only                                   
56 1.74  
(1.71, 3.29) 
21.43  
(11.85, 32.88) 
1.25 
(0.84, 1.87)    
0.27 
df=1   
119 1.81  
(1.74, 2.10) 
16.81  
(10.74, 24.04) 
1.03  
(0.79, 1.34) 
0.82 
df=1 
Number of target 
lesions                    
          
        0-1                                   119 1.94  
(1.81, 2.76) 
20.34  
(13.63, 28.01) 
1.00                 0.02
df=1 
253 1.84  
(1.77, 2.10) 
16.27  
(12.02, 21.09) 
1.00                 0.007 
df=1 
        >1                                   19 1.61  
(1.45, 2.04) 
5.26  
(0.36, 21.43) 
1.86  
(1.12, 3.08)    
         47 1.58  
(1.38, 1.81) 
6.38  
(1.66, 15.75) 
1.55  
(1.13, 2.13)    
         
Presence of non 
target lesions              
          
        No                                  117 1.82  
(1.74, 2.10) 
17.24  
(11.02, 24.63) 
1.00                 0.13
df=1 
254 1.81  
(1.74, 1.87) 
13.83  
(9.92, 18.39) 
1.00                 0.34 
df=1 
        Yes                                 21 4.04  
(1.48, 5.52) 
23.81  
(8.67, 43.08) 
0.68  
(0.42, 1.12)    
         46 1.68  
(1.48, 4.04) 
19.57  
(9.67, 32.01) 
0.85  
(0.62, 1.18)    
         
Frontal location           
        No                                  75 1.89  
(1.74, 2.76) 
16.22  
(8.91, 25.45) 
1.00                 0.48
df=1 
125 1.84  
(1.74, 2.10) 
16.13  
(10.30, 23.12) 
1.00                 0.27 
df=1 
        Yes                                 42 1.84  
(1.58, 4.47) 
21.43  
(10.61, 34.72) 
0.87 
(0.58, 1.30)    
         69 1.94  
(1.84, 3.75) 
23.19  
(14.08, 33.64) 
0.84  
(0.62, 1.15)    
         
Largest lesion area  
(quartiles)                                                                                                                                                                                    
132 N/A N/A 1.06  
(0.90, 1.23)
0.49 
df=1   
292 N/A N/A 1.09  
(0.99, 1.21)    
0.09 
df=1   
Largest lesion 132 N/A N/A 1.08  0.36 292 N/A N/A 1.09  0.11 
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diameter  (quartiles)                                                                                                                                                                                    (0.92, 1.27) df=1 (0.98, 1.21)    df=1   
Largest lesion 
diameter  (median) 
          
       <=42 mm 66 1.77  
(1.71, 2.37) 
18.46  
(10.17, 28.69) 
1.00                 0.77
df=1 
147 1.79  
(1.71, 1.94) 
17.81  
(12.10, 24.42) 
1.00                  0.13 
df=1 
       >42 mm 66 1.84  
(1.74, 2.76) 
16.67  
(8.88, 26.56) 
1.05  
(0.74, 1.50)    
         145 1.81  
(1.71, 2.04) 
10.34  
(6.07, 15.93) 
1.20  
(0.95, 1.52)    
         
Note: df= degree of freedom of the statistical test. df=1 for binary factors, for continuous variables and scores (eg WHO 
performance status). df=9 is for the global homogeneity test among the 10 protocol treatment arms. Imatinib was used as the 
reference arm.  Because sample sizes are small and treatments were not randomized, no pairwise comparisons were performed.  
 
Table VI-6: Univariate screening of prognostic factors for OS 
 
  GBM pre-treated with TMZ/RTTMZ  
(n=138) 
 All GBM  
(n=300) 
 N Median OS  
(95% CI) 
1-year OS 
probability 
(95% CI) 
HR  
(95% CI) 
p N Median OS 
(95% CI) 
1-year OS 
probability 
(95% CI) 
HR  
(95% CI) 
p 
All patients 138 7.13  
(6.21, 8.71) 
26.64  
(19.52, 34.27) 
N/A N/A 300 6.21 
(5.68, 7.13) 
22.07  
(17.53, 26.95) 
N/A N/A 
Treatment at the 
recurrence 
          
16011: 
Imatinib 
15 5.75  
(2.96, 14.39) 
26.67  
(8.26, 49.63) 
1.00 0.37  
df=7 
51 6.14  
(4.53, 8.97) 
23.53  
(13.04, 35.78) 
1.00                 0.0006 
(df=9)   
16027: 
TMZ+Lonafarnib 
15 7.00  
(5.32, 10.74) 
6.67  
(0.43, 26.03) 
1.10  
(0.53, 2.26) 
 19 6.37  
(5.32, 9.92) 
5.26  
(0.36, 21.43)   
1.26  
(0.74, 2.14)    
 
16991: 
XR5000 
0 N/A N/A N/A  16 3.19  
(2.50, 5.06) 
0.00  
( ,  )          
3.15  
(1.74, 5.69)    
 
16994G: 
Glufosfamide 
3 12.88  
(11.01, 15.93) 
66.67  
(5.41, 94.52) 
0.58  
(0.17, 2.03) 
 32 4.83  
(4.17, 9.26) 
13.04  
(4.12, 27.22)  
1.20  
(0.76, 1.90)    
 
16996G: 
RFS 2000 
2 3.58  
(3.58, N) 
50.00  
(0.60, 91.04) 
0.23  
(0.03, 1.74) 
 17 5.88  
(4.47, 14.69) 
29.41  
(10.71, 51.15) 
0.79  
(0.45, 1.38)    
 
26054: 
TMZ+Enzastaurin 
11 11.63  
(7.39, 22.57) 
36.36  
(11.18, 62.68) 
0.63  
(0.28, 1.40) 
 17 11.70  
(7.39, 22.57) 
47.06  
(22.96, 67.97) 
0.52  
(0.28, 0.96)    
 
26061: 
Sagopilone 
35 7.72  
(5.29, 12.32) 
31.43  
(17.09, 46.84) 
0.79  
(0.43, 1.47) 
 38 7.56  
(5.29, 12.32) 
31.58  
(17.73, 46.39) 
0.85  
(0.55, 1.30)    
 
26034: 
TMZ 
0 N/A N/A N/A  27 9.59  
(8.11, 13.21) 
33.33  
(16.77, 50.86) 
0.76  
(0.48, 1.23)    
 
26034: 
BCNU 
29 5.65  
(4.70, 7.13) 
14.29  
(4.50, 29.50) 
1.05  
(0.55, 1.99) 
 29 5.65  
(4.70, 7.13) 
14.29  
(4.50, 29.50)  
1.11  
(0.68, 1.79)    
 
26034: 
Erlotinib 
28 8.38  
(6.28, 15.24) 
34.03  
(17.26, 51.61) 
0.63  
(0.34, 1.20) 
 54 6.65  
(5.22, 8.44) 
19.23  
(9.95, 30.80)  
0.94  
(0.64, 1.39)    
 
Category of 
treatment 
          
No cytotoxic 
(targeted agent only) 
83  33.22  
(23.32, 43.43) 
1.00                 0.29  
df=2   
208 5.75  
(5.06, 6.80) 
21.15  
(15.85, 26.98) 
1.00                 0.42  
df=2   
Cytotoxic  
(BCNU or TMZ) 
29  14.29  
(4.50, 29.50)  
1.43  
(0.91, 2.25)    
0.12  
df=1   
56 7.13  
(5.49, 8.71) 
23.64  
(13.47, 35.43) 
0.89  
(0.66, 1.22)    
0.48  
df=1   
Combination (TMZ + 
targeted agent) 
26  19.23  
(7.01, 35.97)  
1.15  
(0.73, 1.81)    
0.55  
df=1   
36 7.57  
(5.88, 10.94) 
25.00  
(12.43, 39.78) 
0.79  
(0.54, 1.15)    
0.22  
df=1   
Sex                                                  
        Male                                95 6.93  
(5.59, 9.49)              
27.66  
(19.06, 36.92) 
1.00                   
0.86  
df=1 
196 5.62  
(4.83, 7.39) 
21.66  
(16.17, 27.69) 
1.00                   0.20  
df=1 
        Female                              43 7.75  
(5.75, 10.94)             
24.22  
(12.61, 37.88) 
0.97  
(0.66, 1.41)    
         104 6.14  
(5.19, 10.15) 
22.80  
(15.20, 31.33) 
0.85  
(0.66, 1.09)    
         
WHO Performance 
Status                          
          
        0                                   40 10.94  
(9.49, 12.88) 
35.00  
(20.81, 49.55) 
1.68  
(1.22, 2.31)    
2E-3  
df=1   
84 9.61  
(8.41, 11.10) 
33.33  
(23.53, 43.42) 
1.64  
(1.35, 1.99)    
<.1E-4 
df=1   
        1                                   84 6.37  
(5.75, 7.43) 
24.73  
(16.01, 34.45) 
  172 5.82  
(5.19, 7.00) 
19.85  
(14.20, 26.21) 
  
        2                                   14 3.07  
(2.07, 9.76) 
14.29  
(2.32, 36.55) 
  44 3.68  
(3.02, 5.19) 
9.09  
(2.90, 19.71)   
  
           
        0 40 10.94  
(9.49, 12.88) 
35.00  
(20.81, 49.55) 
1.00                   
0.02  
df=1 
84 9.61  
(8.41, 11.10) 
33.33  
(23.53, 43.42) 
1.00                   
0.0001  
df=1 
        >0 98 5.88  
(5.49, 7.26) 
23.22  
(15.35, 32.06) 
1.60  
(1.07, 2.41)    
         216 5.29  
(4.76, 5.88) 
17.63  
(12.83, 23.06) 
1.70  
(1.30, 2.24)    
         
Neurological deficit                                           
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        No          50 7.92  
(6.21, 11.04) 
32.00  
(19.70, 44.97) 
1.28  
(0.99, 1.66)    
0.06  
df=1   
100 8.18  
(7.13, 9.89) 
30.00  
(21.36, 39.11) 
1.37  
(1.16, 1.62)    
0.0002  
df=1   
        Some   54 6.87  
(5.75, 10.55) 
25.47  
(14.61, 37.82) 
  101 5.82  
(5.22, 7.33) 
19.68  
(12.48, 28.09) 
  
        Moderate/major 22 5.50  
(3.12, 9.76) 
13.64  
(3.41, 30.87) 
  65 4.80  
(3.22, 6.37) 
12.31  
(5.75, 21.50)  
  
Age (quartiles)                                                                                                                                                                                                      138 N/A 1.02
(0.87, 1.20)    
0.81
df=1   
300 N/A N/A 1.07  
(0.96, 1.18)    
0.21  
df=1   
Age (median)                                                                                                                                                                                                           
        < 54 yrs                                                                                                                                                                                            69 7.00
(5.82, 10.15) 
26.09  
(16.43, 36.79) 
1.00   
0.68  
df=1 
150 7.13
(6.21, 8.41) 
23.51
(17.06, 30.57) 
1.00                   0.30  
df=1 
        54 yrs 69 7.26  
(5.75, 10.38) 
27.19  
(17.19, 38.16) 
1.08  
(0.76, 1.53)    
         150 5.72  
(4.93, 6.97) 
20.64  
(14.52, 27.52) 
1.13  
(0.90, 1.43)    
         
Associated chronic 
disease                  
          
        No                                  73 7.26  
(5.82, 9.92) 
23.29  
(14.38, 33.45) 
1.00                   
0.97  
df=1 
183 7.03  
(5.82, 7.75) 
19.38  
(13.99, 25.43) 
1.00                   0.94  
df=1 
        Yes                                 30 6.21  
(5.49, 13.63) 
29.89  
(14.46, 47.03) 
0.99  
(0.63, 1.56)    
         79 5.08  
(4.53, 6.21) 
23.96  
(15.14, 33.93) 
1.01  
(0.77, 1.33)    
         
Time since initial 
diagnosis (quartiles)                                                                                                                                                                 
138 N/A N/A 0.97  
(0.83, 1.14)   
0.73  
df=1   
300 N/A N/A 0.90  
(0.81, 1.00)    
0.06  
df=1   
Time since initial 
surgery (quartiles)                                                                                                                                                                                 
131 N/A N/A 1.00  
(0.85, 1.17)  
0.99  
df=1
288 N/A N/A 0.94  
(0.84, 1.04)    
0.23  
df=1   
Time since  last  
irradiation (quartiles)                                                                                                                                                                            
138 N/A N/A 0.99  
(0.85, 1.16)
0.91  
df=1  
294 N/A N/A 0.94  
(0.84, 1.04)    
0.23  
df=1   
Prior chemotherapy                                
        No  0 N/A N/A N/A N/A 89 6.14  
(5.03, 7.79) 
13.87  
(7.61, 22.00)  
1.00                 0.096  
df=2   
        Yes, without 
temozolomide                
0 N/A N/A N/A N/A 55 5.19  
(4.34, 7.13) 
25.45  
(14.89, 37.41) 
0.76  
(0.53, 1.09)    
0.14  
df=1   
        Yes, with 
temozolomide                  
138 7.13  
(6.21, 8.71) 
26.64  
(19.52, 34.27) 
N/A N/A 156 6.87  
(5.82, 8.21) 
25.49  
(18.90, 32.57) 
0.74  
(0.56, 0.98)    
0.03  
df=1   
Time since last 
chemotherapy 
(quartiles)                                                                                                                                                                                
138  N/A 1.03  
(0.87, 1.23)    
0.70  
df=1   
211 N/A N/A 0.99  
(0.87, 1.13)    
0.87  
df=1   
Surgery for 
recurrence                      
          
        No                                  118 7.13  
(5.85, 9.92) 
28.68  
(20.76, 37.06) 
1.00                   .27  
df=1 
263 6.18  
(5.62, 7.29) 
22.53  
(17.65, 27.79) 
1.00                   0.25  
df=1 
        Yes                                 20 7.13  
(4.44, 8.71) 
15.00  
(3.73, 33.47) 
1.32  
(0.81, 2.15)    
         37 6.87  
(4.53, 8.41) 
18.92  
(8.33, 32.78)  
1.23  
(0.87, 1.74)    
         
Baseline steroids                                
        No                                  60 10.74  
(9.76, 13.73) 
39.85  
(27.32, 52.08) 
1.00                 0.00
01  
df=1 
104 10.74  
(9.23, 13.21) 
42.31 
(32.65, 51.64) 
1.00                  < 1E-4  
df=1 
        Yes                                 78 5.40  
(4.70, 6.28) 
16.67  
(9.41, 25.71) 
2.05  
(1.42, 2.98)    
         196 5.09  
(4.37, 5.72) 
11.37  
(7.39, 16.30)  
2.28  
(1.75, 2.97)    
         
Baseline anti-
epileptic                     
          
        No AED                                   51 7.26  
(5.75, 10.94) 
29.00  
(17.12, 41.97) 
1.00                 0.28  
df=2   
107 6.28  
(5.26, 7.79) 
22.38  
(14.92, 30.80) 
1.00                 0.69  
df=2   
        EIAED                                   31 5.82  
(5.19, 7.72) 
16.13  
(5.88, 30.88)  
1.40  
(0.87, 2.24)    
0.16  
df=1   
74 5.83  
(5.19, 7.43) 
18.92  
(10.97, 28.53) 
1.12  
(0.82, 1.52)    
0.47  
df=1   
        Non EIAED only                                   56 7.92  
(6.21, 11.37) 
30.36  
(18.96, 42.54) 
0.99  
(0.66, 1.49)    
0.98  
df=1   
119 7.03  
(5.55, 8.21) 
23.75  
(16.53, 31.73) 
0.99  
(0.75, 1.30)    
0.92  
df=1   
Number of target 
lesions                    
          
        0-1                                   119 7.75  
(6.44, 10.38) 
29.24  
(21.29, 37.62) 
1.00                 1E-4  
df=1 
253 7.03  
(5.88, 7.92) 
25.03  
(19.83, 30.55) 
1.00                 < 1E-4  
df=1 
        >1                                   19 4.90  
(4.37, 6.44) 
10.53  
(1.78, 28.43) 
2.93  
(1.73, 4.98)    
         47 4.70  
(3.98, 5.85) 
6.38  
(1.66, 15.75)   
1.98  
(1.43, 2.74)    
         
Presence of non 
target lesions              
          
        No                                  117 7.00  
(5.85, 8.71) 
24.76  
(17.27, 32.97) 
1.00                  0.24  
df=1 
254 6.21  
(5.55, 7.13) 
21.01  
(16.19, 26.27) 
1.00                   0.27  
df=1 
        Yes                                 21 7.41  
(5.72, 20.44) 
36.36  
(17.43, 55.67) 
0.74  
(0.45, 1.22)    
         46 6.26  
(5.26, 9.13) 
27.66  
(15.86, 40.78) 
0.83  
(0.60, 1.16)    
         
Frontal location           
        No                                  75 6.41  
(5.82, 8.38) 
24.31  
(15.07, 34.74) 
1.00                   
0.12  
df=1 
125 6.37  
(5.75, 7.79) 
22.96  
(15.61, 31.18) 
1.00                   0.04  
df=1 
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma. 
 
107 
 
        Yes                                 42 8.41  
(6.97, 11.10) 
28.57  
(15.96, 42.52) 
0.72  
(0.48, 1.09)    
         69 8.41  
(7.36, 10.78) 
28.99  
(18.85, 39.89) 
0.71  
(0.52, 0.98)    
         
Largest lesion area  
(quartiles)                                                                                                                                                                                    
132 N/A N/A 1.53  
(1.30, 1.80)
<1E-4 
df=1
292 N/A N/A 1.44  
(1.29, 1.60)    
<1E-4  
df=1   
Largest lesion 
diameter (quartiles)                                                                                                                                                                                    
132 N/A N/A 1.56 
(1.32, 1.85)
<1E-4  
df=1
292 N/A N/A 1.39  
(1.24, 1.56)    
<1E-4 
df=1   
Largest lesion 
diameter  (median) 
          
       <=42 mm 66 10.94  
(8.41, 13.34) 
39.36  
(27.47, 51.02) 
1.00                 <1E-4  
df=1 
147 8.48  
(7.10, 10.58) 
32.57  
(25.10, 40.24) 
1.00                 <1E-4  
df=1 
       >42 mm 66 5.40  
(4.47, 6.97) 
12.12  
(5.66, 21.20) 
2.15  
(1.49, 3.10)    
         145 4.96  
(4.17, 5.72) 
9.83  
(5.65, 15.38)   
1.97  
(1.54, 2.52)    
         
Note: HR: Hazard Ratio. df= degree of freedom of the statistical test. df=1 for binary factors, for continuous variables and 
scores (eg WHO performance status). df=9 is for the global homogeneity test among the 10 protocol treatment arms. Imatinib 
was used as the reference arm.  Because sample sizes are small and treatments were not randomized, no pairwise comparisons 
were performed.  
 
Progression free survival  
 
For all GBM patients, median PFS was 1.8 months (1.7–1.9) and PFS6 was 14.7% (11.0–19.0). Patients 
treated with experimental agents at the recurrence had a lower PFS6 (9.6%) compared to patients who 
received a combined therapy of an experimental agent and TMZ (27.8%, p = 0.003) or BCNU (25.5%, p = 
0.003). Among the factors screened, a higher WHO PS (p = 0.0003), the presence of neurological deficits 
(p = 0.06), the administration of steroids (p = 0.08), multiple target lesions (p = 0.007), larger area of the 
target lesions (p = 0.09), were negatively associated to PFS in univariate analyses stratified by the 
category of treatment (p < 10%). The maximum diameter of the largest lesion was borderline not 
significant (p = 0.11). After stepwise selection and assessment of the model’s internal validity by the 
bootstrap technique, two factors remained in the final prognostic model: WHO PS (code: 0/1/2, p = 
0.0002, PI = 91%) and the number of target lesions (p = 0.004, PI = 84%). The C-index corrected for 
optimism was 0.62 and PEV was 3.4%. In the subset having received TMZ/RT → TMZ as first-line 
therapy (n = 138), median PFS was 1.84 months (1.74, 2.14) and PFS6 was 18.3% (12.3, 25.1). There was 
no significant difference of PFS between the three categories of treatment for the recurrence (p = 0.35). 
WHO PS (code: 0, >0) (p = 0.04), the number of target lesions (p = 0.02) were the only factors selected by 
univariate analysis. Both variables were selected by stepwise technique. Although performance status had 
a PI lower than 0%, it was maintained in the final model (PI = 58%) assuming that the reason was a lack 
of power in this subset. Discrimination and goodness of fit of this two factors model was low (C index = 
0.56, PEV = 4.6%).  
 
Overall survival  
 
For all GBM patients, median OS was 6.2 months (5.7, 7.1), OS12 was 22.1% (17.5, 27.0). There was no 
significant difference of survival between the three categories of treatment (p = 0.42). WHO PS (p 6 
0.0001), presence of neurological deficits (p = 0.0002), time since initial diagnosis (p = 0.06), baseline 
administration of steroids (p < 0.0001), number of target lesions (p < 0.0001), tumour size (largest tumour 
diameter, p < 0.0001), frontal tumour location (p = 0.02) and prior chemotherapy with TMZ (p = 0.096) 
were the factors which passed the 10% significance criterion (see 
http://www.eortc.be/tools/recgbmcalculator/Curves.aspx). Age was not related to survival outcome (p = 
0.21) and undergoing a surgery for recurrence did not significantly impact on the survival (p = 0.25). After 
stepwise selection and assessment of factor importance by bootstrap, WHO PS (p = 0.008, PI = 69%), 
baseline steroids (p = 0.0001, PI = 91%), the number of target lesions (p = 0.003, PI = 80%), frontal 
location (p = 0.02,PI = 62%), tumour size (maximum diameter of the largest lesion, split by the median ie 
≤42 mm versus >42 mm, p = 0.015, PI = 70%) were retained in the final multivariate model. The C-index 
was 0.68 and PEV = 15.7%. The C-index was not substantially increased when continuous measures for 
tumour size were considered (C-index = 0.69). Therefore, for ease of interpretation the model with binary 
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tumour size was considered. In the patient group having received TMZ/RT → TMZ as first-line therapy, 
median OS was 7.1 months (6.2, 8.7) and OS12 was equal to 26.6% (19.5, 34.3) not significantly different 
from the EORTC/NCIC phase III trial patient population (n = 125, median OS = 8.0 months (6.5,9.3), 
OS12 = 28.8% (21.1,37.0), p = 0.91, Figure VI.1). Our pooled dataset was considered representative of 
the recurrent GBM population receiving further chemotherapy at progression. There was no significant 
difference in survival between the three categories of treatment at recurrence (p = 0.29). In this pre-treated 
subgroup the same factors were selected in univariate analysis except the time since initial diagnosis 
and the frontal location. The final model included four factors: WHO PS (p = 0.009 PI = 79%), baseline 
steroids (p = 0.02, PI = 71%), number of target lesions (p < 0.0001, PI = 99%), maximum diameter of the 
largest lesion (binary, p = 0.0003, PI = 95%). The C-index was 0.70 and PEV was 19%.  
 
Figure VI.1: OS in the pooled dataset compared to historical data. 
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Table VI-7: Cox multivariate models for PFS and OS  
 
 Final models for progression free survival  Final models for overall survival 
GBM pretreated with 
TMZ/RTTMZ 
(n=138, 138 used, 
136 PFS events)  
All GBM 
(n=300, 300 used,  
298 PFS events)  
 GBM pretreated with 
TMZ/RTTMZ 
(n=138, 132 used, 
122 deaths)  
All GBM 
(n=300,  189 used, 
176 deaths) 
Hazard 
Ratio  
(95% CI) 
p-value 
(Imp %) 
Hazard  
Ratio  
(95% CI) 
p-value 
(Imp %) 
 Hazard  
Ratio  
(95% CI) 
p-value 
(Imp %) 
Hazard 
Ratio 
(95% CI) 
p-value 
(Imp %) 
Performance Status                                  
        0                                   N/A N/A 1.42 
(1.18-1.71) 
0.0002(91)  1.54  
(1.11-2.13) 
0.009 (79) 1.42  
(1.10-1.83) 
0.008 (69) 
        1                                           
        2                                           
or          
        0 1.56  
(1.06-2.29) 
0.02 (58)        
        >0          
Neurological deficit                                  NI NI NS NS (9)  NS NS (11) NS NS (13) 
        No                   
        Some            
        Moderate/major          
Prior chemotherapy                      NI NI NI NI  NI NI NS NS (14) 
        No           
       Yes, without      
 temozolo
mide                
         
        Yes, with 
 temozolo
mide                  
         
Baseline steroids                      NI NI NS NS (6)      
        No                                      1.60  
(1.09-2.36) 
0.02 (71) 2.01  
(1.40-2.88) 
0.0001 (91) 
        Yes                                         
Number of target 
lesions                    
         
        0-1                                   2.14  
(1.29-3.53) 
0.003(83)  1.6  
(1.16-2.19) 
0.004 (84)  3.09 
(1.82-5.27) 
<0.0001 
(100) 
1.87 
(1.24-2.82) 
0.003 (80) 
        >1                                            
Frontal location NI NI NI NI  NI NI   
        No                                        0.69 
(0.50-0.95) 
0.02 (62) 
        Yes                                         
Largest lesion 
diameter  (median) 
NI NI NI NI      
       <=42 mm      2.01 
(1.37-2.94) 
0.0003 
(95) 
1.49 
(1.08-2.05) 
0.015 (70) 
       >42 mm          
          
C-index corrected 
for optimism 
0.56 0.62  0.70 0.68 
Note: Only factors selected in the univariate analysis were included. NA: Not Applicable, NI: Not Included, factor was not 
selected in univariate analysis for the outcome in the subset, NS: Not Selected in multivariate model. Imp: Importance. 
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Development of prognostic calculators 
 
The final multivariate models for PFS and OS in recurrent GBM patients having received TMZ/RT → 
TMZ as first line therapy were used to compute two prognostic calculators. They are available online at 
http://www.eortc.be/tools/recgbmcalculator/Default.aspx. Their calibration was satisfactory (see 
http://www.eortc.be/tools/recgbmcalculator/Calibration.aspx).  
 
6.5 Discussion 
 
In this report, baseline characteristics and outcome data were available for 300 patients diagnosed with 
GBM by the local pathologist. In all pooled phase II trials, the last dose of radiotherapy had to be 
administered more than 3 months from the time of recruitment thus making the chance of 
pseudoprogression less likely.
26,27
 One hundred thirty eight had received TMZ/RT → TMZ at initial 
diagnosis. We have shown that tumour load measured by the maximum diameter of the largest target 
lesion and the number of target lesions have strong prognostic relevance for OS. In previous studies, 
WHO PS and baseline steroids were identified as major prognostic factors for OS. This report confirms 
these findings. Our patients tended to be older compared to previous report, nevertheless age did not show 
prognostic significance.
7
 WHO PS and the number of target lesions were the two main factors selected in 
the PFS models. Patients with an initially large lesion and/or who were receiving steroids at baseline 
tended to progress more rapidly but the association was not statistically significant in this subset. The use 
of anti-angiogenic therapies might change the prognostic potential of some factors e.g. bevacizumab 
administration might reduce the detrimental effect of the need for steroids and of larger or multiple 
tumours, at least on PFS. Recently, Weller et al. assessed the prognostic value of 11 molecular markers in 
patients treated by TMZ/RT → TMZ.28 The only factor of prognostic significance was MGMT gene 
promoter methylation.
29
 It is however not clear if the status of molecular markers remains constant over 
time and how eventual changes might affect the markers prognostic value.
6,30
 In our study, biological 
material was not systematically collected or analysed for molecular prognostic factors. Potentially, more 
accurate models for PFS and OS could be obtained by the addition of prognostic genomic signatures or 
biologically relevant biomarkers assessed at initial diagnosis and at recurrence, respectively, taking into 
account prior therapies.
31
 The model’s accuracy will also be improved once biomarkers predicting the 
activity of new active targeted agents are identified.
32
 This study is exploratory and suffers some 
limitations: the heterogeneity of the treatments for recurrence, the small sample size, the lack of molecular 
data and the absence of validation of the prognostic models in a large independent dataset. This validation 
might be complicated because more and more patients will receive bevacizumab or other active treatments 
at different times of their disease, which may change their outcome. In the present study we developed 
prognostic calculators in the patients treated at initial diagnosis with TMZ/RT → TMZ. Four factors were 
retained for OS: WHOPS, baseline administration of steroids, tumour size (maximum diameter of the 
largest lesion; split by the median (≤ 42 mm versus >42 mm) and initial number of target lesions (1 versus 
>1). All four should be used as stratification factors in randomised trials when OS is the primary end-
point. When PFS is the end-point stratifying by the WHO PS and the number of target lesions may suffice. 
The prognostic calculators provide outcome estimates with 95% confidence intervals. Our models and 
calculators can help physicians by providing objective information to patients and their families about 
their disease prognosis, discussing with them the best therapeutic strategy or the opportunity to participate 
to a clinical trial taking patient’s individual characteristics into account.  
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7.1 Abstract 
 
Background:   
The prognosis of patients with oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable. 
Biomarkers might be helpful to identify more homogeneous disease subtypes and improve therapeutic 
index. The aim of this study is to develop new clinical, pathological and molecular prognostic models for 
locally diagnosed anaplastic gliomas with oligodendroglial features (AOD or AOA).  
 
Methods:  
Data from 368 patients with AOD or AOA recruited in EORTC trial 26951 on adjuvant PCV 
chemotherapy in anaplastic oligodendroglial tumors were used to develop multifactor models to predict 
progression free survival (PFS) and overall survival (OS). Different models were compared by their 
percentage of explained variation (PEV). Prognostic calculators were derived from these new models.  
 
Results:  
Treatment (for PFS only), younger age, confirmed absence of  residual tumor on imaging,  frontal 
location,  good WHO performance status, absence of endothelial abnormalities and/or  necrosis, 1p/19q 
codeletion and IDH1 mutation were  independent factors that predicted better PFS and OS.  
 
Conclusions:  
We identified important prognostic factors for AOD and AOA and showed that molecular markers added 
a major contribution to clinical and pathological factors in explaining PFS and OS. With a positive 
predictive value of 92% for PFS and 94% for OS, our models allow physicians to precisely identify high 
risk patients and aid in making therapeutic decisions. 
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7.2 Introduction 
Anaplastic oligodendrogliomas (AOD), and anaplastic oligoastrocytomas (AOA) are classified as Grade 
III gliomas by the WHO classification and account for up to 20% of all newly diagnosed primary brain 
tumors. Recently, updated results of the EORTC 26951 trial have shown that the addition of 6 cycles of 
PCV (Procarbazine, CCNU, Vincristine) to 59.4 Gy radiotherapy significantly improves both progression 
free (PFS) and overall survival (OS) in patients with anaplastic oligodendroglial tumors. Patients with co-
deletion of chromosomes 1p and 19q had a better prognosis and appear to benefit more from RT/PCV 
therapy. Similar results were obtained in a North American trial (RTOG 9402).
1,2
. In absence of more 
reproducible pathological criteria for typing and grading of gliomas, the management of anaplastic 
gliomas may remain sub-optimal.
3,4
 Whether molecular diagnosis improves the situation is still a matter of 
debate, but accumulating data suggest these markers are indeed relevant for treatment decisions. In 
particular 1p/19q status, MGMT promoter methylation and IDH mutations are candidate markers to guide 
treatment decisions. Recent studies have shown a significant prognostic value for IDH1 mutations but 
whether it predicts benefit to PCV chemotherapy is still unclear.
5
 MGMT promoter methylation had a 
predictive value for the efficacy of chemoradiation with temozolomide in glioblastoma but has prognostic 
value in anaplastic gliomas treated with either RT or RT/PCV.
6,7
 This appears due to a relationship with 
CpG island hypermethylation in grade III gliomas, which may be induced by IDH mutation. 
8,9
   
In order to further evaluate the role of molecular factors for patient outcome prediction in this tumor type, 
we further analysed them in multivariate models together with clinical and pathological factors. Finally, 
prognostic calculators were derived from the regression models in order to provide clinicians with 
individualized outcome predictions.  
 
7.3 Patients and methods 
 
Patient selection 
 
Between October 2
nd
 1996 and February 27
th
 2002, 368 patients with AOD or AOA (at least 25% 
oligodendroglioma components) diagnosed by local pathologists were randomized in EORTC trial 26951  
to either receive radiotherapy alone or radiotherapy followed by 6 cycles of PCV regimen (Procarbazine, 
CCNU, Vincristine). The details of this study and the results have been published elsewhere.
1,10
 All 
randomized patients (Intent-To-Treat) were used for prognostic model development.  
 
Candidate prognostic factors 
 
Twenty four available factors split into three categories (clinical, pathological, molecular) were screened 
for their prognostic value.  Clinical factors analysed were: treatment, age, sex, time since first symptoms 
(< or ≥1 year), previous resection for low grade glioma, time since surgery  (< or ≥ 42 days), tumor 
contrast enhancement on imaging, tumor location, extent of surgery (resection versus biopsy), presence of 
residual tumor on postoperative imaging (CT or MRI), postoperative Mini Mental State Examination 
(MMSE) score and WHO performance status. Pathological features as assessed by local pathologists 
were: tumor histological subtype (WHO classification 1993), presence of high cellularity, nuclear 
abnormalities, mitoses, endothelial abnormalities and necrosis. The analysed molecular markers were: 
1p/19q codeletion, IDH1/2 mutation, MGMT methylation status, EGFR amplification, trisomy 7, loss of 
chromosome 10, loss of chromosome 10q (Table VII-1, see supplemental table 1). The methods with 
which these molecular abnormalities were assessed have been described elsewhere. 
5, 6, 11
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Table VII-1: Clinically relevant factors for Grade III glioma patients with their coding conventions. 
 
 Coding conventions 
1) Clinical factors  
Treatment 0=RT,1=RT/PCV 
Age Continuous 
Sex 0=Male,1=Female 
Time since first 
symptoms (days) 
0=1 year, 1=<1 year 
Previous resection 
for low grade 
glioma 
0=No,1=Yes 
Time since surgery 
(days) 
0=>42, 1=<=42 days 
Tumor contrast 
enhancement on 
imaging 
0=No,1=Yes 
Frontal location 0=No/1=Yes 
Extent of resection with 
confirmation 
1=Biopsy with residual tumor on CT/MRI 
or status of residual tumor missing. 
2=Partial Removal (PR) or Complete 
Removal (CR) with residual tumor on 
CT/MRI or status of residual tumor 
missing 
3=Biopsy or PR or CR without residual 
tumor on CT/MRI. 
Mini Mental State 
Examination 
(MMSE)  
0=<27,1=[27-30] 
WHO performance 
status 
0=WHO 0,1=WHO 1,2=WHO 2 
2) Pathological factors  
Tumor histological 
subtype 
0=AOD/1=AOA>25% oligo compents 
Presence of high 
cellularity 
0=No/1=Yes 
Presence of nuclear 
abnormalities 
0=No/1=Yes 
Presence of mitoses 0=No/1=Yes 
Presence of  endothelial 
abnormalities 
0=No/1=Yes 
Presence of  necrosis 0=No/1=Yes 
3) Molecular factors  
1p/19q 0=non codeleted/1=codeleted 
MGMT 0=Unmethylated, 1=Methylated 
IDH1 0=Normal, 1=Mutated 
EGFR 0=Normal, 1=Amplified 
Trisomy 7 0=Normal, 1=Amplified 
Chromosome 10 0=No loss,1=Loss 
Chromosome 10q 0=No loss,1=Loss 
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Patient outcome measurements 
 
Macdonald’s criteria were used to define progression.12 Progression free survival (PFS) was computed as 
the time from randomization till signs of clinical or radiological progression or death whichever occurred 
first. Overall Survival (OS) was calculated as the time from randomization until death regardless of cause. 
In absence of events, PFS and OS were censored at the last follow-up date.  
 
Statistical considerations 
 
Categorical data were tabulated with frequencies and percentages. Medians and ranges (minimum-
maximum) were used to summarize continuous variables. The Spearman rank correlation coefficient 
(SCC) was computed pairwise for all factors. SCC superior or equal to 0.40 are reported. For each factor, 
Kaplan Meier curves and log-rank tests were computed. Proportional Hazards (PH) assumptions were 
tested by examining the plot of the log of negative log estimates over the log survival time (LLS) and by 
assessing the Schoenfeld residual plots.
13
 All clinically relevant factors independent of their significance 
in univariate analyses were considered for Cox multivariate analyses. For factors whose percentage of 
missing value was more than 5%, the missing value was replaced by a dummy category in the Cox 
analyses. Factors with SSC greater than +0.4 were at risk to generate multicolinearity problems in the 
models. They were pre-screened in separate Cox models. Factors who did not add to the model 
discrimination (see definition below) were not retained for further multivariate modeling. For the final 
multivariate models, the stepwise backward method was used for factor selection. Model internal validity 
was assessed by the bootstrap method. Factors with an importance (percentage of bootstrap samples with 
factor selected in multivariate analysis) lower than 60% were not included in the final models. 
14
 A 
significance level of 5% was used in multivariate analyses.  Harrel’s C-index  corrected for optimism by 
bootstrap resampling was used to assess model’s discrimination.15 Calibration plots and Schemper’s 
percentage of explained variation (PEV) were also computed.
16,17
 A PEV of at least 20% was considered a 
minimum requirement for a model to provide sufficiently precise individual survival predictions.
 18 
From 
the final models, prognostic calculators were developed and predictions for median PFS, OS, 2-year PFS 
(PFS2y) and 5-year OS (OS5y) were derived. Individual prognostic scores were computed. Based on their 
scores, patients were classified into three distinct risk groups of equal size (low, intermediate, high).  For 
all statistical analyses, SAS version 9.2 (SAS Institute Inc., Cary, NC, USA.) was used except for the 
computation of the C-index and calibration plots which were obtained from the R “Design” and “Hmisc” 
Packages. The percentage of explained variation was computed using the SAS macro RELIMPCR.
 17
 The 
reflected method was used to estimate the 95% confidence interval (CI) for the median survival .
 19
 The 
loglog transformation was used for the 95% CI of PFS2y and OS5y.  
Model sensitivity, specificity, positive and negative predictive value (PPV/NPV) were computed. In this 
study, PPV measures the ability of the model to correctly identify patients at high risk of progression or 
death within two years (PFS2y) or of death within five years (OS5y). The capacity of the model to 
correctly identify patients at low risk for these events is measured by the NPV (see table VII-6 for the 
other definitions). In absence of an independent dataset, no external validation could be realized. 
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7.4 Results 
 
Correlation analysis  
 
Table VII-2 displays patient and disease characteristics for all patients. SSC >=0.4 are presented in table 
VII-3 (supplemental table 2) (all p-values lower than 0.001). Time since first symptoms and previous 
resection for LGG had SSC=0.4. IDH1 mutation was positively correlated with 1p/19q codeletion 
(SSC=0.47) and MGMT methylation (SSC=0.51) and was negatively correlated with EGFR amplification 
(SSC=-0.40). Trisomy 7 (SSC=0.40) and chromosome 10 loss (SSC=0.49) were positively correlated with 
EGFR amplification. 
 
Table VII-2: Patients and disease characteristics. 
 
 Baseline characteristics 
 
 
All 
patients 
(N=368) 
 N (%) 
Treatment                                                                                                                        
        RT                  183 (49.7) 
        RT/PCV              185 (50.3) 
Age                                                                                                                                                                                                       
        Median                                                                                                                                                                                           49.5
        Range                                                                                                                                                                                            18.6 - 68.7 
        N obs                                                                                                                                                                                            368
Sex                          
        Male                212 (57.6) 
        Female              156 (42.4) 
Time since first symptoms                                                                                                                                                                                 
        1 year                                                                                                                                                                                           90 (24.5) 
        <1 year                                                                                                                                                                                            268 (72.8)
        Missing                                                                                                                                                                                           10 (2.7)
Previous resection for LGG   
        No                  313 (85.1) 
        Yes                 52 (14.1) 
        Missing             3 (0.8) 
Time since surgery (days)                                                                                                                                                                              
        Median                                                                                                                                                                                           27.0
        Range                                                                                                                                                                                            5.0 - 132.0 
        N obs                                                                                                                                                                                            368
        >42 days                                  38 (10.3)                                                                                          
        <=42 days                                330 (89.7)                                                                                          
Tumor contrast enhancement on imaging  
        No                  63 (17.1) 
        Yes                 286 (77.7) 
        Missing             19 (5.2) 
Frontal location               
        No     190 (51.6) 
        Yes        178 (48.4) 
Extent of resection with confirmation                                                                                                             
        Biopsy                             51 (13.9)                                                                                          
        Not confirmed without residual 
tumor on imaging 
 208 (56.5)                                                                                          
        Confirmed without residual tumor 
on imaging 
 109 (29.6)                                                                                          
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 Baseline characteristics 
 
 
All 
patients 
(N=368) 
 N (%) 
MMSE                         
        <27                 99 (26.9) 
        27-30               230 (62.5) 
        Missing             39 (10.6) 
WHO performance status       
        0                   134 (36.4) 
        1                   171 (46.5) 
        2                   58 (15.8) 
        Missing             5 (1.4) 
Local diagnosis       
        AOD                 266 (72.3) 
        AOA>25% oligo components           100 (27.2) 
        Missing             2 (0.5) 
High cellularity                                                                                                                              
        No                                 28 (7.6)                                                                                           
        Yes                               338 (91.8)                                                                                          
        Missing                             2 (0.5)                                                                                           
Nuclear abnormalities                                                                                                                         
        No                                 33 (9.0)                                                                                           
        Yes                               333 (90.5)                                                                                          
        Missing                             2 (0.5)                                                                                           
Mitoses                                                                                                                                       
        No                                 31 (8.4)                                                                                           
        Yes                               335 (91.0)                                                                                          
        Missing                             2 (0.5)                                                                                           
Endothelial Abnormalities                                                                                                                     
        No                                 86 (23.4)                                                                                          
        Yes                               280 (76.1)                                                                                          
        Missing                             2 (0.5)                                                                                           
Necrosis                                                                                                                                      
        No                                166 (45.1)                                                                                          
        Yes                               200 (54.3)                                                                                          
        Missing                             2 (0.5)                                                                                           
1p/19q                                                                                                                                        
        Non codeleted                     236 (64.1)                                                                                          
        Codeleted                          80 (21.7)                                                                                          
        Missing                            52 (14.1)                                                                                          
MGMT                                                                                                                                          
        Unmethylated                       45 (12.2)                                                                                          
        Methylated                        138 (37.5)                                                                                          
        Missing                           185 (50.3)                                                                                          
IDH1                                                                                                                                          
        Normal                             99 (26.9)                                                                                          
        Mutated                            83 (22.6)                                                                                          
        Missing                           186 (50.5)                                                                                          
EGFR                                                                                                                                         
        Normal                            193 (52.4)                                                                                          
        Amplified                          58 (15.8)                                                                                          
        Missing                           117 (31.8)                                                                                          
Trisomy 7                                                                                                                                     
        No                                168 (45.7)                                                                                          
        Yes                                73 (19.8)                                                                                          
        Missing                           127 (34.5)                                                                                          
Chromosome 10                                                                                                                               
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 Baseline characteristics 
 
 
All 
patients 
(N=368) 
 N (%) 
        No loss                           205 (55.7)                                                                                          
        Loss                               46 (12.5)                                                                                          
        Missing                           117 (31.8)                                                                                          
Chromosome 10q                                                                                                                             
        No                                221 (60.1)                                                                                          
        Yes                                38 (10.3)                                                                                          
        Missing                           109 (29.6)                                                                                          
 
Table VII-3: Correlation analyses. 
 
 
 
Previous 
resectio
n for 
LGG 
Time 
since 
first 
sympto
ms 1p/19q MGMT IDH1 EGFR 
Trisomy 
7 10 loss 10q loss 
Previous resection for 
LGG 
1.00000 
 
365 
        
Time since first symptoms 0.40 
<.0001 
356 
1.00000 
 
358 
       
1p/19q 0.21 
0.0002 
313 
0.08 
0.16 
307 
1.00000 
 
316 
      
MGMT 0.16 
0.03 
181 
0.16 
0.05 
178 
0.28 
0.0002 
179 
1.00000 
 
183 
     
IDH1 0.28 
0.0002 
176 
0.29 
0.0001 
173 
0.47 
<.0001 
176 
0.51 
<.0001 
152 
1.00000 
 
178 
    
EGFR -0.17 
0.009 
248 
-0.25 
0.0001 
244 
-0.28 
<.0001 
249 
-0.13 
0.08 
166 
-0.40 
<.0001 
158 
1.00000 
 
251 
   
Trisomy 7 -0.08 
0.21 
238 
-0.12 
0.07 
234 
-0.11 
0.09 
239 
-0.16 
0.04 
160 
-0.28 
0.0004 
150 
0.40 
<.0001 
241 
1.00000 
 
241 
  
10 loss -0.13 
0.04 
248 
-0.17 
0.006 
244 
-0.24 
0.0002 
247 
-0.15 
0.06 
166 
-0.33 
<.0001 
156 
0.49 
<.0001 
223 
0.30 
<.0001 
220 
1.00000 
 
251 
 
10q loss -0.07 
0.29 
256 
-0.08 
0.20 
251 
-0.12 
0.06 
255 
-0.10 
0.21 
167 
-0.09 
0.25 
158 
0.22 
0.0007 
229 
0.07 
0.31 
224 
-0.19 
0.002 
251 
1.00000 
 
259 
Note: Factors with at least one correlation coefficient >=0.4. In each cell, the three lines corresponds to : 
Spearman Correlation Coefficients (SSC), P-value, number of observations. 
 
Development of prognostic models 
 
Table VII-5 (Supplemental table 3) displays the results of PFS and OS univariate analyses. MMSE and all 
molecular markers were missing in more than 5% of the patients, here a dummy category (“missing”) was 
used . Molecular factors which passed the pre-screening process and were considered for further 
multivariate modeling are: 1p/19q codeletion, IDH1 mutation, EGFR amplification and Trisomy 7. 
MGMT did not add to discrimination in the model that includes 1p/19q and IDH1. Loss of chromosome 
10 of loss or chromosome 10q did not add to models that include EGFR and trisomy 7.  Extent of surgery 
and confirmed absence of residual tumor were combined into the factor named “confirmed extent of 
resection” (see definition in table VII-1). There was no strong violation of PH assumptions based on 
Schoenfeld residuals (data not shown). For PFS, 9 independent factors were included in the final Cox 
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model: treatment (p<0.0001), age (p<0.0001), confirmed extent of resection (p=0.0001), frontal location 
(p=0.0008), WHO performance status (p=0.00007), endothelial abnormalities (p=0.013), necrosis 
(p<0.0001), 1p/19q codeletion (p<0.0001), IDH1 mutation (p<0.0001). Discrimination of the model was 
good (C-index=0.725). The factors included could explain 26.7% of PFS variations.  For OS, 8 factors 
were selected: age (p<0.0001), extent of resection with confirmation (p<0.0001), frontal location (p=0.02), 
WHO performance status (p=0.0008), endothelial abnormalities (p=0.028), necrosis (p<0.0001), 1p/19q 
codeletion (p<0.0001), IDH1/2 mutation (p<0.0001). Treatment was not selected (p>0.05). For OS, C-
index was 0.737 and PEV 27.5%. For both PFS and OS, MMSE and tumor histological subtype had no 
independent prognostic value. Calibration plots indicated that PFS and OS models might provide slightly 
pessimistic predictions for low risk patients (data not shown). Final multivariate models are presented in 
Table VII-6. The added value of different combinations of factors was assessed by comparing the PEV of 
each model. For both PFS and OS, molecular factors significantly increased PEV when added to clinical 
factors alone (PFS: 22.5 vs 14.4 p<0.0001, OS:22.8 vs 13.1 p<0.0001) or clinical and pathological factors 
(PFS: 26.7 vs 18.9 p<0.0001, OS:27.5 vs 18.3 p<0.0001; see Tables VII-7 and VII-8). For final PFS and 
OS multivariate models, figures VII.1 and VII.2 show PFS and OS Kaplan Meier curves split by the three 
risk groups. Table VII-6 displays also PFS and OS estimates by risk group and models performance. 
Median OS was 127 months 95% CI (95 mo - not reached) in low risk patients, 42 months 95% CI (29-56) 
in intermediate risk patients and 14 months 95% CI (12 mo – 16 mo) in the high risk group. NPV was 
77% for PFS and 74% for OS. PPV was 92% for PFS and 94% for OS. For both PFS and OS, sensitivity 
and specificity were below 70%.  
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Table VII-4: Univariate analyses of PFS and OS 
 
Progression Free Survival Overall Survival 
 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 2 Years 
(95% CI) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 5 Years 
(95% CI) 
Treatment            
RT                                    183        161 1.00                   0.0003 13.21  
(9.23, 17.91)            
39.34  
(32.26, 46.34) 
       153 1.00                   0.0179 30.62  
(21.45, 44.45)           
36.98  
(30.01, 43.95) 
RT/PCV                              185        137 0.66  
(0.52, 0.83)    
         24.31  
(17.38, 40.67)           
50.00  
(42.58, 56.97) 
       128 0.75  
(0.60, 0.95)    
         42.33  
(28.71, 62.03)           
43.44  
(36.20, 50.46) 
Age (years)            
<41         92         64 1.00                 0.0000 
(df=3)   
39.84  
(19.38, 61.40)           
57.61  
(46.87, 66.94) 
        58 1.00                 0.0000 
(df=3)   
75.73  
(44.45, 103.75)          
56.52  
(45.79, 65.92) 
[41-49.5)         92         68 1.19  
(0.85, 1.68)    
0.31 
(df=1)   
23.66  
(15.05, 47.11)           
49.45  
(38.84, 59.20) 
        65 1.26  
(0.88, 1.79)    
0.21 
(df=1)   
59.30  
(30.03, 79.80)           
49.17  
(38.52, 58.97) 
[49.5-56)         92         81 1.64  
(1.18, 2.28)    
0.003 
(df=1)   
14.82  
(9.79, 26.48)            
41.30  
(31.20, 51.11) 
        75 1.70  
(1.20, 2.39)    
0.0026 
(df=1)   
28.68  
(19.91, 45.83)           
34.78  
(25.25, 44.47) 
56         92         85 2.18  
(1.57, 3.02)    
<0.0001 
(df=1)   
8.30  
(7.06, 13.96)             
30.43  
(21.39, 39.95) 
        83 2.46  
(1.75, 3.44)    
0.0000 
(df=1)   
18.79  
(14.85, 26.61)           
20.50  
(12.93, 29.28) 
Sex            
Male                                  212        174 1.00                   0.35 16.08  
(12.12, 22.11)           
41.98  
(35.29, 48.52) 
       167 1.00                   0.2094 30.19  
(22.54, 41.46)           
37.58  
(31.07, 44.07) 
Female                                156        124 0.90  
(0.71, 1.13)    
         21.98  
(13.27, 40.67)           
48.39  
(40.33, 55.98) 
       114 0.86 
(0.68, 1.09)    
         45.83  
(28.48, 66.23)           
43.82  
(35.90, 51.44) 
Time since first sym
ptoms 
           
<1 year         90         69 1.00                   0.0009 47.80  
(32.03, 57.03)           
64.44  
(53.63, 73.36) 
        64 1.00                   0.0007 75.71  
(59.30, 101.0)          
60.00  
(49.13, 69.27) 
>=1 year        268        222 1.58  
(1.20, 2.07)    
         12.12  
(9.46, 17.15)            
37.08  
(31.31, 42.85) 
       211 1.61  
(1.22, 2.14)    
         25.46  
(20.34, 34.43)           
32.79  
(27.22, 38.46) 
Previous resection 
for LGG 
           
No                                    313        258 1.00                   0.003 14.82  
(11.14, 17.91)           
40.06  
(34.61, 45.45) 
       243 1.00                   0.0072 28.83  
(22.14, 38.64)           
36.53  
(31.21, 41.86) 
Yes                                    52         37 0.60  
(0.42, 0.85)    
         54.08  
(37.09, 75.43)           
73.08  
(58.82, 83.08) 
        35 0.62  
(0.43, 0.88)    
         79.80  
(66.33, 111.8)          
64.88  
(50.17, 76.23) 
Time since surgery 
(days) 
           
>42                               38         33 1.00                   0.3028 15.64  
(6.90, 32.03)            
42.11  
(26.42, 57.00) 
        31 1.00                   0.2042 27.19  
(16.59, 44.45)           
30.56  
(16.74, 45.55) 
<=42                              330        265 0.83  
(0.58, 1.19)    
         17.91  
(13.96, 24.25)           
44.99  
(39.54, 50.27) 
       250 0.79  
(0.54, 1.14)    
         38.31  
(28.71, 50.73)           
41.30  
(35.95, 46.57) 
Tumor contrast 
enhancement on 
imaging 
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Progression Free Survival Overall Survival 
 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 2 Years 
(95% CI) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 5 Years 
(95% CI) 
No                                     63         48 1.00                   0.07 29.57  
(16.26, 49.94)           
53.97  
(40.95, 65.30) 
        45 1.00                   0.1518 61.17  
(28.71, 94.95)           
50.79  
(37.92, 62.30) 
Yes                                   286        236 1.33  
(0.97, 1.81)    
         16.89  
(11.89, 22.11)           
42.81  
(37.02, 48.47) 
       222 1.26  
(0.92, 1.74)    
         34.43  
(25.26, 44.35)           
38.46  
(32.80, 44.08) 
Frontal location            
No                                    190        168 1.00                 <0.0001 9.92  
(8.25, 12.32)             
31.58  
(25.10, 38.24) 
       160 1.00                   0.0000 21.13  
(17.61, 28.48)           
27.17  
(21.03, 33.64) 
Yes                                   178        130 0.54 (0.43, 
0.68)    
         42.09  
(28.71, 54.08)           
58.76 (51.14, 65.60)        121 0.55  
(0.43, 0.70)    
         70.93 
 (44.45, 87.95)           
54.20  
(46.57, 61.20) 
Extent of resection 
with confirmation 
           
Biopsy                                52         49 0.66 (0.55, 
0.79)    
<0.0001 
(df=1)   
6.87  
(5.36, 9.95)              
26.92 
(15.79, 39.34) 
        49 0.64  
(0.53, 0.77)    
0.0000 
(df=1)   
16.15  
(11.56, 24.18)           
17.31  
(8.53, 28.65)  
Not confirmed 
without residual 
tumor on imaging 
       202        163                                      17.15  
(12.78, 22.31)           
42.29  
(35.41, 49.00) 
       153                                      34.43  
(26.61, 45.31)           
38.59  
(31.85, 45.28) 
Confirmed without 
residual tumor on 
imaging 
       114         86                                      43.48  
(19.12, 62.13)           
57.02  
(47.42, 65.51) 
        79                                      70.87  
(44.45, 94.95)           
53.49  
(43.93, 62.14) 
MMSE            
<27                                    99         85 1.00                 0.31 
(df=2)   
13.96  
(9.79, 23.66)            
40.40  
(30.73, 49.86) 
        81 1.00                 0.4362 
(df=2)   
28.71  
(20.80, 56.21)           
38.28  
(28.74, 47.73) 
27-30                                 230        183 0.83 (0.65, 
1.08)    
0.17 
(df=1)   
18.27  
(14.78, 27.76)           
45.85  
(39.30, 52.15) 
       172 0.86  
(0.66, 1.12)    
0.2515 
(df=1)   
38.64  
(27.70, 51.94)           
40.91 
(34.50, 47.20) 
                             
Missing 
        39         30 0.78 (0.51, 
1.18)    
0.24 
(df=1)   
22.11  
(8.74, 42.09)            
48.72  
(32.46, 63.16) 
        28 0.80  
(0.52, 1.23)    
0.3112 
(df=1)   
45.31  
(16.89, 84.24)           
41.03  
(25.69, 55.76) 
WHO performance 
status      
           
0        134         97 1.59 (1.34, 
1.88)    
<0.0001 
(df=1)   
40.25  
(22.31, 52.90)           
58.21  
(49.39, 66.03) 
        89 1.59  
(1.33, 1.89)    
0.0000 
(df=1)   
66.33  
(41.99, 89.40)           
52.06  
(43.27, 60.14) 
1        171        143                                      18.23  
(11.89, 25.17)           
43.53  
(35.99, 50.82) 
       135                                      37.60  
(25.26, 55.56)           
39.34  
(31.99, 46.61) 
2         58         53                                      6.72  
(5.52, 11.89)             
18.97  
(10.13, 29.90) 
        52                                      17.18  
(12.55, 21.65)           
15.33  
(7.46, 25.78)  
Local diagnosis                 
AOD                                   266        212 1.00                   0.12 20.01  
(14.82, 33.02)           
47.37  
(41.26, 53.22) 
       200 1.00                   0.13 43.37  
(30.03, 59.30)           
43.47  
(37.44, 49.34) 
AOA>25% O                      100         84 1.22 (0.95, 
1.57)    
         14.62  
(9.43, 19.38)            
38.38  
(28.86, 47.81) 
        79 1.22  
(0.94, 1.58)    
         28.48  
(18.00, 37.39)           
32.32  
(23.37, 41.58) 
High cellularity            
No                                     28         23 1.00                   0.16 6.57  
(4.34, 11.89)             
28.57  
(13.54, 45.61) 
        21 1.00                   0.96 28.68  
(14.55, 101.72)          
42.86  
(24.57, 59.96) 
Yes                                   338        273 0.74 (0.48, 
1.13)    
         18.53  
(15.38, 26.48)           
46.29  
(40.89, 51.51) 
       258 0.99  
(0.63, 1.54)    
         38.31  
(28.71, 45.77)           
40.24  
(34.97, 45.43) 
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Progression Free Survival Overall Survival 
 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 2 Years 
(95% CI) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 5 Years 
(95% CI) 
Nuclear 
abnormalities 
           
No                                     33         28 1.00                   0.15 13.73  
(5.06, 24.34)            
36.36  
(20.59, 52.34) 
        27 1.00                   0.34 28.78  
(16.69, 70.93)           
35.42  
(19.62, 51.61) 
Yes                                   333        268 0.75 (0.51, 
1.11)    
         18.33  
(14.78, 25.49)           
45.78  
(40.35, 51.04) 
       252 0.82  
(0.55, 1.22)    
         37.85  
(28.71, 49.94)           
40.94  
(35.62, 46.17) 
Mitoses            
No                                     31         25 1.00                   0.87 22.31  
(7.16, 49.48)            
48.39  
(30.18, 64.41) 
        22 1.00                   0.67 33.54  
(16.03, 101.06)          
38.71  
(22.01, 55.15) 
Yes                                   335        271 1.04 (0.69, 
1.56)    
         17.68  
(13.73, 23.66)           
44.61  
(39.22, 49.85) 
       257 1.10  
(0.71, 1.70)    
         36.90  
(28.48, 45.31)           
40.61  
(35.31, 45.83) 
Endothelial 
abnormalities 
           
No                                     86         61 1.00                   0.001 38.80  
(23.66, 68.96)           
60.47  
(49.33, 69.89) 
        58 1.00                   0.002 79.80  
(45.77, 114.07)          
53.17  
(42.06, 63.08) 
Yes                                   280        235 1.58 (1.19, 
2.10)    
         14.78  
(10.87, 18.33)           
40.14  
(34.38, 45.84) 
       221 1.57  
(1.17, 2.09)    
         28.78  
(21.91, 37.39)           
36.53  
(30.90, 42.17) 
Necrosis            
No                                    166        123 1.00                 <0.0001 38.88  
(24.25, 52.90)           
58.43  
(50.55, 65.50) 
       115 1.00                 <0.0001 68.63  
(50.46, 85.36)           
54.79  
(46.91, 62.00) 
Yes                                   200        173 1.70 (1.35, 
2.15)    
         11.01  
(8.74, 15.38)            
33.67  
(27.19, 40.25) 
       164 1.74  
(1.37, 2.21)    
         21.91  
(17.87, 28.71)           
28.43  
(22.33, 34.83) 
1p/19q            
Non codeleted                   236        206 1.00                 <0.0001 
(df=2)   
11.07  
(8.74, 15.21)            
33.05  
(27.13, 39.08) 
       197 1.00                 <0.0001 
(df=2)   
22.72  
(18.89, 28.71)           
28.21  
(22.61, 34.06) 
Codeleted                           80         50 0.39 (0.28, 
0.53)    
<0.0001 
(df=1)   
75.70  
(49.94, 136.77)          
78.48  
(67.69, 86.03) 
        44 0.36  
(0.26, 0.50)    
<0.0001 
(df=1)   
122.71  
(94.95, N)              
74.64  
(63.50, 82.83) 
                             
Missing 
        52         42 0.76 (0.54, 
1.06)    
0.11 
(df=1)   
17.68  
(10.87, 49.48)           
46.15  
(32.29, 58.92) 
        40 0.76  
(0.54, 1.07)    
0.12 
(df=1)   
35.06  
(20.67, 84.24)           
42.22  
(28.72, 55.10) 
MGMT            
Normal                               97         91 1.00                 <0.0001 
(df=2)   
8.38  
(6.60, 9.63)              
21.65  
(14.09, 30.28) 
        42 1.00                 <0.0001 
(df=2)   
15.90  
(11.60, 19.02)           
12.77  
(5.18, 23.89)  
Mutated                              81         55 0.34 (0.24, 
0.48)    
<0.0001 
(df=1)   
53.01  
(38.80, 71.20)           
66.25  
(54.77, 75.46) 
        93 0.39  
(0.27, 0.57)    
<0.0001 
(df=1)   
59.30  
(36.90, 73.56)           
48.89  
(40.23, 56.99) 
                             
Missing 
       190        152 0.53 (0.41, 
0.69)    
<0.0001 
(df=1)   
18.99  
(13.73, 33.02)           
47.37  
(40.12, 54.26) 
       146 0.52  
(0.36, 0.73)    
0.0002 
(df=1)   
38.87  
(25.13, 51.94)           
40.92  
(33.78, 47.91) 
IDH1            
Normal                               97         90 1.00                 <0.0001 
(df=2)   
16.46  
(12.75, 19.55)           
39.18  
(29.49, 48.71) 
        90 1.00                 <0.0001 
(df=2)   
16.46 
(12.75, 19.55)           
18.56  
(11.56, 26.85) 
Mutated                              81         47 0.30 (0.21, 
0.43)    
<0.0001 
(df=1)   
101.13 
(59.40, 140.09)         
83.75  
(73.67, 90.22) 
        47 0.30  
(0.21, 0.43)    
<0.0001 
(df=1)   
101.13  
(59.40, 140.09)         
61.18  
(49.59, 70.87) 
                             
Missing 
       190        144 0.54 (0.41, 
0.70)    
<0.0001 
(df=1)   
38.64  
(25.13, 56.18)           
58.42  
(51.07, 65.05) 
       144 0.54  
(0.41, 0.70)    
<0.0001 
(df=1)   
38.64  
(25.13, 56.18)           
42.49  
(35.39, 49.40) 
EGFR            
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Progression Free Survival Overall Survival 
 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 2 Years 
(95% CI) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
p 
 
Median  
(95% CI) 
(Months) 
% at 5 Years 
(95% CI) 
Normal                              193        152 1.00                 <0.0001 
(df=2)   
30.37  
(19.65, 43.37)           
53.13  
(45.82, 59.89) 
       140 1.00                 <0.0001 
(df=2)   
55.23  
(40.34, 68.63)           
47.40  
(40.19, 54.25) 
Amplified                           58         55 2.54 (1.85, 
3.47)    
<0.0001 
(df=1)   
7.01  
(5.62, 9.43)              
13.79  
(6.45, 23.89)  
        54 2.55  
(1.85, 3.51)    
<0.0001 
(df=1)   
16.51  
(12.75, 19.09)           
12.07  
(5.30, 21.82)  
                             
Missing 
       117         91 1.09 (0.84, 
1.42)    
0.50 
(df=1)   
17.38  
(11.89, 38.47)           
46.15 
(36.94, 54.87) 
        87 1.15  
(0.88, 1.51)    
0.29 
(df=1)   
34.07  
(21.65, 71.36)           
42.53  
(33.46, 51.29) 
Trisomy 7            
No                                    168        130 1.00                 <0.0001 
(df=2)   
28.71  
(18.23, 40.67)           
52.69  
(44.85, 59.93) 
       118 1.00                 0.0001 
(df=2)   
51.42  
(36.90, 68.24)           
47.31  
(39.57, 54.64) 
Yes                                    73         69 1.84 (1.37, 
2.47)    
<0.0001 
(df=1)   
9.89  
(7.13, 15.38)             
26.03  
(16.63, 36.43) 
        68 1.96  
(1.45, 2.64)    
<0.0001 
(df=1)   
19.09  
(16.46, 30.00)           
21.92  
(13.28, 31.94) 
                             
Missing 
       127         99 1.11 (0.86, 
1.45)    
0.41 
(df=1)   
16.26  
(10.87, 33.35)           
44.88  
(36.09, 53.27) 
        95 1.19  
(0.91, 1.57)    
0.20 
(df=1)   
34.07  
(21.59, 56.18)           
41.53  
(32.88, 49.94) 
10 loss            
No loss                              205        164 1.00                 <0.0001 
(df=2)   
27.24  
(18.23, 38.80)           
51.96  
(44.90, 58.56) 
       150 1.00                 0.0001 
(df=2)   
49.94  
(38.87, 66.33)           
45.92  
(38.95, 52.60) 
Loss                                   46         43 2.34 (1.67, 
3.29)    
<0.0001 
(df=1)   
6.31  
(4.40, 8.74)              
15.22  
(6.69, 26.97)  
        42 2.17  
(1.54, 3.07)    
<0.0001 
(df=1)   
16.94  
(12.55, 24.87)           
15.22  
(6.69, 26.97)  
                             
Missing 
       117         91 1.04 (0.80, 
1.34)    
0.76 
(df=1)   
16.26  
(11.89, 31.38)           
43.59  
(34.50, 52.32) 
        89 1.16  
(0.89, 1.51)    
0.27 
(df=1)   
30.62  
(20.80, 55.56)           
40.15  
(31.26, 48.87) 
10q loss            
No                                    221        179 1.00                 0.47 
(df=2)   
19.65  
(13.37, 34.46)           
46.82  
(40.11, 53.24) 
       164 1.00                 0.18 
(df=2)   
42.68  
(30.19, 58.64)           
42.57  
(35.96, 49.00) 
Yes                                    38         33 1.25 (0.86, 
1.81)    
0.24 
(df=1)   
15.64  
(7.82, 24.31)            
36.84  
(21.98, 51.78) 
        33 1.41  
(0.97, 2.06)    
0.07 
(df=1)   
20.34  
(16.46, 42.81)           
28.95  
(15.68, 43.63) 
                             
Missing 
       109         86 0.99 (0.77, 
1.28)    
0.95 
(df=1)   
15.38  
(10.87, 31.38)           
43.12  
(33.72, 52.15) 
        84 1.12  
(0.86, 1.46)    
0.38 
(df=1)   
28.71  
(20.34, 55.56)           
39.43  
(30.27, 48.45) 
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Figure VII.1: PFS curves split by risk group 
(years)
0 2 4 6 8 10 12 14 16
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk group
72 121 93 76 60 56 47 16 0
101 121 60 40 26 23 15 8 2
120 121 10 7 2 2 1 1 0
Low
Intermediate
High
 
Wald test: p<0.0001 (df=1)
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Figure VII.2: OS curves split by risk group  
 
(years)
0 2 4 6 8 10 12 14 16
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk group
63 121 108 94 82 68 56 18 1
95 121 76 54 42 36 26 12 1
118 121 29 11 4 2 2 1 0
Low
Intermediate
High
 
Wald test: p<0.0001 (df=1)
 
 
Table VII-5: Multivariate analyses of PFS and OS, performance, outcome estimates by risk group. 
  
Multivariate analyses 
  Progression Free Survival 
N/E(363/293) 
Overall Survival 
N/E(363/276) 
Parameter  P 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits p 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
    Low 
boundary 
High 
boundary 
  Low 
boundary 
High 
boundary 
Treatment  0.0001 0.631 0.498 0.800 NS NA NA NA 
Age 
(quartiles)‡ 
 <.0001 
(df=1) 
1.303  1.168 1.454 <.0001 
(df=1) 
1.383 1.232 1.553 
Frontal 
location 
 0.0008 0.654 0.510 0.838 0.0197 0.738 0.572 0.953 
Extent of 
resection with 
confirmation * 
Not 
confirmed 
without 
residual 
tumor on 
imaging 
0.0010 0.571† 0.410 0.797 0.0005 0.545† 0.387 0.769 
 Confirmed 
without 
residual 
<.0001 0.437† 0.298 0.639 <.0001 0.408† 0.274 0.607 
New clinical, pathological and molecular prognostic models and calculators in patients with 
locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma.  
 
128 
 
tumor on 
imaging 
WHO 
performance 
status 
 0.0007 1.361 1.140 1.625 0.0008 1.355 1.135 1.617 
Endothelial 
abnormalities 
 0.0133 1.457 1.081 1.962 0.0281 1.409 1.038 1.914 
Necrosis  <.0001 1.704 1.329 2.185 <.0001 1.794 1.379 2.335 
1p/19q Missing 
(dummy) 
0.7076 0.930 0.638 1.356 0.3411 0.831 0.567 1.217 
 Codeleted <.0001 0.470 0.338 0.655 <.0001 0.429 0.303 0.607 
IDH1 Missing 
(dummy) 
<.0001 0.520 0.384 0.703 <.0001 0.551 0.410 0.741 
 Mutated <.0001 0.478 0.334 0.682 <.0001 0.422 0.291 0.610 
Models performance 
Discrimination 
(C-index)  
 0.725 0.737 
Sensitivity (%)  57 62 
Specificity (%)  54 51 
Negative 
Predictive 
Value  (%) 
 77 74 
Positive 
Predictive 
value (%) 
 92 94 
 Outcome estimates 
  Median PFS PFS 2 years Median OS OS 5 years 
Risk group      
Low  76.9 (61.9, 136.8)          77.5 (68.9, 84.0) 126.8 (95.0, N)              75.8 (67.1, 82.5) 
Intermediate  23.5 (16.9, 33.8)           49.6 (40.4, 58.1) 41.7 (28.7, 56.2)           39.4 (30.7, 48.0) 
High  6.3 (5.7, 7.2)              8.3 (4.2, 14.0)   14.0 (11.8, 16.5)           5.6 (2.4, 10.8)   
Note: N: Not reached. NS: not significant. NA: not applicable. N/E: Number of patient data used/ Number of events. * 
Global test: PFS: p=0.0001, OS: p<0.0001. † Biopsy is the reference value (Hazard Ratio=1) . ‡ Age quartiles are 
considered as scores (df=1).   
 
 
Table VII-6: Definition of predictive accuracy parameters. 
 
Criteria Definitions for Progression Free 
Survival 
Definitions for Overall Survival 
Sensitivity Percentage of patients alive 
without progressive disease at 
year 2, who were classified as 
low risk 
Percentage of patients alive at year 5, who 
were classified as low risk. 
Specificity Percentage of patients who died 
or had progressive disease prior 
to year 2, who were classified as 
high risk 
Percentage of patients who died prior to year 
5, who were classified as high risk. 
Negative Predictive 
Value (NPV) 
Percentage of patients classified 
as low risk, who were alive 
without progressive disease at 
year 2. 
Percentage of patients classified as low risk, 
who were alive at year 5. 
Positive Predictive 
Value (PPV) 
Percentage of patients classified 
as high risk who died or had 
progressive disease prior to year 
2. 
Percentage of patients classified as high risk 
who died prior to year 5. 
Note: patients lost to follow-up before years 2 or 5 were considered as failures for PFS and OS respectively.
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Table VII-7: Percentage of explained PFS variation between different prognostic models. 
 
  Clinical+pathological Clinical+molecular Clinical+pathological+molecular 
 PEV(%) 18.9 22.5 26.7 
Clinical 14.4 0.0042 <0.0001 <0.0001 
Pathological 4.6 <0.0001 <0.0001 <0.0001 
Molecular 11.2 0.014 <0.0001 <0.0001 
Clinical+pathological 18.9 NA 0.15 <0.0001 
 
Table VII-8: Percentage of explained OS variation between different prognostic models. 
 
  Clinical+pathological Clinical+molecular Clinical+pathological+molecular 
 PEV(%) 18.3 22.8 27.5 
Clinical 13.1 0.0026 <0.0001 <0.0001 
Pathological 4.9 <0.0001 <0.0001 <0.0001 
Molecular 12.4 0.067 <0.0001 <0.0001 
Clinical+pathological 18.3 NA 0.080 <0.0001 
 
Prognostic  calculators 
 
Prognostic calculators were developed based on final prognostic models. They provide with 
estimates for median PFS and OS and for PFS2y and OS5y based on individual patient 
characteristics and classified according to their risk group (low/intermediate/high). Prognostic 
calculators are available online at http://www.eortc.be/tools/GIIIcalculator/.  
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7.5 Discussion 
 
In this prognostic factor analysis, we used baseline patient’s characteristics and outcome data from 
prospective EORTC 26951 trial on RT vs RT/PCV in anaplastic oligodendroglial tumors. Patients 
were entered in this trial based on the diagnosis of the local pathologists. The analyses showed that 
younger age, a good WHO performance status, frontal location of the tumor, an extensive and 
confirmed resection without residual tumor on scan, absence of endothelial abnormalities and of 
necrosis, 1p/19q codeletion and IDH1 mutation had significant positive prognostic value both for 
PFS and OS. Thus, prognosis is related to a mixture of patient, tumor and treatment characteristics. 
In contrast to trials on glioblastoma and low grade tumors, in this study MMSE was not related to 
outcome 
20,21
. Of the histological features, only endothelial abnormalities and necrosis had significant 
prognostic value, pointing to worse outcome in histologically more anaplastic tumors regardless of 
molecular features. Of note, the histological classification (AOD vs AOA) by the local pathologist 
did not impact outcome.  The substantial contribution of the presence of 1p/19q codeletion and of 
IDH1 to prognostic models advocates for molecular studies in oligodendroglial tumors in a routine 
diagnostic setting.  Extent of resection clearly matters, especially if at post-operative imaging prior to 
initiation of radiotherapy no residual tumor was described. Although this was not a randomized trial 
into the role of extent of surgery, our analysis supports the assumption that the optimal management 
of brain tumors starts with an extensive but safe resection, leaving the least possible amount of 
residual tumor. 
22
 RT/PCV therapy was selected for PFS but not for OS. An explanation might be the 
crossover, as many patients (75%) in the radiotherapy alone arm received PCV or Temozolomide at 
the progression. Recent reports showed that treatment effect might be confined patients with 1p/19q 
codeletion. This study was not powered for subgroup analyses. 
In this study, models including clinical, pathological and molecular factors had PEV greater than 
20% and significantly added to PEV compared to other models. A limitation of this prognostic study 
is the absence of external validation. Results might suffer from a lack of generalizability (calibration) 
when used outside the population of patients that do not meet the inclusion criteria for this clinical 
trial. Nevertheless, with PPV of 92% and 94% for PFS and OS respectively, our models are able to 
identify patients at high risk of progression and/or death and provide clinically useful information to 
physicians for treatment decision and discuss patients’ prognosis. 
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8.1 Abstract 
 
Background:  
In a previous study, the European Organisation for Research and Treatment of Cancer (EORTC) 
reported a scoring system to predict survival of patients with low-grade gliomas (LGG). This was 
recently validated by the North Central Cancer Treatment Group (NCCTG) using a dataset from a 
US LGG clinical trial. A major issue in the diagnosis of brain tumors is the lack of agreement 
between pathologists. New models in patients with low grade gliomas diagnosed by central 
pathology review are needed.   
 
Methods:  
Data from 339 EORTC patients with LGG diagnosed by central pathology review were used to 
develop new prognostic models utilizing clinical and histopathologic data, but not including 
molecular features for Progression Free Survival (PFS) and Overall Survival (OS). Data from 450 
patients with centrally diagnosed LGG recruited into two large studies conducted by North American 
cooperative groups [Radiation Therapy Oncology Group (RTOG), and North Central Cancer 
Treatment Group (NCCTG)] were used to validate the models.  
 
Results:  
Both PFS and OS were negatively influenced by the presence of baseline neurological deficits 
assessed by the Medical Research Council (MRC) score, a shorter time since first symptoms (<30 
weeks), an astrocytic tumor type, and tumors larger than 5 cm in diameter. As previously reported, 
early irradiation improved PFS but not OS. Three risk groups have been identified 
(low/intermediate/high) and validated.  
 
Conclusions:  
We have developed new prognostic models in a more homogenous LGG population diagnosed by 
central pathology review. This population better fits to modern practice where patients are enrolled 
in clinical trials based on central or panel pathology review. We could validate the models in a large, 
external and independent dataset. They can divide LGG patients into three risk groups and provide 
reliable individual survival predictions that can help physicians and their patients or families to 
discuss disease prognosis and therapeutic options. In the future, inclusion of other clinical (e.g. 
MMSE) and molecular factors might still improve models predictions. 
 
 
New validated prognostic models and prognostic calculators in patients with low grade gliomas 
diagnosed by central pathology review.  
 
135 
 
 
8.2 Introduction 
 
Low-grade glioma (LGG) is a heterogeneous group of primary, diffuse and slowly growing glial 
brain tumors. These tumors often remain clinically stable for many years, and patients are commonly 
only followed clinically without specific antitumor therapy. Based on retrospective studies 
suggesting an improved survival with early, extensive and maximal tumor resections, radical surgery 
is often advocated. Prospective controlled studies evaluating the role of surgery are lacking, and a 
large part of the benefit presumed from extensive resection may be due to patient selection. If tumor 
location makes the surgery difficult or even impossible, a biopsy is performed to ascertain the nature 
of the tumor and establish a pathological diagnosis. 
Immediate (postoperative) radiotherapy has not been shown to offer an advantage in overall survival 
over deferred radiotherapy, although progression-free survival is lengthened, the optimal timing 
remains debatable. There is no apparent effect of dose; two randomized studies of the European 
Organisation for Research and Treatment of Cancer (EORTC) and of the North Central Cancer 
Treatment Group (NCCTG) - Radiation Therapy Oncology Group (RTOG) - Eastern Cooperative 
Oncology Group (ECOG) Intergroup showed no significant difference in survival when lower and 
higher irradiation doses (45 vs 59.4 Gy and 50.4 vs 64.8 Gy, respectively) were compared
1,2
. The 
role of postoperative chemotherapy alone or in combination with radiation therapy remains 
investigational.
3
   
Individual prognosis of patients is highly variable. In order to choose the best strategy for a patient 
among the various treatment options, prognostic models and score can be useful. A major limitation 
in addressing prognostic models for LGG is the considerable inter-observer variability in both the 
grading and typing of these tumors.
4,5
 The widely used EORTC prognostic scoring model for LGG 
was based on 2 prospective randomized clinical trials. However, patient inclusion into these trials 
relied upon a diagnosis made by the local pathologist, that was often not confirmed by central 
pathology review.
6
 The external validity of the EORTC scoring system was recently evaluated in a 
dataset of LGG patients treated in a North American Intergroup trial (NCCTG 86-72-51).
7
 In that 
dataset, the distinction between the low-risk and the high-risk group was predominantly determined 
by the prognostic impact of histology and tumor size; other factors like age or extent of surgery did 
not contribute significantly. As a major difference between the US and European trials was the 
mandatory central pathology review prior to inclusion in the American trials. Thus, we re-analysed 
the pooled data from the 2 EORTC studies restricting the analysis to patients with LGG whose 
histology had been confirmed upon central pathology review. Patients with histologies other than 
grade II glioma and patients where no tumor tissue was available for central review were excluded. 
We subsequently assessed the external validity of the EORTC studies with the individual patient data 
from large studies conducted by two US cooperative group (RTOG and NCCTG).
8,9
 Based on this 
analysis, we developed prognostic calculators for progression free and overall survival that provide 
estimates for both median and fixed time probabilities of survival. 
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8.3 Patients and Methods 
 
Patient selection 
 
Three hundred seventy nine and 311 patients with LGG at first diagnosis were randomized in 
EORTC trials 22844 and 22845, respectively. Central pathology review was available for 428 
patients, 182 (53%) in 22844 and 246 (81%) in 22845, out of 648 eligible patients 
6
.  
 
Candidate prognostic factors 
 
Factors screened for their prognostic value were: patient’s age, gender, postoperative neurological 
signs and symptoms (history of seizures and/or headaches, presence of mental and/or motor 
disturbance), time since first tumor-associated symptoms, postoperative World Health Organization 
(WHO) performance status (PS) and Medical Research Council (MRC) neurological score, extent of 
resection assessed by the surgeon, time since surgery, baseline administration of steroids and/or 
anticonvulsants, histological type (astrocytic vs oligodendroglial), predominant tumor location, 
tumor crossing midline, and largest tumor diameter (details are provided in Table VIII-1, 
supplemental table 1). 
 
Table VIII-1:Clinically relevant factors for LGG patients with their coding conventions. 
  
Factors Coding conventions 
  
Patient’s age (years) Split by median 0=<median  , 1= 
>=median or  
0=<40 vs 1 >=40  
Patient’s sex 0=M vs 1= F 
Time since first 
symptoms (weeks) 
Split by median 
0=<median  , 1= median 
Post-op neurological 
signs and symptoms 
Seizures 
Headache 
Mental disturbance 
Motor disturbance 
Neurologic deficits 
 
 
 
 
0=no,1=yes 
0=no,1=yes 
0=no,1=yes 
0=no,1=yes 
0=no,1=yes 
Post-op WHO PS Binary: 0 vs >0  or score 0,1,2 
Post-op MRC 
Neurological scale 
0=no deficit,1=some deficit,2=moderate 
or major deficit 
Extent of resection 0=biopsy only, 1=resection  
Time since surgery Split by median  
0=<median , 1=>=median 
Steroids intake 0=no, 1 =yes 
AED intake 0=no, 1 =yes 
Histology type 
 
0=astrocytoma (AA), 1=oligoastrocytoma 
(OA), 2=oligodendroglioma (OD) or  
0=OD or OA,  1=AA 
Predominant tumor 
location 
Frontal 
Parietal 
Temporal 
Occipital 
 
 
 
0=no,1=yes 
0=no,1=yes 
0=no,1=yes 
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Other locations 
 
0=no,1=yes 
Tumor: 
Lateralization 
Left 
Right  
 
 
0=no,1=yes 
0=no,1=yes 
Tumor crossing the 
midline 
0=no,1=yes 
Tumor: 
Pre-op largest 
diameter (cm) 
0= <5cm, 1= >=5cm 
 
Patient outcome measurements 
 
Computed tomography (CT) scans were used pre and post-operatively for diagnosis and for 
evaluation of disease progression. Progression free survival (PFS) was computed as the time from 
randomization till signs of clinical or radiological progression or death whichever occurred first. 
Overall Survival (OS) was calculated as the time from randomization until death regardless of cause. 
In the absence of events, PFS and OS were censored at the last follow-up date. For descriptive 
purpose, PFS and OS from the date of first LGG symptoms were also computed. 
 
 
Statistical considerations 
 
For model development 
 
Categorical data were tabulated with frequencies and percentages. Medians and ranges (minimum-
maximum) were used to summarize continuous variables. Spearman rank correlation coefficient 
(SCC) was computed pairwise for all factors. The significance of the association between categorical 
(nominal) factors was assessed by the Fisher Exact test. For the association between continuous 
covariates or scores and categorical (nominal) factors, the Wilcoxon rank sum test was used. P-
values less than 1% and SCC superior or equal to 0.40 were reported. Immediate versus delayed 
irradiation (RT) was entered as a factor in PFS analyses. Since treatment effect did not impact OS, it 
was not entered in the OS models but used as a stratification factor. For each factor, Kaplan Meier 
curves and log-rank tests were computed. All factors were considered for Cox multivariate analyses, 
i.e. no systematic screening by univariate analysis was performed. The number of factors was lower 
than the number of PFS or OS events divided by 10 which is generally considered to provide 
sufficient power in multivariate analyses.
10
 Proportional Hazards (PH) assumptions were tested by 
examining the plot of the log of negative log estimates over the log survival time (LLS) and by 
interpreting the Schoenfeld residual plots.
11
 The stepwise backward method was used for factor 
selection. For factors whose missing value rate was more than 5%, the missing value was considered 
as a dummy category in the Cox analyses. Model internal validity was assessed by the bootstrap 
method. Factors with an importance (percentage of bootstrap samples with factor selected in 
multivariate analysis) lower than 60% were not included in the final models.
12
 A significance level of 
5% was used in multivariate analyses.  Harrel’s C-index corrected for optimism by bootstrap 
resampling was used to assess the model’s discrimination.13 Calibration plots and Schemper’s 
percentage of explained variation (PEV) were also computed.
14,15
 A PEV of at least 20% was 
considered a minimum requirement for a model to provide sufficiently precise individual survival 
predictions.
 16
 From the final models, prognostic calculators were developed and predictions for 
median PFS, OS, 3-year PFS (PFS3y) and 5-year OS (OS5y) were derived. Individual prognostic 
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scores were computed. Based on their scores, patients were classified into three distinct risk groups 
(low, intermediate, high). In absence of predefined cut-offs, groups were taken with equal size.   
For all statistical analyses, SAS version 9.2 (SAS Institute Inc., Cary, NC, USA.) was used except 
for the computation of the C-index and calibration plots which were obtained from the R “Design” 
and “Hmisc” Packages. The percentage of explained variation was computed using the SAS macro 
RELIMPCR.
 12
 The reflected method was used to estimate median survival with 95% confidence 
interval (CI).
 17
 The loglog transformation was used for the 95% CI of PFS3y and OS5y. The 
model’s sensitivity, specificity, positive and negative predictive value (PPV/NPV) were also 
computed. In this study, PPV measures the ability of the model to identify patients at high risk of 
progression or death at year 3 (PFS3y) or of death at year 5 (OS5y). The capacity of the model to 
identify patients at low risk for these events is measured by the NPV. See table VIII-7 for more 
definitions. 
 
For model validation 
 
Data from RTOG 98-02 and NCCTG 86-72-51 trials were pooled for model validation. PFS and OS 
curves in US data were split according to the EORTC risk groups and compared between EORTC 
and RTOG/NCCTG cooperative groups. EORTC Cox models were fit on US data to determine 
which factors kept their prognostic influence. Model sensitivity, specificity, NPV and PPV were 
computed on US data.  
 
 
8.4 Results 
 
Comparison of EORTC patient characteristics and outcomes 
 
Among the 585 EORTC patients locally diagnosed with LGG, 390 were centrally reviewed and 308 
(79%) were confirmed as LGG, sixty five patients (16.7%) being high grade gliomas (HGG, GIII or 
GIV). Six (1.5%) had grade I and another pathology was diagnosed in 11 patients (2.8%). The 
central pathologist identified 339 LGG (79%) and 69 HGG (16%). HGG patients were older (median 
43 years vs 39 years, p=0.008), had a worse performance status (p=0.007), more often underwent 
resection (89.9% vs 64.6%, p<0.0001), had less frequent astrocytoma (50.7% vs 68.4%, p=0.02) and 
had worse PFS (p=0.01) and OS (p=0.03). Table VIII-2 displays tumor grade by local and central 
pathology review. Table VIII-3 compares patient and disease characteristics between various 
subgroups. There were no significant different characteristics and outcomes between patients with 
and without central pathological review (PFS, p=0.08, OS, p=0.92). 
 
Table VIII-2: Comparison of tumor grade by local and central pathology review. 
 
Central by local grade 
 
Tumor grade by local pathology review 
Total 
(N=648) 
Missing 
(N=16) 
Grade 
I 
(N=47) 
LGG 
(N=585) 
 N (%) N (%) N (%) N (%) 
Tumor grade by central pathology review                                                                                                                                                                                                                         
        Missing          2 (12.5)                                                                                          23 (48.9)                                195 (33.3)                                220 (34.0)                               
        LGG              12 (75.0)                                                                                          19 (40.4)                               308 (52.6)                                339 (52.3)                                            
        HGG             2 (12.5)                                                                                          2 (4.3)                              65 (11.1)                                 69 (10.6)                                
        Grade I               0 (0.0)                                                                                           3 (6.4)                               6 (1.0)                                  9 (1.4)                                
        Other pathology           0 (0.0)                                                                                           0 (0.0)                               11 (1.9)                                 11 (1.7)                                
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Table VIII-3: Patients characteristics and outcomes: various subsets comparisons 
 
No central 
review 
(1) 
Central review 
(2) 
 
 
 
 
p 
(2)/(1) 
EORTC 
centrally 
reviewed  
LGG 
(3) 
EORTC 
centrally 
reviewed 
HGG 
(4) 
 
 
 
 
p 
(4)/(3) 
RTOG/NCCT
G 
 centrally 
reviewed 
LGG 
(5) 
 
 
 
 
p 
(5)/(3) 
 (N=220)  (N=428) 
  
(N=339) 
 
(n=99) 
  (n=450) 
 
 
 N (%) N (%)  N (%) N (%)  N (%)  
Age (years)                                                                                                                                                                                                                                        
        Median                                                                                                                                                                                           39.2           39.3           0.60 39.0               43.0               0.008 40.0               0.07 
        Range                                                                                                                                                                                            16.0 - 66.4 17.2 - 65.7  17.2 - 65.3        18.1 - 65.7         18.0 - 82.0         
Gender                                                  
        Male                                  122 (55.5)                                                                                          264 (61.7)                               0.13 214 (63.1)                                                                               41 (59.4)                              0.59  259 (57.6)                                                                                       0.12
        Female                                 98 (44.5)                                                                                          164 (38.3)                                125 (36.9)                                                                                          28 (40.6)                               191 (42.4)                                                                          
History of seizure                                              
        No                                    143 (65.0)                                                                                          304 (71.0)                               0.10 235 (69.3)                                                                       54 (78.3)                                                     0.19 101 (22.4)                                                                                       <0.0001
        Yes                                    77 (35.0)                                                                                          121 (28.3)                                101 (29.8)                                                                 15 (21.7)                                 98 (21.8)                                                                                      
        Missing                                 0 (0.0)                                                                                           3 (0.7)                               3 (0.9)                                                                                  0 (0.0)                                251 (55.8)                                                                                          
Headache                                             
        No                                    181 (82.3)                                                                                          334 (78.0)                               0.30 267 (78.8)                                                                       53 (76.8)                             0.63  143 (31.8)                                                                                       0.06
        Yes                                    39 (17.7)                                                                                          91 (21.3)                               69 (20.4)                                                                      16 (23.2)                                             56 (12.4)                                                                                       
        Missing                                 0 (0.0)                                                                                           3 (0.7)                               3 (0.9)                                                                        0 (0.0)                                251 (55.8)                                                                                         
Mental disturbance                                   
        No                                    184 (83.6)                                                                                          347 (81.1)                               0.51 277 (81.7)                                                                                          52 (75.4)                              0.18  178 (39.6)                                                                                       0.03
        Yes                                    35 (15.9)                                                                                          78 (18.2)                               59 (17.4)                                                                      17 (24.6)                                21 (4.7)                                                                                      
        Missing                                 1 (0.5)                                                                                           3 (0.7)                               3 (0.9)                                                                        0 (0.0)                                251 (55.8)                                                                                         
Motor disturbance                                    
        No                                    186 (84.5)                                                                                          312 (72.9)                               0.05 245 (72.3)                                                                       51 (73.9)                              1.0  175 (38.9)                                                                                       0.003
        Yes                                    34 (15.5)                                                                                          90 (21.0)                               72 (21.2)                                                                                          15 (21.7)                                 24 (5.3)                                                                                      
        Missing                                 0 (0.0)                                                                                           26 (6.1)                                22 (6.5)                                                                                           3 (4.3)                              251 (55.8)                                                                                        
Performance Status                                                                                                                                                                  
        0                                      81 (36.8)                                                                                          149 (34.8)                                0.81 127 (37.5)                                                                       15 (21.7)                             0.007  109 (24.2)                                                                                       0.40
        1                                      98 (44.5)                                                                                          216 (50.5)                                164 (48.4)                                                                       42 (60.9)                                                   154 (34.2)                                                                                       
        >1                                     41 (18.6)                                                                                          62 (14.5)                               47 (13.9)                                                                     12 (17.4)                                 25 (5.6)                                                                                      
Missing    0 (0.0)                                                                                           1 (0.2)                               0(0.0) 0(0.0)   162 (36.0)                                                                                          
MRC score          
        No                                    139 (63.2)                                                                                          246 (57.5)                               0.33 194 (57.2)                                                                       42 (60.9)                             0.10  201 (44.7)                                                                                       0.009
        Some                                   49 (22.3)                                                                                          129 (30.1)                                101 (29.8)                                                                       21 (30.4)                               183 (40.7)                                                                                       
        Moderate/Major                         32 (14.5)                                                                                          53 (12.4)                               44 (13.0)                                                                      6 (8.7)                                              56 (12.4)                                                                                      
Missing 0 (0.0) 0 (0.0)  0(0.0) 0(0.0)    10 (2.2)                                                                                           
Extent of resection by neuro-surgeon                                      
        Biopsy                                 84 (38.2)                                                                                          127 (29.7)                                0.04 116 (34.2)                                                                       4 (5.8)                                              <0.0001  211 (46.9)                                                                                      <0.0001
        Resection                             135 (61.4)                                                                                          294 (68.7)                               219 (64.6)                                                                       62 (89.9)                               239 (53.1)                                                                                       
        Missing                                 1 (0.5)                                                                                           7 (1.6)                               4 (1.2)                                                                                           3 (4.3)                                  0 (0.0)                                                                                      
Baseline steroids                                             
        No                                    102 (46.4)                                                                                          201 (47.0)                               0.003 160 (47.2)                                                                       30 (43.5)                              1.0  219 (48.7)                                                                                       <0.0001
        Yes                                    86 (39.1)                                                                                          94 (22.0)                               77 (22.7)                                                                      14 (20.3)                                                 228 (50.7)                                                                                        
        Missing                                32 (14.5)                                                                                          133 (31.1)                                102 (30.1)                                                                       25 (36.2)                                 3 (0.7)                                                                                    
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No central 
review 
(1) 
Central review 
(2) 
 
 
 
 
p 
(2)/(1) 
EORTC 
centrally 
reviewed  
LGG 
(3) 
EORTC 
centrally 
reviewed 
HGG 
(4) 
 
 
 
 
p 
(4)/(3) 
RTOG/NCCT
G 
 centrally 
reviewed 
LGG 
(5) 
 
 
 
 
p 
(5)/(3) 
 (N=220)  (N=428) 
  
(N=339) 
 
(n=99) 
  (n=450) 
 
 
 N (%) N (%)  N (%) N (%)  N (%)  
Baseline anticonvulsants                                       
        No                                     23 (10.5)                                                                                          50 (11.7)                               0.15 36 (10.6)                                                                      13 (18.8)                              0.03   51 (11.3)                                                                                       0.12
        Yes                                   165 (75.0)                                                                                          236 (55.1)                               193 (56.9)                                                                       29 (42.0)                               396 (88.0)                                                                                       
        Missing                                32 (14.5)                                                                                          142 (33.2)                                110 (32.4)                                                                       27 (39.1)                                              3 (0.7)                                                                                    
Local diagnosis                                      
        Astrocytoma                           154 (70.0)                                                                                          279 (65.2)                               0.36 232 (68.4)                                                                                          35 (50.7)                              0.02  104 (23.1)                                                                                       <0.0001
        Mixed Oligoastrocytoma                 21 (9.5)                                                                                           42 (9.8)                               31 (9.1)                                                                        11 (15.9)                                133 (29.6)                                                                                         
        Oligodendroglioma                      44 (20.0)                                                                                          107 (25.0)                                76 (22.4)                                                                      23 (33.3)                                213 (47.3)                                                                                        
        Missing    1 (0.5)                                                                                           0 (0.0)                               0(0.0) 0(0.0)  0(0.0)  
Frontal location                                              
        No                                    137 (62.3)                                                                                          215 (50.2)                               0.004 172 (50.7)                                                                 30 (43.5)                               0.29  176 (39.1)                                                                                       0.001
        Yes                                    83 (37.7)                                                                                          213 (49.8)                                167 (49.3)                                                                                       39 (56.5)                               274 (60.9)                                                                                       
Temporal location                                             
        No                                    145 (65.9)                                                                                          316 (73.8)                               0.04 251 (74.0)                                                                       51 (73.9)                              1.0  289 (64.2)                                                                                       0.007
        Yes                                    75 (34.1)                                                                                          112 (26.2)                                88 (26.0)                                                                      18 (26.1)                                          157 (34.9)                                                                                        
Missing    0 (0.0)                                                                                           0 (0.0)                                   4 (0.9)                                                                                           
Parietal location                                             
        No                                    181 (82.3)                                                                                          356 (83.2)                               0.82 277 (81.7)                                                                       63 (91.3)                             0.05  296 (65.8)                                                                                       <0.0001
        Yes                                    39 (17.7)                                                                                          72 (16.8)                               62 (18.3)                                                                      6 (8.7)                                151 (33.6)                                                                                       
Missing    0 (0.0)                                                                                           0 (0.0)                                   3 (0.7)                                                                                           
Occipital location                                            
        No                                    213 (96.8)                                                                                          424 (99.1)                               0.05 336 (99.1)                                                                                          69 (100.0)                               1.0  426 (94.7)                                                                           0.002
        Yes                                     7 (3.2)                                                                                           4 (0.9)                                3 (0.9)                                                                        0 (0.0)                                20 (4.4)                                                                                       
Missing          4 (0.9)                                                                                           
Other location                                       
        No                                    204 (92.7)                                                                                          401 (93.7)                               0.62 320 (94.4)                                                                                          63 (91.3)                              0.41  227 (50.4)                                                                 0.08 
        Yes                                    16 (7.3)                                                                                           27 (6.3)                               19 (5.6)                                                                        6 (8.7)                                24 (5.3)                                                                                      
Missing        199 (44.2)                                                                                          
Left Lobe                                            
        No                                    114 (51.8)                                                                                          237 (55.4)                               0.45 188 (55.5)                                                                                          39 (56.5)                             0.90  221 (49.1)                                                                                       0.08
        Yes                                   105 (47.7)                                                                                          191 (44.6)                               151 (44.5)                                                                       30 (43.5)                               229 (50.9)                                                                                       
Missing    1 (0.5)                                                                                           0 (0.0)                                   0 (0.0)                                                                                           
Right Lobe                                           
        No                                    114 (51.8)                                                                                          201 (47.0)                               0.24 158 (46.6)                                                                                          31 (44.9)                              0.89  252 (56.0)                                                                                       0.01
        Yes                                   105 (47.7)                                                                                          227 (53.0)                               181 (53.4)                                                                       38 (55.1)                              198 (44.0)                                                                                       
Missing    1 (0.5)                                                                                           0 (0.0)                                0(0.0)  
Midline crossing                                     
        No                                    163 (74.1)                                                                                          310 (72.4)                               0.55 247 (72.9)                                                                       50 (72.5)                                  0.87  136 (30.2)                                                                                       0.06
        Yes                                    53 (24.1)                                                                                          88 (20.6)                               68 (20.1)                                                                      15 (21.7)                                 57 (12.7)                                                                                       
        Missing                                 4 (1.8)                                                                                           30 (7.0)                                24 (7.1)                                                                       4 (5.8)                               257 (57.1)                                                                                        
Tumor size (cm)                            
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No central 
review 
(1) 
Central review 
(2) 
 
 
 
 
p 
(2)/(1) 
EORTC 
centrally 
reviewed  
LGG 
(3) 
EORTC 
centrally 
reviewed 
HGG 
(4) 
 
 
 
 
p 
(4)/(3) 
RTOG/NCCT
G 
 centrally 
reviewed 
LGG 
(5) 
 
 
 
 
p 
(5)/(3) 
 (N=220)  (N=428) 
  
(N=339) 
 
(n=99) 
  (n=450) 
 
 
 N (%) N (%)  N (%) N (%)  N (%)  
        <5                                     84 (38.2)                                                                                          157 (36.7)                                0.47 124 (36.6)                                                                                          24 (34.8)                             0.67  218 (48.4)                                                                                       0.07
        >=5                                   102 (46.4)                                                                                          220 (51.4)                               173 (51.0)                                                                       38 (55.1)                               231 (51.3)                                                                                       
        Missing                                34 (15.5)                                                                                          51 (11.9)                               42 (12.4)                                                                      7 (10.1)                                                     1 (0.2)                                                                                     
Time since first LGG symptoms (weeks)                                                                                                                                                                             
        Median                                                                                                                                                                                           27.9               30.0               0.55 30.5               26.3               0.40 14.5               <0.0001 
        Range                                                                                                                                                                                            2.9 - 1749.0 2.0 - 1542.4  2.0 - 1542.4       2.1 - 828.7         1.3 - 787.7         
        N obs                                                                                                                                                                                            220 426 338                68                  426                 
Time since surgery (weeks)                                                                                                                                                                                                     
        Median                                                                                                                                                                                           3.6          2.3           <0.0001 2.3                1.7                <0.0001 4.1                <0.0001 
        Range                                                                                                                                                                                            0.0 - 31.7 0.3 - 157.6  0.3 - 157.6        0.4 - 9.7           0.3 - 214.6         
        N obs                                                                                                                                                                                            220 428 339                69                  420                 
Median PFS (months – 95% CI) 53 (44,76) 54 (47,60) 0.08  55 (49,63) 41 (27,55) 0.01 66 (55,75) 0.01 
Median OS(months – 95% CI) 80 (61,111) 84 (77,95) 0.92 87 (79,99) 62 (44,89) 0.03 110(96,129) 0.02 
Note: LGG: Low Grade Glioma. MRC: Medical Research Council. Fisher test was used for binary or categorical factors. Wilcoxon rank sum test was used for continuous 
variables and scores.  Log-rank test used for outcome comparisons. 
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Development of prognostic models 
 
Table VIII-4 (Supplemental Table 2) presents the factors with correlation coefficients greater than or 
equal to 0.40.  Presence of mental (rho=0.44, p<0.0001) or motor disturbances (rho=0.59, p<0.0001) 
and WHO performance status (rho=0.46, p<0.0001) were correlated with the MRC neurological 
scale. In order to minimize the problems linked to multicolinearity, separate multivariate models 
with MRC score or WHO performance were fit and their performance was compared. Supplemental 
Table VIII-5 displays the results of PFS and OS univariate analyses. Use of steroids and 
anticonvulsants were collected during radiotherapy and not collected in the delayed RT arm. They 
did not show prognostic significance in univariate analyses in the RT arms and were not used in the 
multivariate analyses. Only tumor location involving the temporal lobe was significant for OS and 
thus considered for multivariate analyses. Information on tumor crossing midline was not 
systematically available in the US dataset. Models without and with this factor were fit for 
sensitivity. Midline crossing and tumor size were missing in 8 and 13% of the EORTC patients 
respectively.  A dummy category (“missing”) was used instead.  For all LGG patients (n=339), 
median PFS was 55.3 months (95% CI 49.4, 63.4) and the 3-year progression-free survival rate 
(PFS3y) was 68.0% (62.6-72.7). Median OS was 86.5 months (95% CI 78.6-99.2) and 5-year 
Overall Survival (OS5y) was 65.9% (60.4-70.9).  For both PFS and OS, models had all similar 
discrimination power (for PFS, C-index ranging 64-66% and PEV ranging 10-13%, for OS, C-
index=67% for all models, PEV ranging 9-15%) irrespective of the combination of covariates. For all 
these models, Percentage of Explained Variation (PEV) was below the 20% threshold necessary to 
consider a model sufficiently precise for individual predictions. Extent of resection and age were not 
identified with significant prognostic value in any analysis. Among all tested EORTC models, final 
ones were selected taking into account availability of covariates and maximal sample size in the US 
validation datasets. Five factors were retained in the final PFS prognostic model: immediate 
irradiation (p=0.0008, HR=0.62 95% CI (0.47-0.82), time since first LGG symptoms (<30 weeks vs 
>=30 weeks, p=0.01, HR=0.70 95% CI (0.53-0.92)), presence of neurological deficit (p=0.0003, 
HR=1.64 95% CI (1.25-2.15)), independent confirmation of astrocytoma (p=<0.0001, HR=1.93 95% 
CI (1.47-2.54)), and tumor size (<5cm/>=5cm, p=0.004, HR=1.53 95% CI (1.15-2.03)). C-index was 
0.64 and PEV was 10.1%.  In the final OS model, time since first LGG symptoms (p=0.009, 
HR=0.67 95% CI (0.49-0.91)), MRC score (p=0.0001, HR=1.51 95% CI (1.22-1.86)), independent 
confirmation of astrocytoma (p<0.0001, HR=1.96 95% CI (1.43-2.69)), and tumor size (p=0.001, 
HR=1.74 95% CI (1.25-2.43) were identified as independent prognostic factors. C-index was 0.67 
and PEV was 8.8%.  Final multivariate models are presented in Table VIII-6.  Figures VIII.1 and 
VIII.2 show PFS and OS Kaplan Meier curves by the three equally sized risk group in EORTC data. 
For PFS and OS, sensitivity, specificity, PPV were low (36-57%).  NPV was 74% for PFS and 61% 
for OS. See Table VIII-6 for details. In both PFS and OS models, calibrations plots did not suggest 
large systematic differences (biases) between predicted and observed outcomes (data not shown). 
Variability was nevertheless high. 
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Table VIII-4: Correlation analyses.  
 
Spearman Correlation Coefficients 
 
 
Mental 
disturba
nce 
Motor 
disturba
nce 
Neurolo
gical 
deficit 
MRC 
score 
WHO  
perform
ance 
Status 
Mental disturbance 
(No/Yes) 
1.0 
N=336 
    
Motor disturbance 
(No/Yes) 
0.18 
p=1E-3 
N=316 
1.0 
 
N=317 
   
Neurologic deficit 
(No/Yes) 
0.41 
p<1E-4 
N=336 
0.56 
p<1E-4 
N=317 
1.0 
 
N=339 
  
MRC score 
(No/Some/Moderat
e-Major) 
0.44 
p<1E-4 
N=336 
0.59 
p<1E-4 
N=317 
0.97 
p<1E-4 
N=339 
1.0 
 
N=339 
 
Performance Status 
0,1,>1 
0.32 
p<.1E-4 
N=335 
0.31 
p<1E-4 
N=317 
0.46 
p<1E-4 
N=338 
0.52 
p<1E-4 
N=338 
1.0 
 
N=338 
Note: Factors with at least a spearman correlation equal or superior to 0.40. 
In each cell, the three lines corresponds to :  Spearman Correlation Coefficients (SSC), P-value, number of observations. 
 
 
Validation in RTOG/NCCTG data 
 
Baseline characteristics were different between EORTC and RTOG/NCCTG patients (Table VIII-3). 
In particular, tumor of EORTC and RTOG/NCCTG patients had different histological types. 
Oligodendrogliomas or mixed oligoastrocytoma were diagnosed in 76.9% of US patients compared 
to 31.5% of EORTC patients (p<0.0001). It is beyond the scope of this manuscript to interpret these 
differences. For both PFS and OS, MRC score or presence of neurological deficit, central pathology 
diagnosis (non astrocytic vs astrocytic tumor type) and tumor size but not time since first LGG 
symptoms had significant prognostic influence in US data. (Table VIII-6) An explanation for this 
could be that time since first LGG symptoms was significantly shorter in US data (p<0.0001, median 
14 vs 30 weeks), which may reflect a more aggressive therapeutic approach. Compared to EORTC, 
the C-index and PEV were slightly lower in US data (Table VIII-6, PFS: C-index=0.61, PEV=5.5%; 
OS: C-index=0.62, PEV=7.1%). Table VIII-7 compares PFS and OS by risk groups between EORTC 
and US data. Overall, US patients had significantly different outcome compared to EORTC patients 
(PFS:, p=0.01, OS: p=0.03). Nevertheless, there was no significant difference in PFS and OS 
between EORTC and US patients within risk groups. There was no difference in both PFS and OS 
when they were computed from the time of first symptoms (PFS: p=0.95, OS: p=0.92, curves not 
shown). Figure VIII.2 shows PFS and OS Kaplan Meier curves by risk group in US data. Curves 
separated well between the three risk groups. Sensitivity, specificity and PPV were low (<70%). 
NPV was equal to 73% for PFS and 71% for OS. See Table VIII-3.  
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Table VIII-5: Univariate analyses of PFS and OS  
 Progression Free Survival Overall Survival 
 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
P 
 
Median 
(95% CI) 
(Months) 
% at 3 Year(s) 
(95% CI) 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
P 
 
Median  
(95% CI) 
(Months) 
% at 5 Year(s) 
(95% CI) 
LGG by central 
review 
       339        235 N/A N/A 55.33  
(49.35, 63.38)           
67.96  
(62.60, 72.73)      
       339        183 N/A N/A 86.54  
(78.55, 99.19)           
65.92  
(60.36, 70.90)      
Treatment             
Delayed RT         96         79 1.00                   
0.0002 
41.33  
(34.63, 53.26)           
57.93  
(47.34, 67.13) 
        96         50 1.00                   0.13 96.13  
(80.39, 126.42)          
73.66  
(63.28, 81.53) 
Immediate RT        243        156 0.60  
(0.46, 0.79)    
         62.13  
(52.96, 70.60)           
72.03  
(65.77, 77.35) 
       243        133 1.29  
(0.93, 1.79)    
         81.94  
(70.70, 98.10)           
62.78  
(56.03, 68.79) 
RT dose (Gy)             
45         80         52 0.95  
(0.78, 1.15)    
0.59 
(df=1)   
56.08  
(42.81, 75.17)           
70.07  
(58.47, 79.00) 
        80         40 1.07  
(0.86, 1.33)    
0.56 
(df=1)   
85.55  
(53.45, 179.61)          
58.70  
(46.41, 69.10) 
54         85         59                                      63.08  
(53.55, 74.84)           
76.09  
(65.42, 83.86) 
        85         52                                      84.73  
(69.13, 105.49)          
68.71  
(57.23, 77.70) 
59.4         78         45                                      64.76  
(47.41, 80.95)           
69.63  
(57.57, 78.87) 
        78         41                                      74.28  
(55.13, 101.72)          
60.21  
(47.74, 70.61) 
Age (median)             
<=39 yrs        169        122 1.00                  0.77 56.08  
(46.42, 64.07)           
72.93  
(65.38, 79.09) 
       169         93 1.00                   0.78 82.40  
(75.27, 100.60)          
67.58  
(59.52, 74.38) 
>39 yrs        170        113 0.96  
(0.74, 1.24)    
         55.13  
(44.48, 72.94)           
63.05  
(55.18, 69.92) 
       170         90 1.04 
 (0.78, 1.39)    
         89.76  
(71.92, 105.49)          
64.28  
(56.27, 71.21) 
Gender                                                      
        Male                                 214        153 1.00                  0.23 53.26  
(42.81, 59.79)           
64.28  
(57.33, 70.40) 
       214        121 1.00                   0.17 80.07  
(70.70, 91.24)           
64.93  
(57.76, 71.19) 
        Female                               125         82 0.85  
(0.65, 1.11)    
         64.07  
(49.45, 73.86)           
74.26  
(65.45, 81.15) 
       125         62 0.80 
(0.59, 1.09)    
         98.10  
(81.94, 110.98)          
67.57  
(58.25, 75.25) 
History  of 
Seizure                                      
            
        No                                          235        171 1.00                  0.49 57.59  
(50.20, 65.71)           
69.60  
(63.20, 75.11) 
       235        132 1.00                   0.61 86.54  
(78.55, 99.19)           
66.56  
(59.89, 72.38) 
        Yes                                  101         64 1.11  
(0.83, 1.48)    
         47.41  
(39.33, 64.07)           
63.39  
(52.85, 72.19) 
       101         51 1.09  
(0.79, 1.51)    
         80.39  
(62.85, 107.43)          
63.62  
(52.71, 72.66) 
Headache                                                 
        No                                          267        185 1.00                   >0.99 55.33  
(49.18, 64.07)           
68.72  
(62.68, 73.99) 
       267        145 1.00                   0.95 86.64  
(77.34, 99.19)           
65.22 
(58.89, 70.83) 
        Yes                                  69         50 1.00  
(0.73, 1.37)    
         51.78  
(37.65, 70.51)           
64.20  
(51.49, 74.39) 
        69         38 1.01  
(0.71, 1.45)    
         80.39  
(68.01, 106.84)          
67.66  
(54.76, 77.60) 
Mental 
disturbance                           
            
        No                                          277        186 1.00                   0.003 61.60  
(52.96, 68.90)           
72.75  
(66.99, 77.68) 
       277        144 1.00                   0.02 89.76  
(80.39, 103.82)          
70.02  
(63.98, 75.25) 
        Yes                                  59         49 1.63  
(1.18, 2.24)    
         31.08  
(18.83, 41.69)           
44.57  
(31.49, 56.84) 
        59         39 1.55  
(1.08, 2.22)    
         45.17  
(32.82, 89.30)           
44.83  
(31.25, 57.50) 
Motor 
disturbance                            
            
        No                                          245        166 1.00                   0.09 57.23 71.95         245        130 1.00                   0.15 86.54  67.20  
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(51.55, 65.77)           (65.72, 77.24) (78.26, 102.14)          (60.62, 72.93) 
        Yes                                  72         54 1.31  
(0.96, 1.78)    
         44.09  
(29.77, 63.08)           
56.48  
(44.17, 67.07) 
        72         44 1.29  
(0.91, 1.83)    
         84.53  
(55.75, 104.11)          
60.09  
(47.30, 70.72) 
Performance 
Status                           
            
        0                                           127         81 1.41  
(1.15, 1.71)    
0.0007 
(df=1)   
69.68  
(57.13, 76.94)           
77.19  
(68.68, 83.65) 
       127         57 1.50  
(1.20, 1.87)    
0.0004 
(df=1)   
102.14  
(84.73, 119.79)         
77.04 
(68.29, 83.66) 
        1                                           164        118                                      51.91  
(43.43, 64.76)           
67.37  
(59.48, 74.06) 
       164         95                                      82.99  
(71.26, 103.82)          
64.16  
(55.99, 71.21) 
        >1                                   47         35                                      35.09  
(13.40, 50.20)           
46.09  
(31.05, 59.88) 
        47         30                                      47.34  
(33.64, 88.15)           
43.05  
(27.82, 57.41) 
MRC score 
(class)                            
            
        No                                          194        125 1.38  
(1.16, 1.65)    
0.0003 
(df=1)   
67.19  
(57.13, 74.84)           
77.46  
(70.75, 82.82) 
       194         93 1.42  
(1.16, 1.73)    
0.0006 
(df=1)   
98.10 
 (82.99, 108.02)          
73.53  
(66.34, 79.42) 
        Some                                 101         75                                      41.59  
(35.38, 56.94)           
60.29  
(49.88, 69.21) 
       101         60                                      80.39  
(60.58, 104.11)          
62.14  
(51.54, 71.07) 
Moderate/Major             44         35                                      31.31  
(13.40, 52.96)           
44.15  
(29.02, 58.25) 
        44         30                                      40.02  
(27.93, 91.24)           
41.22 (25.94, 
55.87) 
Extent of 
resection by 
neuro-surgeon                              
            
        Biopsy                               116         81 1.00                   0.38 53.26  
(38.77, 70.01)           
61.48  
(51.75, 69.82) 
       116         57 1.00                   0.73 102.14  
(81.94, 107.43)         
65.50  
(55.61, 73.71) 
        Resection                            219        151 0.89  
(0.68, 1.16)    
         56.48  
(47.57, 64.95)           
71.22  
(64.61, 76.83) 
       219        123 1.06  
(0.77, 1.45)    
         82.40 
(74.28, 94.36)           
66.00  
(59.00, 72.10) 
             
Baseline steroids                                               
        No                                          160        105 1.00                   0.08 65.45  
(55.13, 74.84)           
77.53  
(70.12, 83.31) 
       160         91 1.00                   0.16 85.29  
(71.26, 99.19)           
66.43  
(58.29, 73.35) 
        Yes                                  77         48 1.35  
(0.96, 1.91)    
         47.57  
(35.09, 70.60)           
59.46  
(47.10, 69.83) 
        77         41 1.31  
(0.90, 1.89)    
         62.85  
(43.33, 110.26)          
52.64  
(39.88, 63.89) 
Baseline 
anticonvulsants                               
            
        No                                           36         22 1.00                   0.99 59.70  
(37.09, 76.94)           
68.51  
(50.36, 81.18) 
        36         21 1.00                   0.70 73.46  
(40.02, 175.28)          
58.63  
(40.20, 73.13) 
        Yes                                  193        125 1.00  
(0.63, 1.57)    
         63.08  
(51.91, 71.00)           
73.45  
(66.43, 79.23) 
       193        105 0.91  
(0.57, 1.46)    
         82.99 
(70.67, 98.10)           
63.37  
(55.78, 70.02) 
Central 
diagnosis                              
            
Astrocytoma                                 200        155 1.00                 <1E-4 
(df=2)   
45.34  
(39.72, 52.96)           
60.89  
(53.64, 67.36) 
       200        124 1.00                 0.0006 
(df=2)   
75.27  
(62.69, 84.53)           
58.82  
(51.35, 65.53) 
Oligoastrocytom               81         39 0.41  
(0.29, 0.59)    
<1E-4 
(df=1)   
93.11  
(74.55, N)               
81.14  
(70.67, 88.18) 
        81         31 0.47  
(0.31, 0.70)    
0.0002 
(df=1)   
103.82 
 (95.31, N)              
81.97  
(71.43, 88.91) 
Oligodendroglio 
                    
        58         41 0.86  
(0.61, 1.21)    
0.38 
(df=1)   
55.13  
(43.43, 72.31)           
74.18  
(60.29, 83.83) 
        58         28 0.72  
(0.48, 1.10)    
0.13 
(df=1)   
105.49  
(62.85, 152.02)         
68.21  
(53.32, 79.23) 
Frontal location                                                
        No                                          172        116 1.00                   0.83 53.55  
(41.59, 65.48)           
65.51  
(57.78, 72.16) 
       172         96 1.00                   0.20 80.95  
(71.56, 101.72)          
63.21 
(55.26, 70.13) 
        Yes                                  167        119 0.97          56.94  70.55         167         87 0.82           90.71  68.84  
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(0.75, 1.26)    (49.18, 65.71)           (62.79, 76.98) (0.61, 1.11)    (78.26, 105.49)          (60.74, 75.60) 
Temporal 
location                                     
            
        No                                          251        171 1.00                   0.21 57.59  
(51.55, 68.27)           
67.82  
(61.53, 73.31) 
       251        125 1.00                   0.008 95.31  
(81.94, 106.97)          
68.86  
(62.42, 74.43) 
        Yes                                  88         64 1.20  
(0.90, 1.60)    
         47.57  
(41.00, 59.14)           
68.47  
(57.46, 77.19) 
        88         58 1.53  
(1.12, 2.09)    
         71.56 
(55.36, 84.73)           
57.71  
(46.29, 67.56) 
Parietal location                                               
        No                                          277        197 1.00                   0.65 54.21  
(47.34, 62.13)           
69.27  
(63.34, 74.44) 
       277        157 1.00                   0.31 84.73  
(75.27, 95.31)           
65.13  
(58.91, 70.66) 
        Yes                                  62         38 0.92  
(0.65, 1.31)    
         64.95 
(35.09, 77.67)           
62.21  
(48.80, 73.04) 
        62         26 0.81  
(0.53, 1.22)    
         111.80  
(73.69, N)              
69.68  
(56.20, 79.74) 
Occipital 
location                                   
            
        No                                          336        235 1.00                   0.04 55.13  
(49.18, 63.08)           
67.67  
(62.27, 72.47) 
       336        183 1.00                   0.97 85.55  
(78.26, 98.10)           
65.60  
(59.99, 70.61) 
        Yes                                  3          0 0.00  
(0.00, 2.66) 
          
Not reached                    
  ( ,  )                      3          0 0.00  
(0.00, )       
          
Not reached                    
 
  ( ,  )             
Other location                                           
        No                                          320        221 1.00                   0.98 56.08  
(49.35, 63.38)           
68.60  
(63.09, 73.47) 
       320        171 1.00                   0.69 86.54  
(78.55, 98.10)           
66.16  
(60.42, 71.27) 
        Yes                                  19         14 1.01  
(0.59, 1.73)    
         40.94  
(22.77, 107.43)          
57.89  
(33.21, 76.26) 
        19         12 1.13  
(0.63, 2.03)    
         79.44  
(40.02, 126.42)          
62.20  
(36.44, 79.98) 
Left Lobe                                                
        No                                          188        132 1.00                   0.90 56.94  
(47.34, 67.19)           
68.96  
(61.64, 75.17) 
       188        103 1.00                   0.81 88.67  
(74.71, 102.14)          
66.71  
(59.14, 73.19) 
        Yes                                  151        103 1.02  
(0.78, 1.32)    
         54.21  
(41.69, 65.48)           
66.76  
(58.50, 73.74) 
       151         80 1.04  
(0.77, 1.39)    
         84.53  
(73.69, 106.84)          
64.99  
(56.39, 72.30) 
Right Lobe                                              
        No                                          158        109 1.00                   0.61 53.55  
(41.33, 63.08)           
65.00  
(56.89, 71.97) 
       158         85 1.00                   0.55 82.40  
(71.56, 99.19)           
63.96  
(55.57, 71.18) 
        Yes                                  181        126 0.94  
(0.72, 1.21)    
         59.14  
(49.35, 68.90)           
70.60  
(63.20, 76.79) 
       181         98 0.91  
(0.68, 1.22)    
         89.30  
(75.27, 103.82)          
67.68  
(59.98, 74.23) 
Midline crossing                                        
        No                                          247        164 1.00                   
0.0001 
64.07  
(53.06, 71.00)           
72.83  
(66.71, 78.02) 
       247        122 1.00                 < 1E-4 98.10  
(84.73, 108.02)          
71.43  
(65.03, 76.86) 
        Yes                                  68         55 1.83  
(1.35, 2.50)    
         37.65  
(23.98, 44.09)           
51.56 
(38.92, 62.81) 
        68         51 2.26  
(1.62, 3.16)    
         45.04  
(37.78, 70.67)           
43.72  
(31.33, 55.45) 
Tumor size (cm)             
        <5                                   124         77 1.00                   0.008 69.68  
(55.33, 76.88)           
70.50  
(61.38, 77.85) 
       124         51 1.00                   0.0007 128.76 
(85.55, N)              
70.47  
(60.99, 78.05) 
        >=5                                  173        132 1.46 
(1.10, 1.93)    
         46.42  
(41.20, 55.13)           
64.88  
(57.20, 71.52) 
       173        113 1.78  
(1.28, 2.48)    
         75.27  
(67.35, 84.53)           
60.55  
(52.60, 67.58) 
Time since first 
LGG symptoms 
(weeks) 
            
<30        169        127 1.00                   0.03 53.26  
(44.48, 61.60)           
66.67  
(58.90, 73.30) 
       169        101 1.00                   0.05 82.40  
(70.67, 94.36)           
63.89  
(55.91, 70.82) 
>=30        169        108 0.76  
(0.58, 0.98)    
         56.94  
(47.18, 74.55)           
69.06  
(61.30, 75.58) 
       169         82 0.74  
(0.55, 1.00)    
         100.60 
(78.55, 119.79)         
67.82  
(59.72, 74.64) 
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Time since 
surgery(weeks) 
            
<2.3        172        129 1.00                   0.16 52.24  
(43.43, 57.13)           
69.81  
(62.26, 76.13) 
       172        103 1.00                   0.22 81.22  
(69.13, 90.71)           
63.21  
(55.27, 70.12) 
>=2.3        167        106 0.83  
(0.64, 1.07)    
         65.45  
(51.55, 75.17)           
65.99  
(58.02, 72.80) 
       167         80 0.83  
(0.62, 1.12)    
         96.13  
(77.34, 106.97)          
68.98  
(60.90, 75.73) 
Note: RT: Ratiotherpapy. df=degree of freedom of the statistical test. df=1 for binary factors  (not added to the table) and  for scores (eg WHO performance status). df=2 is 
for the global homogeneity test among the 3 histological subtypes. Astrocytoma was used as reference subgroup. 
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Table VIII-6: Multivariate analyses of PFS and OS  
 
 Progression Free Survival Overall Survival 
 EORTC RTOG/NCCTG EORTC RTOG/NCCTG 
 p Hazard 
Ratio  
(95% CI) 
p Hazard 
Ratio  
(95% CI) 
p Hazard Ratio  
(95% CI) 
p Hazard 
Ratio  
(95% CI) 
 N=338/E=235 N=418/E=293 N=338/E=183 N=418/E=239 
Treatment 
(delayed/immediate 
irradiation)* 
0.0008 0.62  
(0.47-0.82) 
N/A† N/A†* N/A† 
Time since first symptoms  
(<30 weeks/>=30 weeks) 
0.01 0.70 
(0.53-0.92) 
0.34 1.14  
(0.87-1.47) 
0.009 0.67 
(0.49-0.91) 
0.42 1.13  
(0.85-1.50) 
MRC score 
(no/some/moderate or major 
deficit) 
NI NI NI NI 0.0001 1.51  
(1.22-1.86) 
<.0001 1.46 
(1.22-1.75) 
MRC score (no/at least some 
deficit) 
0.0003 1.64  
(1.25-2.15) 
0.01 1.36  
(1.07-1.71) 
NI NI NI NI 
Central histological type (OA 
or OD/AA) 
<.0001 1.93  
(1.47-2.54) 
<0.0001 1.93  
(1.49-2.52) 
<0.0001 1.96 
(1.43-2.69) 
<.0001 2.08 
(1.56-2.76) 
Tumor size (cm) (<5/>=5) 
 
0.004 1.53  
(1.15-2.03) 
<0.0001 1.78  
(1.41-2.26) 
0.001 1.74 
(1.25-2.43) 
0.0005 1.58 
(1.22-2.05) 
C-index♪ 0.64 0.61 0.67 0.62 
PEV(%)‡ 10.1 5.5 8.8 7.1 
Sensitivity (%)♫ 36 65 38 61 
Specificity (%)♫ 47 26 43 29 
NPV (%)♫ 74 73 61 71 
PPV (%)♫ 50 58 57 51 
Note: N=sample size, E=Number of events. NI: Not included in this model. * In PFS analyses, treatment was considered 
a variable in the regression equation. In OS analyses it was used as a stratification factor in the Cox model. † All US 
patients were treated with immediate radiotherapy. ♪ C-index was corrected for optimism by bootstrap technique. ‡ A 
PEV of at least 20% is considered a minimum requirement for a model to provide sufficiently precise individual survival 
predictions. ♫, see table VIII-7 for definition.  
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 Table VIII-7: Sensitivity, Specificity, NPV and PPV. 
 
Criteria Definitions for Progression Free 
Survival 
Definitions for Overall Survival 
Sensitivity Percentage of patients alive 
without progressive disease at 
year 3, who were classified as 
low risk 
Percentage of patients alive at year 5, who 
were classified as low risk 
Specificity Percentage of patients who died 
or had progressive disease prior 
to year 3, who were classified as 
high risk 
Percentage of patients who died prior to year 
5, who were classified as high risk 
NPV Percentage of patients classified 
as low risk, who were alive 
without progressive disease at 
year 3. 
Percentage of patients classified as low risk, 
who were alive at year 5. 
PPV Percentage of patients classified 
as high risk who died or had 
progressive disease prior to year 
3. 
Percentage of patients classified as high risk 
who died prior to year 5. 
Note: patients lost to follow-up before years 3 or 5 were considered as failures for PFS and OS respectively. 
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Figure VIII.1: PFS curves split by risk group in the EORTC dataset. 
(years)
0 2 4 6 8 10 12 14 16 18
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk groups
50 104 84 68 50 21 8 5 3 1
77 115 91 57 33 18 5 3 0 0
108 119 72 44 17 8 2 1 1 0
Low
Intermediate
High
 
 
Note: Compared to low risk patients, patients with intermediate risk had PFS Hazard Ratio= 1.78 with 95% Confidence 
Interval (1.24, 2.55) and patients with high risk had PFS Hazard Ratio=3.32 with 95% Confidence Interval (2.36, 4.67). 
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Figure VIII.2: PFS curves split by prognostic risk group in the NCCTG/RTOG dataset.  
(years)
0 3 6 9 12 15 18 21
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk groups
153 240 176 120 62 26 10 2
89 113 67 40 20 9 4 1
51 65 27 18 7 2 1 0
Low
Intermediate
High
 
p<0.0001 (df=1)
 
Note: PFS Hazard Ratios with 95% Confidence Intervals and p-values were 1.56 (1.20,2.03),p=0.0009 for intermediate 
risk patients and 2.17 (1.58,2.99),p<0.0001 for high risk compared to low risk patients. 
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Figure VIII.3: OS curves split by prognostic risk group in the EORTC dataset.  
(years)
0 2 4 6 8 10 12 14 16 18 20
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk groups
41 116 100 83 63 36 16 10 7 4 0
56 106 94 71 51 32 8 3 0 0 0
86 116 88 63 40 19 9 6 3 1 1
Low
Intermediate
High
 
 
Note: Compared to low risk patients, patients with intermediate risk had  OS Hazard Ratio= 1.67 with 95% Confidence 
Interval (1.12, 2.51)) and patients with high risk had OS Hazard Ratio=2.90 with 95% Confidence Interval (2.00, 4.22). 
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Figure VIII.4: OS curves split by prognostic risk group in the NCCTG/RTOG dataset. 
(years)
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0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Risk groups
110 229 196 151 83 42 21 6 1
65 102 83 54 27 14 7 2 0
64 87 51 41 16 5 3 0 0
Low
Intermediate
High
 
p<0.0001 (df=1)
 
Note: OS Hazard Ratios with 95% Confidence Intervals and p-values were 1.58(1.16,2.14), p=0.004 for intermediate risk 
patients and 2.47(1.81,3.38),p<0.0001 for high risk compared to low risk patients. 
 
Prognostic calculators 
 
Prognostic calculators based on new prognostic models have been developed. Like nomograms, 
these prognostic calculators provide patients with PFS3y and OS5y estimates based on their 
individual characteristics. Prognostic calculators are available online for physicians and patients at 
http://www.eortc.be/tools/lggcalculator. As a disclaimer, prognostic calculators must be used 
cautiously, individual precision and prediction of outcome is limited.  A patient's prognosis may 
depend on other factors than those taken into account. Any decisions concerning patient care should 
not be based only on the use of these calculators, but should also take into account the patient's past 
history, other current patient and tumor characteristics, and new therapeutic development.  
 
8.5 Discussion 
 
This is a pooled prognostic factor analysis of two large EORTC trials of patients with LGG. Only 
patient with independently confirmed eligible histology were included, thus providing a more 
homogenous dataset and increasing the precision of the prediction.  A total of 21% of cases reviewed 
had to be excluded due to differing central review pathology diagnosis, 17% were qualified as a 
high-grade glioma. Survival was substantially worse for the excluded patients retrospectively 
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considered as HGG.  This inter-observer variation is a known factor in trials on LGG and HGG, and 
is related to the subjectivity of the criteria used.
5
  
Both PFS and OS were negatively influenced by a worse baseline neurological status (i.e. presence 
of neurological deficits (PFS) or MRC score (OS)), a shorter time since first symptoms (<30 weeks), 
an astrocytic histology, and a tumor size of more than 5 cm in diameter. Of note, presence of 
neurological deficits and WHO performance status measure are interrelated. Treatment, namely 
immediate irradiation improved PFS, but not OS.
1
  Contrary to earlier report, age no longer showed a 
prognostic importance in the now more homogenous dataset of histologically confirmed low-grade 
tumors.
6
 Elderly high-grade patients were removed from this dataset. In this analysis, debulking 
surgery or complete tumor resection (as reported by the operating neurosurgeon without 
confirmation by imaging) did not significantly improve neither PFS nor OS (although tumor size was 
inversely correlated with extent of resection).
6
  In everyday clinical practice, histological diagnosis is 
based on the skills and expertise of the local pathologist, independent and central expert review is 
rarely routine practice. Thus general applicability of our data may be confounded by a higher 
variation in histological subtypes and grades seen in clinical practice. Our models had moderate 
discrimination measured by C-index (max 0.67). Their percentage of explained variation in survival 
times was limited (PEV<20%) leading to large confidence intervals for outcome estimates. 
Sensitivity, specificity, PPV were low for both PFS and OS in all datasets as well as NPV for OS in 
EORTC data. Our models had moderate NPV in both EORTC and US dataset for PFS (~74%). They 
could nevertheless separate patients into three distinct risk groups (low/intermediate/high) in both 
EORTC (development) and US (validation) datasets.  A major limitation of our study is the absence 
of molecular data in EORTC trials designed in the mid eighties, without tissue collection, as well as 
the estimation of tumor size based on CT as opposed to MR imaging. The prognostic value of new 
biomarkers relevant for gliomas could therefore not be assessed in our dataset. In particular, 1p/19q 
co-deletion was since identified as a favorable prognostic factor for oligodendroglial tumors 
associated with more indolent disease, prolonged natural history, and increased responsiveness to 
therapy.
18
 Results of randomized trials must further distinguish between prognostic and predictive 
information related to 1p/19q status. Similarly, IDH mutations are of major prognostic significance 
in diffuse gliomas, although its value in grade II tumors is disputed.
19
 Furthermore, not all trials 
collected the same clinical data. As an example, the Mini Mental State Examination (MMSE) score 
was not collected in the EORTC patients. Previous reports showed that presence of an abnormal 
baseline MMSE score was a strong predictor of poorer PFS and OS.
20
  The addition of these factors 
to our prognostic models might significantly improve their predictive accuracy and precision.  
 
Conclusions: 
 
In our previous report, all patients diagnosed by local pathologists were used in the prognostic 
modeling.
6
 In this study, patients were selected based on the LGG diagnosis of a central pathology 
reviewer.  This population is more homogeneous because fewer patients with higher grade were 
included. It better fits to modern practice where patients are enrolled in clinical trials based on 
central or panel pathology review. With more similar patients, the new prognostic models provide 
more reliable and precise predictions. With their limitations correctly understood, they can help 
physicians to classify patients into three risk groups and propose them most adapted therapeutic 
strategy including their participation to clinical trials. They can be used to discuss disease prognosis 
with patients and families. Characteristics of patients and how they were managed were different 
between EORTC and RTOG/NCCTG patients but discrimination and predictive accuracy were 
comparable making these prognostic models useful for both European and American patients. 
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Chapter IX. Summary and conclusions 
 
Chapter 1 briefly presents brain cancer as a public health problem including the most recent 
incidence and epidemiological data. The history of the classification of brain tumor by the World 
Health Organization is summarized. The problem of using this classification in the clinical practice 
die to the large inter-observer variability is outlined. This thesis further characterizes this variability 
for the diagnosis of anaplastic oligodendrogliomas (AOD)/oligoastrocytomas (AOA) and 
glioblastomas. The importance of prognosis and prognostic factors in patient clinal management is 
reviewed. The methods used to build statistical prognostic models were explained to prepare the 
reading of chapters on prognostic modeling (Chapters 5-8).    
 
Chapter 2 presents the result of a study which aim was to estimate consensus in typing and grading 
of AOD and AOA by a panel of 9 independent neuropathologists using tumor material collected in 
EORTC 26951 trial. Consensus diagnosis was correlated with the 1p/19q status of the tumors and the 
clinical outcome.  Confirmation rate by the panel of the diagnosis of AOD (52%) and AOA (8%) 
made by local pathologists was low. Within the panel, the concordance on the diagnosis of AOD was 
high (86%). Survival curves split by consensus diagnosis (AOD/AOA) and 1p/19q status were 
significantly separated (AOD with 1p/19q loss vs AOD without these losses vs AOA without 1p/19q 
loss). In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent 
prognostic factors.  
 
In Chapter 3 the results of a central pathology review of EORTC 26981/22981 NCIC CE.3 trial on 
GBM made by three independent reviewers are presented. Whether patients with GBM displaying 
distinct morphologic features had different response to combined chemo-radition was evaluated. 
GBM with an oligodendroglioma-like component (GBM-O) was found not associated with a more 
favorable outcome compared to classical GBM. GBM-O were found to be enriched for IDH1 
mutations and EGFR amplifications. Co-deletion of 1p/19q was found in only one case and the 
MGMT methylation rate was found to be similar compared with other GBMs. Unexpectedly the 
presence of pseudo-palisading necrosis (PPN) displayed a trend for a higher benefit from 
chemotherapy. No treatment effect was significantly present in the absence of PPN. The presence of 
PPN should be systematically collected in new prospective trials to confirm its clinical interpretation.  
 
In Chapter 4, the added value of 5 molecular markers (1p/19q codeletion, polysomy of chromosome 
7, epidermal growth factor receptor (EGFR) gene amplification (EGFR
amp
), and loss of chromosome 
10 or 10q) to predict the outcome of patients with AOA or AOD treated with RT/PCV was assessed 
based on survival data from EORTC 26951 trial. In patient with AOD/AOA diagnosis confirmed by 
central pathology, codeleted 1p/19q only, AOA type and WHO performance status had independent 
prognostic value.  We showed that AOA tumors with necrosis had similar survival when compared 
to GBM from EORTC 26981 trial and should also be considered WHO Grade IV tumors. However, 
patients with AOA with only endothelial abnormalities had better overall survival and should not be 
confounded with GBM. 
 
In Chapter 5, data from patients with newly diagnosed GBM enrolled in EORTC 26981/22981 
NCIC CE.3 trial to receive either radiotherapy alone or radiotherapy plus temozolomide where used 
for prognostic modeling in GBM. Prognostic factors with a strong independent prognostic impact 
were combined treatment with temozolomide, more extensive tumour resection, younger age, Mini-
Mental State Examination (MMSE) score of 27 or higher, and no corticosteroid treatment at baseline 
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In patients who were assigned temozolomide and radiotherapy, methylated MGMT , better WHO 
performance status, and MMSE score of 27 or higher were associated with improved survival. These 
factors should be used as eligibility or stratification factors for future trials in patients with newly 
diagnosed GBM. Stratifying by MGMT promoter methylation status should be mandatory in all 
glioblastoma trials that use alkylating chemotherapy. Implemented nomograms and online 
calculators can be useful tools which contribute to individualised patient management.  
 
In Chapter 6, data from patients in eight EORTC phase I or II trials were pooled to update the 
prognosis information of GBM patients at the recurrence of the disease. Patients with poor WHO 
performance status, multiple lesions, large tumours measured by the maximum diameter of the 
largest lesion (42 mm) and treated with steroids at baseline had shorter OS. Tumours with 
predominant frontal location had better survival. Age and sex did not show independent prognostic 
influence. 
 
In Chapter 7, the prognosis of patients with Grade III gliomas (oligodendrogliomas (AOD) and 
oligoastrocytomas (AOA)) was studied. In view of the high interobserver variability in the diagnosis 
of these tumors, identification of biomarkers with prognostic significance is helpful to identify more 
homogeneous disease subtypes and improve patient management. Data from patients with AOD or 
AOA recruited in EORTC trial 26951 on adjuvant PCV chemotherapy were used to develop 
multifactor prognostic models. Younger age, confirmed absence of  residual tumor on imaging,  
frontal location,  good WHO performance status, absence of endothelial abnormalities and/or  
necrosis, 1p/19q codeletion and IDH1 mutation were  independent factors that predicted better 
Progression Free and Overall Survival, treatment was found to influence Progression Free Survival. 
The prognostic models have high positive predictive value (>90%). Patients at high risk of disease 
progression and death can be better identified which can help physician in making therapeutic 
decisions. 
 
In Chapter 8, new prognostic models were developed for patients with at central pathology review 
confirmed low grade gliomas (LGG) based on data from two EORTC trials where newly diagnosed 
patients had received either no radiotherapy or immediate radiotherapy at different doses. Data from 
centrally reviewed LGG patients recruited in two studies conducted by North American cooperative 
groups [Radiation Therapy Oncology Group (RTOG), and North Central Cancer Treatment Group 
(NCCTG)] were used to validate the models. The presence of baseline neurological deficits assessed 
by the Medical Research Council (MRC) score, a shorter time since first symptoms (<30 weeks), an 
astrocytic tumor type, and tumors larger than 5 cm in diameter identified patients with poor 
outcomes. Prognostic models allow dividing LGG patients into three well discriminated risk groups 
which proved to be valid for both European and American patients. In the future, inclusion of other 
clinical (e.g. MMSE) and molecular factors might further improve the predictive value of prognostic 
models. 
 
Conclusion. In this thesis on brain tumors in clinical trials, we contributed to a further 
characterization of the inter-observer variability for the diagnosis in grade III glioma, to clarify the 
role of biomarkers for both diagnosis and prognosis, to validate known prognostic factors and 
identify new factors for grade II – IV glioma, to develop (for the first time in neuro-oncology) 
nomograms and prognosis calculators for individualized outcome prediction. Low grade gliomas 
prognostic models could be validated in a large external dataset. With these results, this research 
helps to take treatment decisions in individual patients and in the design of new studies on diffuse 
glioma.
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Chapter X. Samenvatting en conclusies 
 
Hoofdstuk 1 geeft een kort overzicht van gliomen, de meest voorkomende primaire hersentumoren 
bij volwassenen, inclusief incidentie en epidemiologische data. De geschiedenis van de glioom 
classificatie door de World Health Organization wordt  kort samengevat, en de problemen die in de 
dagelijkse praktijk ontstaan door interobserver variatie worden belicht. Dit proefschrift brengt de 
variabiliteit van de diagnose van anaplastische oligodendrogliomen (AOD) en anaplastische 
oligoastrocytomen (AOA) verder in kaart. Het belang van het vaststellen van de prognose en 
prognostische factorten voor de behandeling van patiënten wordt benadrukt. De methoden die 
gebruikt worden omstatische prognostische modellen te bouwen worden uitgelegd om het lezen van 
de hoofdstukken in dit proefschrift over het bouwen van prognostische modellen te 
vergemakkelijken 
 
Hoofdstuk 2 presenteert de resultaten van een studie naar de consensus in typering en graderingvan  
AOD en AOA door een panel van 9 neuropathologen die gebruik maakten tumor monsters uit 
EORTC studie 26951. De consensus  bleek gerelateerd aan de 1p/19q status van deze tumoren en de 
overleving. De bevestiging van de lokale gestelde diagnose door het panel was zowel voor AOD 
(bevestiging in 52% van de gevallen) als voor AOA (bevestiging in 9% van de gevallen) laag. 
Binnen het panel was de concordantie voor AOD hoog (86%). Overlevingscurves aan hand van 
consensus diagnose (AOD/AOA) en 1p/19q status lieten (AOD met 1p/19q verlies vs AOD zonder 
1p/19q verlies vs AOA zoner 1p/19q verlies) een duidelijk verschil zien. In multivariate analyse 
bleken de leeftijd van de patient, 1p/19q verlies en de aanwezigheid van necrose in het histologische 
preparaat onafhankelijke prognostische factoren. 
 
Hoofdstuk 3 presenteert de resultaten van de centrale pathologie revisie doro 3 onafhankelijke 
pathologen van EORTC studie 26981/22981 NCIC CE.3 naar gecombineerde radiochemotherapie 
met temozolomide bij glioblastomen. Hierin werd onderzocht of bepaalde histologische 
karakteristieken een verschil in behandeluitkomst met zich mee brachten. Glioblastoma met een 
oligodendrogliale component (GBM-O) bleek niet geassocieerd te zijn met een gunstigere uitkomst 
vergeleken met klassieke glioblastomen. GBM-O bleken een verhoogde incidentie IDH1 mutaties en 
EGFR amplificatie te vertonen. Co-deletie van 1p/19q werd maar in 1 geval vastgesteld, en MGMT 
romoter methylering bleek even frequent voor tekomen in in vergelijking met andere glioblastomen. 
Onverwacht bleek de aanwezigheid van necrose bij pseudopallisadering (PPN) een trend telaten zien 
voro meer winst van chemotherapie. In de afwezigheid vn PPN werd geen significant effect gezien 
van de toevoeging van temozolomide. In toekomstige studies dient de aanwezigheid van PPN 
systematisch moeten worden onderzocht om dit te bevestigen. 
 
In Hoofdstuk 4 wordt de toegevoegde waarde van 5 moleculaire markers (gecombineerd verlies van 
1p/19q, polysomy van chromosoom 7, Epidermal Growth Factor Receptor amplificatie (EGFR
amp
), 
en verlies van chromosoom 10 of 10q) onderzocht op de prognose van patienten met een AOD of 
AOA die behandeld werden in EORTC studie 26951 met radiotherapie (RT) of RT gevolgd door 
PCV chemotherapie . In patienten waarbij centrale pathologie revisie een AOD of AOA bevestigd 
had bleek gecombineerd verlies van1p/19q, type AOA en WHO performance status een 
onafhankelijke prognostische betekenis te hebben. We toonden aan dat AOA met necrose een 
overleving hadden die gelijk was aan die van glioblastomen behandeld in de EORTC studie 26981, 
en dat deze tumoren beschouwd moeten worden als WHO graad IV tumoren. Daarentegen hebben 
AOA met alleen endotheel proliferatie een betere overleving en moeten niet als glioblastoom worden 
beschouwd.
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In Hoofdstuk 5 worden data van patiënten met een nieuw gediagnosticeerd glioblastoom behandeld 
in EORTC 26951/22981 NCIC CE.3 studie met RT of RT met temozolomide gebruikt  voor het 
opstellen van een prognostisch model. Gecombineerde behandeling met temozolomide, een meer 
uitgebreide tumor resectie, jongere leeftijd, MiniMental Status Examination (MMSE) score van 27 of 
hoger en geen behandeling corticosteroiden ten tijde van randomisatie en methylering van de MGMT 
promoter bleken onafhankelijke prognostische factoren voor een betere overleving. Het verdient 
aanbeveling deze factoren te gebruiken bij toekomstige studies naar glioblastoom studies waarbij 
alkylerende chemotherapie gebruikt wordt. Nomogramen en een web-based online prognose 
calculator kunenn zinvolle middelen zijn die kunnen bijdragen aan een meer geïndividualiseerde 
patiënten behandeling.  
 
In Hoofdstuk 6 worden de data van acht EORTC fase I of II studies naar recidief glioblastomen 
geanalyseerd voor prognostische informatie van patiënten met een recidief glioblastoom. Patienten 
met een minder goede WHO performance status, meerdere laesies, tumoren met een grotere 
maximale diameter (> 42 mm), en steroid gebruik bij inclusie in de studie bleken een slechtere 
overleving te hebben. Patienten met een overwegend frontale tumor lokalisatie hadden  een betere 
overleving, leeftijd en geslacht hadden geen invloed op de overleving.  
 
In Hoofdstuk 7 wordt de prognose van AOD en AOA bestudeerd. Gezien de klinisch significante 
interobserver variatie bij het stellen van de diagnose AOD en AOA is het vaststellen van biomarkers 
met prognostische betekenis belangrijk, zowel voor het identificeren van homogene groepen 
patienten als voor de behandeling van individuele patiënten. De gegevens van patienten met een 
AOD of AOA behandeld in EORTC studie 26951 naar de betekenis van adjuvante PCV 
chemotherapie werden gebruikt voor het ontwikkelen van multifactoriële prognostische modellen. 
Jongere leeftijd, bij CT or MRI scan bevestigde totale resectie, frontale lokalisatie van de tumor, 
goede WHO performance status, afwezigheid van necrosis en/of endotheel proliferatie, 
gecombineerd 1p/19q verlies en de aanwezigheid van IDH1 mutaties bleken van onafhankelijke 
prognostische betekening voor OS en Progressie vrije overleving (PFS); de behandeling was ook van 
invloed op de PFS. De prognostische modeleln hebben een hoge positieve predictieve waarde. 
Patienten met een hoog risico op ziekte progressie en dood kunnen hiermee goed worden 
geïdentificeerd hetgeen hun behandelaren kan helpen bij het nemen van behandelingsbeslissingen. 
 
In Hoofdstuk 8 worden nieuwe prognostische modellen ontwikkeld voor laaggradige glioom (LGG) 
patienten waarbij de diagnose bevestigd was door centrale pathologie revisie. Deze werden 
ontwikkeld uit de gegevens van twee prospectieve EORTC studies naar de radiotherapeutische 
behandeling van het LGG. Deze modellen werden gevalideerd met data van patiënten met een 
eveneens bij centrale pathologie revisie bevestigde LGG uit twee Noord-Amerikaanse studies, van 
de Radiation Therapy and Oncology Group (RTOG) en North Central Cancer Treatment Group 
(NCCTG).  De aanwezigheid van neurologische uitval zoals vastgesteld met de Medical Research 
Council (MRC) score, een kortere duur sinds het eerste symptoom, astrocytaire histologie, en 
tumoren met een diameter meer dan 5 cm identificeerden patiënten met een slechte prognose. De 
prognostische modellen maakten het mogelijk de patienten in drie verschillende groepen onder 
teverdelen, die zowel voor Europese als Noord-Amerikaanse patiënten valide bleken. Moleculaire 
facotren en andere klinische factoren als de MMSE zullen het wellicht in de toekomst mogelijk 
maken de prognose nog beter in te schatten.  
 
Conclusie. Dit proefschrift over patienten met hersentumoren die zijn behandeld in klinische studies 
draagt bij aan het vaststellen van de interobserver variatie bij de histologische diagnose van graad III 
gliomen, heldert het de mogelijke betekenis op van moleculaire biomarkers voor zowel prognose als 
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predictie van behandelings resultaat bij graad III gliomen, valideert het bekende prognostische 
factoren  en identificeert nieuwe prognostische factoren bij glioblastomen en graad II /III gliomen, en 
ontwikkelt nomogrammen en prognose calculators voor uitkomst en predictie in individuele 
patiënten. Daarnaast werden  prognostische modellen voor LGG in grote externe datasets 
gevalideerd. Daarmee biedt dit proefschrift steun bij behandelingsbeslissingen bij individuele 
patiënten en bij het opzetten van nieuwe klinische studies. 
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Chapter XI. Future perspectives 
 
Currently, the diffuse glioma are classified and graded based on their morphological appearance. 
This classification was originally built on the presumed cell of origin, and as a consequence tumors 
were named astrocytoma, oligodendroglioma and ependymoma. The sheer existence of the so-called 
mixed oligoastrocytoma’s having elements of both is however already proof that in some cases no 
clear classification was possible. The current WHO classification of brain tumors grades the diffuse 
glioma into grade II (low grade), grade 3 (or anaplastic) and grade 4 (glioblastoma).
1
  The 
importance of this classification is the clear prognostic information that is captured in the histological 
diagnosis, and the fact this is the pillar on which adjuvant therapies following surgery are based. The 
current treatment guidelines for diffuse glioma are based on data from large randomized phase III 
studies in which patient eligibility depended on meeting inclusion criteria which included the 
histopathological diagnosis according to the WHO classification. This underlines the clinical 
relevance of this classification. Historically, the histopathological WHO criteria have been compiled 
based on the results of retrospective studies or expert opinions,  and indeed they are rarely based on 
prospective data related to patient outcome and/or response to therapy.
2-4
 Nevertheless, in 2013 
histopathology remains the gold standard for diagnosing and treating glioma patients and for 
inclusion into trials. However, it is also clear that within individual diagnostic categories outcome 
may vary significantly, and a more individualized, tailored  approach to patients is desirable. A 
further development is the coming of age of molecular subdivisions of the diffuse gliomas, some of 
which are beginning to have therapeutic consequences. 
  
For this thesis, analyses of data from EORTC Brain Tumor Group trials were used to further study 
the ‘performance’ of classical histology. Although this work confirmed that mixed anaplastic 
oligoastrocytomas with tumor necrosis had similar prognosis compared to glioblastomas, and that the 
prognosis of  glioblastomas with oligodendroglial components were not prognostically different from 
other glioblastomas, it also showed major shortcomings of classical histologogical classification.
5-7
 
The amount of the variation in typing and grading of gliomas between neuropathologists was found 
to be unacceptably high in grade III gliomas, experiences have also been documented in trials on low 
grade glioma. In order to improve the functioning of the histopathological diagnosis of gliomas: 
 
• Histopathological criteria must be made more objective and reproducible. 
• They must better reflect the prognosis of the patients. 
• They must be evaluated together with recently established molecular markers. 
 
Review by panel of neuropathologists of materials collected in prospective trials from 
homogeneously treated patients can be used to select the most reproducible criteria. Non -
reproducible phenotypic criteria, and those irrelevant to predict patient outcome must be eliminated. 
Selected histopathological criteria must be analysed together with molecular markers in multivariate 
prognostic models. The results of ongoing panel review of histological materials collected in EORTC 
trial 26951 (AOD/AOA) and 26882 (GBM/AA) is expected to contribute to establish a more 
reproducible and prognostically more meaningful glioma typing and grading for gliomas. 
The two other major shortcomings of the current WHO classification are the variation in prognosis 
within one tumor class/grade, and the absence of molecular factors. The other element is that even in 
clearly defined subgroups of patients outcome may differ substantially. This has great clinical 
relevance, as in the outcome of poor prognostic factors intensive treatments may not be warranted, 
and a more conservative approach or less aggressive in some patients with very favorable outcome 
may be indicated. For this analysis of well-defined and homogeneously treated patients populations 
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is crucial. To make a more indidualized prognostication possible, even within defined 
histopathological subsets of glioma, as part of this thesis prognostic models were developed for all 
grades of gliomas including recurrent glioblastomas.
8
 To have clinical relevance,  
 
• The prognostic models must be validated in large independent datasets of the same 
 population.  
• Old factors must be challenged and/or replaced by new markers if shown to be clinically 
 and/or biologically more relevant. 
• Improvement in prognostication must be measured by assessing model’s discrimination and 
 predictive accuracy.  
 
One rationale to leave out molecular factors in the current WHO classification is that this 
classification aimed at being suitable for use throughout the world – and molecular marker 
assessment is not. The current advances in molecular understanding of glioma make this ‘leaving 
out’ of molecular factors however untenable. Current data show that the strong predictive and 
prognostic factors which were identified in the recent years are overriding the prognostic information 
derived from the histopathological classification alone. For the assessment of the clinical relevance 
of these molecular factors several items are relevant:  
 
• Their respective role and utility for the management of gliomas must be further investigated, 
 preferably in prospective trials 
• The difference must be made between factors which can predict patient outcome (prognostic 
 value) and those which can identify patient responding to therapy (predictive value) 
 
Such analysis were presented in this thesis for several molecular factors.
5,8
 In addition, assays must 
be available that allow reliable assessment of these markers, according to clinical standards.
9-11
 This 
requires quality control as part of the implementation process. Unfortunately, this principle is more 
often ignored than adhered to.
10
 Despite the demonstrated clinical relevance of these molecular 
factors, the implementation of these factors does not imply that the histopathological classification 
has lost it’s relevance. Molecular factors need to be understood in the histopathological context. 
Also, even the presence of molecular factors with demonstrated relevance, other clinical factors 
remain of independent prognostic value. For some factors, the relevance could no longer be 
demonstrated in the presence of clinical factors (although that may have been related to the limited 
group size of some projects).
5
 It remains likely though, that prognostication will remain a process of 
several factors  of different nature (clinical, molecular, and treatment related). 
It is at present unclear which molecular techniques are required for an optimal classification of 
gliomas: single gene studies for IDH, MGMT status, and1p/19q determination, or more genome wide 
approaches like whole genome sequencing, expression analysis or genome wide methylation 
analysis; or any combination of these techniques. As all of these approaches have advantages and 
shortcomings, this matter remains at present unresolved. This is further complicated by the 
improvement on an almost daily basis of techniques to demonstrate DNA changes, RNA expression 
and epigenetic changes. More powerful techniques are rapidly approaching and will affect the day to 
day clinical practice in a few years. The challenge is how to implement these techniques in order to 
optimize patient treatment, or even to advance patient treatment. Now that whole genome approaches 
are becoming robust enough to be used on formalin fixed, paraffin embedded tumor samples these 
techniques are ready to be evaluated in clinical trials as well.
12,13
  
With more targeted treatments approaching the clinical arena of brain tumors further a routinely 
conducted full molecular characterization of gliomas becomes of interest. Indeed, the holy grail of 
molecular diagnostic oncology is to identify predictive factors that are correlated to outcome, in 
particular those that are qualitative. This implies that in the presence of a factor a treatment will work 
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but not in its absence (or vice versa). These are the most relevant factors for patient treatment. 
Currently, within the field of neuro-oncology two of these predictive factors have been defined: 
MGMT promoter methylation and 1p/19q loss. These factors however predict responsiveness to 
classical chemotherapy, which is useful to avoid overtreatment in patients that will not respond. The 
implementation of these factors will therefore not improve overall outcome, for that novel treatments 
are needed. Since several other molecularly targeted therapies are actively being explored, and new 
molecularly defined targets – that may exist in only small subgroups of glioma patients- are likely to 
follow. Again, clinical studies are needed to fully elucidate the clinical relevance of these factors, 
and whether established targets in gliomas response to the same treatments as the patients with 
similar targets in other cancers. The concept of personalised medicin based on target identification as 
opposed treatment based on classical diagnostic procedures remains to be proven for gliomas. Such a 
proof of concept requires well considered studies and genome wide screening procedures of large 
groups of patients. The rarity of ‘drug-able’ chromosomal lesions in gliomas prohibit the classical 
phase II and phase III approaches. But targeted therapies in glioma patients should no longer be 
conducted in all comers, but only in molecularly relevant glioma subtypes. This is the challenge for 
the future of glioma treatment.  
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